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Identification and Analysis of a New Tumor and Metastasis Suppressor Gene, RASAL2 
 
Abstract 
 RAS is one of the most commonly mutated genes in human cancer; its aberrant 
activation drives tumor cell proliferation and survival.  However, RAS mutations are rare in some 
cancers, including breast cancer, even though the Ras pathway is hyperactivated, suggesting 
that alternative mechanisms deregulate Ras signaling in these settings.  The RasGAPs are 
negative regulators of Ras and, as such, are poised to function as tumor suppressors whose 
loss might contribute to Ras pathway hyperactivation in cancer.  However, the RasGAPs remain 
an understudied family of genes whose role in cancer has not been fully explored.  In this 
Dissertation I identify a previously uncharacterized RasGAP, RASAL2, as the newest tumor 
suppressor in this gene family. 
 We find reports of RASAL2 mutations in breast and other cancers, and determine that 
RASAL2 expression is lost or suppressed in an even higher fraction of breast cancer cell lines 
and tumors.  We find that RASAL2 functions to suppress transformation and that its inactivation 
promotes transformation.  Further, we determine that RASAL2 inactivation also promotes cell 
migration, invasion, and tumor progression, suggesting distinct roles for RASAL2 inactivation in 
tumor formation and progression.  To study RASAL2 in vivo, we generate a Rasal2 mutant 
mouse model.  We cross Rasal2 mutant mice to a breast cancer-prone strain and discover that 
in this context Rasal2 loss potently increases metastasis.  Additionally, we cross Rasal2 mutant 
mice into a broad tumor-prone background, and find increased tumorigenesis and widespread 
metastasis in various tissues.  Together these findings reveal RASAL2 as a tumor and 
metastasis suppressor. 
 We explore mechanisms of RASAL2 inactivation in breast cancer and implicate 
epigenetic and miRNA-mediated suppression.  We find that RASAL2 inactivation cooperates 
	  iv 
with estrogen to drive proliferation of estrogen receptor-positive breast cancer cell lines.  Finally, 
we discover that the RasGAPs RASAL2 and DAB2IP interact, suggesting that RasGAPs may 
act in concert. 
 In summary we have identified a new tumor suppressor in the RasGAP gene family, 
elucidated the biological consequences of its inactivation, and explored its regulation and 
function.  We believe that these studies highlight the importance of RasGAPs as tumor 
suppressors and open exciting avenues for future exploration. 
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Introduction 
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 This Dissertation focuses on the previously uncharacterized RasGAP gene, RASAL2, 
and how its inactivation promotes the Ras pathway and cancer.  In this Introduction Chapter I 
discuss the Ras pathway in normal biology and cancer to provide context for my studies.  My 
research primarily addresses RASAL2 inactivation in breast cancer tumorigenesis and 
metastasis; therefore in this Chapter I also provide background on breast cancer and metastasis.  
Lastly, I discuss p53 and epigenetics, two important cancer-related topics relevant to the work in 
this Dissertation.  
 
THE RAS PATHWAY 
The Ras pathway is an essential cell signaling pathway through which cells respond to 
external stimuli and appropriately control growth and proliferation.  There are over thirty RAS 
genes, which belong to the ~150-member Ras superfamily of small GTPases1.  However, in this 
Dissertation I limit the discussion to the three main RAS genes with roles in cancer (which also 
were the founding members of the superfamily): KRAS, HRAS, and NRAS.  Although initially 
identified for their transforming properties when mutated2-6, it is now clear that K-, H-, and N-
RAS have widespread roles in normal development, particularly in controlling cell growth, 
proliferation, and differentiation7.  Interestingly, mouse modeling and cell culture studies, as well 
as differences among the Ras proteins, including expression pattern, subcellular localization, 
post-translational modification, and protein structure, support the notion that K-, H-, and N-Ras 
have both overlapping and distinct functions in normal biology8-11. 
 
Regulation of Ras activity 
The Ras GTPases cycle between GTP-bound and GDP-bound states (Figure 1-1).  
When bound to GTP, Ras adopts an active conformation and binds downstream effector 
proteins with high affinity12.  When bound to GDP, Ras is inactive; thus, Ras functions as a 
molecular switch that cycles between on and off states.  Two families of regulatory proteins 
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Figure 1-1: RasGTP – RasGDP cycle 
Ras is active and signals to downstream effectors when GTP-bound.  RasGAPs catalyze the 
hydrolysis of RasGTP to RasGDP, thereby inactivating Ras.  RasGEFs catalyze the exchange 
of GDP for GTP, activating Ras.  Figure adapted from13. 
 
accelerate the otherwise slow conversion of Ras between on and off states and, importantly, 
play central roles in controlling levels and duration of Ras activity (Figure 1-1): Ras proteins 
have intrinsic GTPase activity such that GTP bound to Ras will be hydrolyzed to GDP, and Ras 
inactivated14.  In the cell, Ras GTPase activating proteins (RasGAPs) catalyze the hydrolysis of 
RasGTP, greatly accelerating this process15,16.  By promoting GTP hydrolysis, RasGAPs 
promote Ras inactivation and thus are direct negative regulators of Ras signaling.  The 
RasGAPs are a main focus of this Dissertation and will be discussed in detail below.  Inactive 
Ras becomes activated when GTP replaces GDP.  Ras guanine nucleotide exchange factors 
(RasGEFs) catalyze this intrinsically slow process by promoting the release of GDP from 
inactive Ras17,18.  The cellular concentration of GTP is approximately 10-fold higher than that of 
cellular GDP, thus, following GDP release, Ras proteins bind GTP and become activated.  By 
promoting the exchange of GDP for GTP, RasGEFs act as direct positive regulators of Ras 
signaling. 
RasGEFs provide one link from external stimuli to Ras.  Following growth factor /mitogen 
binding of receptors such as the EGFR family of receptor tyrosine kinases, receptor tyrosine 
kinases (RTKs) dimerize, trans- or auto-phosphorylate their intracellular tails, and become 
Ras 
Ras 
GDP GTP 
Pi 
GTP GDP 
GAP 
GEF 
Effectors 
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activated19.  Activated RTKs serve as docking sites for a number of adaptor proteins, including 
GRB2.  These adaptor proteins recruit RasGEFs, such as SOS1, which then activate Ras by 
catalyzing the exchange of GDP for GTP, as described above20-24.  Distinct RTKs utilize unique 
combinations of adaptor proteins and RasGEFs, thus activation of distinct RTKs can 
differentially drive the Ras pathway.  The RasGAP neurofibromin (discussed below) provides 
another link between external stimuli and Ras.  Growth factor or serum treatment triggers 
proteasomal degradation of neurofibromin.  Neurofibromin destruction is required for maximal 
Ras activation following growth factor or serum treatment and controls the duration of the Ras 
signal, as neurofibromin re-expression is required to appropriately attenuate Ras pathway 
activation25. 
 
Ras downstream effector pathways 
Ras mediates its effects via activation of downstream signaling pathways (Figure 1-2).  A 
number of Ras effector pathways have been identified, via functional studies and the 
identification of a Ras binding domain in direct Ras effector proteins.  The first identified Ras 
effector pathway was the mitogen-activated protein kinase (MAPK) pathway26-29.  RasGTP 
activates the MAPK pathway by recruiting, binding, and promoting the activation of Raf (there 
are three human Raf proteins, ARaf, BRaf, and Raf1, encoded by ARAF, BRAF, and RAF1).  
Raf is a serine/threonine kinase that upon activation triggers a canonical kinase phosphorylation 
cascade.  Raf phosphorylates and activates MEK serine/threonine kinase (encoded by MAP2K1, 
mitogen-activated protein kinase kinase 1), which in turn phosphorylates and activates ERK1 
and 2 (extracellular signal-regulated kinases 1 and 2, encoded by MAPK1 and 2, mitogen-
activated protein kinases 1 and 2)30.  ERK in turn activates a myriad of nuclear and cytosolic 
proteins from transcription factors (including STAT3, ETS family transcription factors, and c-
JUN) and kinases (including RSK, MSK and MNK family kinases) to cytoskeletal proteins and 
receptors, and, via these effectors, drives cell cycle progression and cell survival7,31.  Notably, 
	  5 
data suggest that the Raf/MEK/ERK pathway plays a key role in Ras-driven tumorigenesis, as 
discussed below. 
 
Figure 1-2: Ras effector pathways 
When GTP-bound, Ras binds effector proteins and triggers numerous downstream pathways, 
as shown.  PI3K and MAPK pathways are indicated in green and purple, respectively.  Figure 
adapted from32. 
 
Ras also drives the phosphatidylinositol 3-kinase (PI3K) pathway (Figure 1-2), through 
direct binding to the p110α catalytic subunit of PI3K (class IA PI3Ks are composed of a catalytic 
subunit, p110, and a regulatory subunit, p85)33.  PI3K drives signaling through the lipid second 
messenger phosphatidylinositol-3,4,5-triphosphate (PIP3), which is generated from 
phosphatidylinositol-4,5-bisphosphate (PIP2) through PI3K phosphorylation.  The phosphatase 
PTEN can dephosphorylate PIP3 and convert it back to PIP2.  As discussed below, both PI3K 
activation and PTEN loss commonly occur in cancer.  PIP3 recruits and promotes activation of 
the AKT serine/threonine kinases34.  Among a number of activities, active AKT inhibits the tumor 
suppressor proteins TSC2 and TSC1.  This leads to an accumulation of active Rheb 
(RhebGTP); RhebGTP activates mTOR, which in turn promotes translation of a set of proteins 
through two major effectors, ribosomal protein S6 (following phosphorylation by S6 kinase), and 
eukaryotic initiation factor 4E (via inhibition of 4EBP1)35,36.  PI3K-AKT-mTOR signaling 
promotes cell growth and proliferation.  PI3K-AKT signaling also regulates cell survival via AKT-
Ras-GTP 
AF6 PLC!  RalGDS TIAM1 Rin1 p190 RASSF 
Apoptosis/ 
Cell-cycle arrest 
Motility Cell cycle Endocytosis Gene expression, 
Survival, Proliferation 
Endocytosis Second messenger 
signaling 
Survival Cytoskeleton 
Raf 
MEK 
ERK 
PI3K 
mTOR 
BAD 
AKT 
Growth, 
Proliferation 
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mediated inhibition of the pro-apoptotic protein BAD37,38.  Ras-independent mechanisms also 
can activate PI3K signaling: activated receptor tyrosine kinases promote PI3K signaling via 
direct binding of the p85 regulatory subunit of PI3K and/or via adaptor proteins36.  Further, it 
should be noted that both the Raf/MEK/ERK and PI3K/AKT pathways are immensely complex 
with multiple inputs, outputs, and feedback loops35,39.  Only the basic components of the 
pathways as they relate to Ras-driven signaling are described here. 
RasGTP also has been shown to stimulate additional effector pathways, including but 
not limited to the RalGDS, TIAM1/Rac, and PLCε pathways (Figure 1-2)32,40-45.  The effects of 
Ras activation on vesicle trafficking, cytoskeletal organization, and calcium signaling have been 
attributed to activation of these pathways7.  However, MAPK and PI3K, and to a lesser extent 
RalGDS, are thought to be the pathways that drive cancer, as discussed in the following section. 
 
THE RAS PATHWAY IN CANCER 
RAS is one of the most commonly mutated genes in human cancer; overall, RAS 
mutations are found in approximately 30% of human tumors46.  Each of the predominant three 
RAS isoforms is commonly mutated in a number of tumor types, although the pattern of 
mutation varies between the RAS genes (Table 1-1).  Overall KRAS mutations are most 
common (approximately 22%), followed by NRAS (8%), and HRAS (3%)46.  Oncogenic RAS 
mutations prevent GTP hydrolysis, thus fixing Ras in its active conformation47-51.  Most 
oncogenic RAS mutations involve amino acids 12, 13, or 6152-54.  Amplification of wildtype RAS 
genes also occurs in some tumor types, including in breast and lung cancers16,55-57.  Oncogenic 
RAS transforms immortalized cells in culture58.  More recently, myriad mouse modeling studies 
have confirmed the potent oncogenicity of mutant RAS, both in tumorigenesis overall and in 
specific tumor types via conditional mouse models59.  
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Table 1-1: Frequency of RAS mutations in human cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data from Catalogue of Somatic Mutations in Cancer (COSMIC) database46. 
 
 
The Ras pathway also is aberrantly activated in cancer via misregulation or mutation of 
upstream regulators of Ras (Table 1-2), such as receptor tyrosine kinases, which promote 
growth factor-independent Ras pathway activation and tumorigenesis.  For example, the ERBB 
family receptor tyrosine kinase EGFR is frequently mutated or overexpressed in non-small cell 
lung cancer and most other epithelial cancers60-64.  Hyperactivated EGFR stimulates Ras, MAPK, 
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and PI3K pathways; these pathways contribute to EGFR-driven tumorigenesis, as evidenced by 
the anti-tumor effects MAPK and PI3K inhibition has on these tumors63.  Additionally, the ERBB 
family receptor tyrosine kinase HER2 (ERBB2) is frequently amplified in, and promotes, breast 
cancer65, as will be discussed in more detail below.  Mutations in PDGFR and KIT receptor 
tyrosine kinases also commonly occur in gastrointestinal stromal tumors (GISTs)66.  Clearly, 
RTK activation contributes to Ras pathway activation across many tumor types; notably, many 
therapeutic strategies aim to target RTKs and/or the PI3K and MAPK effector pathways in these 
tumors67. 
 
Table 1-2: Ras pathway aberrations in human cancer 
Ras pathway aberrations that commonly occur in human cancer (data from sources indicated in 
text body). 
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As direct regulators of Ras, one might hypothesize that RasGEFs and RasGAPs could 
play oncogenic and tumor suppressive roles in human cancer, respectively.  Germline mutations 
in the RasGEF SOS1 cause the developmental disorder Noonan syndrome68,69.  Noonan 
patients have an increased risk of developing juvenile myelomonocytic leukemia (JMML)70; 
however, to date there is no evidence of mutations in SOS1 or other RasGEFs in sporadic 
tumors.  In contrast, expanding evidence supports a role for RasGAPs as tumor suppressors 
inactivated in sporadic cancer, as discussed below.  
Aberrant activation of Ras effector pathways, in particular the MAPK and PI3K pathways, 
frequently drives human cancer as well (Table 1-2).  Activating BRAF mutations are found in 
approximately 60% of melanomas as well as in colorectal and other tumor types71.  
Amplification or mutation of PIK3CA (which encodes the p110α catalytic subunit of PI3K) and 
AKT1 and 2 also occur in a variety of human cancers46,72-82.  Further, PTEN is mutated, deleted, 
or inactivated via other mechanisms at a very high rate in human cancer46,83-88; in fact, after p53, 
PTEN is the most commonly inactivated human tumor suppressor gene7.  Together with mouse 
model and cell culture functional studies (described elsewhere), these findings underscore the 
importance of the Ras pathway in cancer and emphasize the pro-tumorigenic roles of both the 
MAPK and PI3K effector pathways.  In Chapter 2 of this Dissertation I discuss how Ras, MAPK, 
and PI3K signaling contribute to breast cancer tumorigenesis and metastasis following 
inactivation of the RasGAP RASAL2.  
 
RAS GTPASE ACTIVATING PROTEINS 
Ras GTPase Activating Proteins, or RasGAPs, are direct negative regulators of Ras16.  
There are fourteen RasGAPs in the human genome; each contains a region of RasGAP domain 
sequence homology89.  RasGAPs catalyze the hydrolysis of RasGTP to RasGDP by increasing 
Ras’s intrinsic GTPase activity 105-fold15,90.  Structural analysis of the GAP domain (of 
p120RasGAP) bound to Ras revealed that a highly conserved arginine residue in the GAP 
	  10 
domain forms an arginine finger that interacts with Ras side-chain II.  Through this interaction 
RasGAPs stabilize the GTP hydrolysis transition state and catalyze the reaction91.  Notably, 
oncogenic mutations in RAS (such as at Glycine 12 and Glutamine 61) prevent RasGAP 
stabilization of the GTP hydrolysis reaction transition state91.  These findings explain why 
RasGAPs are ineffective against mutant Ras (when Trahey and McCormick discovered 
p120RasGAP they noticed but could not explain how p120RasGAP affected the activity of 
wildtype but not mutant Ras16), and highlight the critical role that RasGAPs normally assume in 
attenuating Ras signaling.  
It should be noted that the RasGAPs are a part of a larger group of GAPs for the Ras 
superfamily of small GTPase proteins.  Nearly 200 proteins contain GAP domains and most 
GAP domain containing proteins likely possess catalytic activity92.  The large number of GAP 
proteins in the human genome further emphasizes the importance of this class of regulatory 
proteins92.   
The fourteen human RasGAPs all contain a GAP homology domain but otherwise 
diverge significantly (Figure 1-3).  The RasGAPs can be divided into subfamilies, grouping those 
with more similar overall homology and domain architecture.  I will now discuss each RasGAP in 
turn, highlighting information that has informed our studies of the RasGAP RASAL2, which is 
the focus of this Dissertation. 
 
NF1 
NF1 is one of the most well characterized RasGAP genes, because germline loss of 
NF1 causes an inherited cancer predisposition syndrome, as discussed below.  The protein 
product of NF1, neurofibromin, plays an important role in normal Ras pathway regulation of cell 
cycle progression: growth factor stimulation triggers ubiquitin-mediated proteasomal 
degradation of neurofibromin, which leads to increased levels of RasGTP and drives entry into 
the G1 phase of the cell cycle25.  NF1 is an extremely large gene, comprising 60 exons and  
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Figure 1-3: The human Ras GTPase Activating Proteins 
The domain structures of the 14 human RasGAPs (GTPase Activating Proteins) are shown, 
grouped by subfamily.  p120RasGAP: SH2 and SH3 (Src homology), PH (pleckstrin homology), 
C2 (C2 phospholipid/Ca2+ binding motif), and RasGAP domains.  NF1: RasGAP, Sec14, and PH 
domains.  GAP1 family: C2, RasGAP, and PH/BTK (PH/Bruton’s Tyrosine Kinase) domains.  
SYNGAP family: PH, C2, and RasGAP domains.  IQGAP family: CH (calponin homology, actin 
binding), WW (tryptophan), IQ (calmodulin binding), and RasGAP domains.  PLXNB2: Sema 
(semaphorin binding), IPT/TIG (immunoglobulin-like fold), and RasGAP domains.  Figure 
adapted from89,93. 
 
encoding a 2818-amino acid protein.  Thus, the RasGAP domain of NF1 occupies a small 
fraction (approximately 10%) of the total gene.  NF1 also contains a Sec14 homology domain, 
which is thought to facility lipid binding and localization to the cell membrane, and a pleckstrin 
homology (PH) domain94.  It is currently unknown whether NF1 contains additional regulatory or 
functional domains. 
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Germline loss of NF1 via deletion or loss-of-function mutation underlies 
neurofibromatosis type 1 (NF1)95,96, a familial tumor predisposition syndrome that affects 1 in 
3500 individuals worldwide97.  NF1 patients develop benign plexiform and dermal neurofibromas 
as well as malignant peripheral nerve sheath tumors (MPNSTs).  MPNSTs are aggressive and 
generally inoperable as they often involve nerves.  Radiation and chemotherapy are minimally 
effective and, in the absence of other therapeutic options, MPNSTs can become lethal within 
months.  Therefore, much NF1-related research today focuses on finding a successful therapy 
for MPNSTs.  NF1 patients also have an elevated risk of developing astrocytomas, myeloid 
leukemia, and pheochromocytomas.  Additionally, NF1 patients display development 
abnormalities, including short stature and lower IQ, and develop a range of benign lesions, 
including café-au-lait spots (hyperpigmentation of the skin) and Lisch nodules (benign lesions of 
the iris)97. 
Malignant tumors from NF1 patients exhibit loss of heterozygosity of NF1, through 
somatic mutation or deletion, making NF1 a canonical tumor suppressor gene that adheres to 
the Knudson’s two-hit hypothesis of gene inactivation98-100.  Consistent with neurofibromin’s 
function as a RasGAP, tumors from NF1 patients have elevated Ras pathway activity, and 
aberrant Ras activity drives tumorigenesis101,102.  Downstream of Ras, the PI3K-AKT-mTOR 
pathway is critical for MPNST growth: using a genetically engineered mouse model of MPNST 
development (cis deletion of Nf1 and Trp53, which reside on the same chromosome), our 
laboratory showed that the mTOR inhibitor rapamycin induces a cytostatic response in 
MPNSTs102,103.  Recently, work from our laboratory has shown that this cytostatic response can 
be converted to a cytotoxic response by combining rapamycin with IPI-504, an Hsp90 inhibitor 
and ER stress-inducing agent104.  Notably, combined rapamycin and IPI-504 treatment induces 
tumor shrinkage not only in MPNSTs, but also more broadly among Ras pathway-driven tumor 
types, including in a KRAS mutant lung cancer model104.  These findings suggest that many 
lessons learned studying the biology of RasGAP inactivation can be applied more broadly to 
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Ras-driven tumors, and that RasGAP inactivation provides a useful system in which to study 
Ras activation in a physiologically and biologically relevant setting. 
Interestingly, neurofibromatosis type 1 patient mutations occur not only within the 
RasGAP domain of NF1, including mutation of the arginine finger crucial for GAP activity 
described above, but also throughout the gene105,106.  This finding suggests that neurofibromin 
may have additional non-RasGAP functions, a hypothesis supported by unpublished data from 
our laboratory.  As I discuss below and in Chapter 4 of this Dissertation, we hypothesize that 
many RasGAPs may have additional functions. 
Recently, studies have shown that NF1 also is inactivated somatically in sporadic cancer, 
including in melanoma107-109, glioblastoma110-112, non-small cell lung cancer113, and 
neuroblastoma114 (Table 1-2).  In melanoma, functional studies have further shown that NF1 
loss cooperates with BRAF mutation to drive melanomagenesis, demonstrating a causal role for 
NF1 loss107.  We believe that the clear role neurofibromin inactivation plays in sporadic 
tumorigenesis points to a possible broader role for the RasGAP family as tumor suppressors 
inactivated in sporadic cancer.  Interestingly, in glioblastoma, both mutation of the NF1 gene 
and aberrant proteasomal degradation of the protein contribute to NF1 inactivation110.  As I 
discuss in Chapters 3 and 4 of this Dissertation, we hypothesize that multiple, some non-genetic, 
mechanisms often contribute to RasGAP gene inactivation in sporadic cancer. 
 
DAB2IP 
To date, other than NF1, the only RasGAP confirmed to be a human tumor suppressor 
gene is DAB2IP.  DAB2IP falls in the SYNGAP subfamily of RasGAPs along with SYNGAP1, 
RASAL3, and RASAL2, each of which will be discussed below and the last of which is the focus 
of this Dissertation.  Prior to recent work from our laboratory, there were hints that DAB2IP may 
be inactivated in sporadic cancer and therefore that it might be a tumor suppressor gene.  A 
translocation disrupts DAB2IP in acute myeloid leukemia115.  Additionally, studies suggested 
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that the DAB2IP promoter was hypermethylated in breast, lung, prostate and gastrointestinal 
cancer cell lines, and limited in vitro experiments suggested that the Polycomb group protein 
EZH2 might target DAB2IP, together suggesting that DAB2IP could be epigenetically silenced in 
cancer116-120.  More recently, mutations in DAB2IP have been found in tumors from breast, 
central nervous system, cervix, endometrium, colon, lung, ovary, pancreas, prostate, and upper 
aerodigestive tract tissues46. 
A 2010 publication from our laboratory demonstrated a causal role for DAB2IP 
inactivation in prostate cancer tumorigenesis and metastasis121.  I collaborated with the lead 
author on this study, and a reprint of this manuscript is included in this Dissertation as Appendix 
B.  The key findings for our understanding of DAB2IP and more generally for RasGAPs in 
cancer are discussed here.  Using an orthotopic xenograft prostate tumor model, our laboratory 
found that DAB2IP inactivation increased prostate cancer tumorigenesis and metastasis.  
Specifically, we found that, in prostate cancer cells, DAB2IP inactivation promoted both the Ras 
and NF-κB pathways, through two distinct domains.  Moreover, we found that DAB2IP loss-
mediated Ras activation drove primary tumorigenesis whereas the NF-κB signal was 
responsible for the metastatic phenotype.  Thus, DAB2IP acts as a signaling scaffold and is a 
potent tumor and metastasis suppressor because of its ability to simultaneously regulate 
multiple critical signaling pathways.  We hypothesize that other RasGAPs, particularly those that 
function as human tumor suppressors, also may act as signaling scaffolds and control multiple 
signaling pathways, a concept I will discuss further in Chapter 4 of this Dissertation. 
Our laboratory determined that DAB2IP is inactivated in prostate cancer via epigenetic 
silencing, a possibility hinted to by earlier studies118,120.  The Polycomb group protein EZH2 
(discussed below) is overexpressed in prostate cancer122.  We showed that EZH2 drives 
prostate cancer tumorigenesis and metastasis, that it suppresses DAB2IP, and that EZH2-
mediated suppression of DAB2IP is important for the oncogenic effects of EZH2 in prostate 
cancer.  These findings are noteworthy because they prove a causal role for EZH2 as a driver of 
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prostate cancer and because they show that epigenetic silencing of a RasGAP is a key 
mechanism of prostate tumorigenesis and metastasis.  Epigenetic silencing of RasGAPs is a 
theme I will discuss further in Chapter 3 of this Dissertation.  Lastly, our laboratory showed that 
DAB2IP expression is lost in human tumors, DAB2IP expression decreases with increasing 
tumor grade, and DAB2IP and EZH2 expression inversely correlate in human prostate cancer, 
further supporting the conclusion that DAB2IP loss plays a role in human prostate cancer 
development. 
 
SynGAP1 and RASAL3 
SYNGAP1 (Synaptic GAP 1) and RASAL3 (RAS protein Activator Like 3) are the two 
RasGAPs that along with RASAL2 and DAB2IP complete the SYNGAP subfamily of RasGAPs.  
The SYNGAP subfamily is defined by the presence of pleckstrin homology (PH) and C2 
phospholipid/Ca2+ binding motif (C2) domains preceding the RasGAP domain.  SynGAP1 
expression is restricted to neurons123,124.  SynGAP1 function also is restricted to neurons, where 
it affects synaptic strength and plasticity125.  SynGAP1 is regulated by Ca2+/calmodulin-
dependent protein kinase II126 and, interestingly, it exhibits both RasGAP and RapGAP activity, 
the latter of which is dependent on both its C2 and RasGAP domains127,128.  Syngap1 mutant 
mice display a range of behavioral and learning defects129,130, and human mutation studies have 
linked SYNGAP1 to autism-spectrum disorders and mental retardation131,132.  SynGAP1, 
however, has not been linked to cancer. 
RASAL3 is a newly identified and completely uncharacterized RasGAP.  RASAL3 
appears to be widely expressed, similar to RASAL2 and DAB2IP and unlike SynGAP1’s tissue 
specific expression pattern.  The final RasGAP in this subfamily, RASAL2, is the subject of this 
Dissertation and will be discussed below. 
 
p120RasGAP 
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p120RasGAP (RASA1) was the initial human RasGAP identified15,16.  N-terminal to its 
RasGAP domain, p120RasGAP contains SH2 and SH3 domains, which are thought to facilitate 
receptor tyrosine kinase binding and suggest a scaffolding role for p120RasGAP133-137, as well 
as PH and C2 domains.  Functional data suggest that p120RasGAP may help to remodel the 
actin cytoskeleton138 and affect cell movement139,140.   
Rasa1 (p120RasGAP) null mice are embryonic lethal141.  Lethality is attributed to 
vascular defects that result from defective endothelial cell organization.  Mutations in RASA1 
have been linked to Parkes-Weber syndrome and capillary and arterial defects, further 
suggesting an important role for p120RasGAP in endothelial cell function142-144.  Additionally, a 
recent publication showed that miRNA-mediated suppression of p120RasGAP in endothelial 
cells promoted neovascularization in tumors145.  In epithelial cells, however, there is no evidence 
that p120RasGAP functions as a tumor suppressor.  
 
RASAL1, CAPRI, Gap1m, and GAP1IP4BP 
RASAL1, CAPRI (RASA4), GAP1M (RASA2), and GAP1IP4BP (RASA3) comprise the 
GAP1 family of RasGAPs.  Each has tandem C2 domains, a RasGAP domain, and a PH/BTK 
domain.  Interestingly, RASAL1, CAPRI, and GAP1IP4BP are dual-function Ras- and Rap-
GAPs146.  Furthermore, a recent study discovered that CAPRI can exist as a monomer or a 
homodimer and that its dimerization state determines whether it acts as a RasGAP or 
RapGAP147.  RasGAP dimerization is a focus of Chapter 3 of this Dissertation, in which we 
study the heterodimerization of the RasGAPs RASAL2 and DAB2IP.  CAPRI and RASAL1 are 
calcium-responsive RasGAPs, via their C2 domains (Gap1m and GAP1IP4BP are not)148,149. 
There have been suggestions in the literature that CAPRI and RASAL1 could potentially 
function as tumor suppressors, although to date no evidence shows that inactivation of these 
RasGAPs drives sporadic tumorigenesis.  A 2005 in vitro RNAi screen for tumor suppressor 
genes that could transform immortalized mammary epithelial cells identified CAPRI as a 
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candidate tumor suppressor150.  However, although Rasa4 (Capri) knockout mice display 
immunological defects, no cancer related phenotype has been reported151.  Publicly available 
databases suggest that CAPRI is very rarely mutated in sporadic cancer; two non-synonymous 
missense mutations in CAPRI have been reported (in lung and prostate cancer), and they do 
not reside within a known domain of the protein46.  A second 2005 RNAi-based tumor 
suppressor screen (in immortalized human fibroblasts) indirectly identified RASAL1 as a 
potential tumor suppressor gene.  The transcription factor PITX1 scored in the screen; follow-up 
analyses revealed that RASAL1 is a transcriptional target of PITX1 and that PITX1 exerts its 
tumor suppressive roles at least in part via up-regulation of RASAL1152.  More recent studies 
have found that RASAL1 expression is low in cancer cell lines of a number of tumor types 
including gastric, colon, and liver cancers, that the RASAL1 promoter is hypermethylated in 
tumor samples, and that ectopic RASAL1 exerts some tumor suppressive properties in cancer 
cell lines153-156.  Non-synonymous missense mutations in RASAL1 have been identified at a low 
frequency (1% overall) in tumors from a number of tissue types including lung, endometrium, 
and skin46.  Although far from conclusive evidence identifying RASAL1 or CAPRI inactivation as 
cancer driving, it seems plausible that future studies could reveal such a role; I return to this 
possibility in Chapter 4 of this Dissertation. 
 
IQGAP1, 2, and 3 
Three human RasGAPs fall into the IQGAP subfamily, IQGAP1, IQGAP2, and IQGAP3.  
The IQGAPs contain a calponin homology (CH) actin binding domain, a WW domain, and an IQ 
calmodulin-binding motif.  IQGAPs only contain a C-terminal portion of the canonical RasGAP 
domain; the segment that the IQGAPs contain lacks an arginine finger and thus does not 
display active RasGAP activity157,158.  A recent study found that IQGAPs could bind Ras through 
their truncated RasGAP domain and that acute inactivation of IQGAP3 led to decreased 
RasGTP levels whereas IQGAP3 expression enhanced MAPK pathway activity159.  These 
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findings suggest that IQGAPs may have pro-proliferative effects and imply that IQGAPs could 
potentially have pro-tumorigenic roles in cancer, but are not likely to function as tumor 
suppressor genes. 
 
PLXNB2 
PLXNB2 contains an N-terminal Sema domain through which it serves as a receptor for 
semaphorins160.  The majority of reported PLXNB2 functions relate to its binding of semaphorins, 
including roles in neuronal and kidney development and function161-164.  Although PLXNB2 
contains a region of RasGAP domain homology, whether it is a functional RasGAP and what 
effects this activity might have remain unknown. 
 
Clearly, the RasGAPs remain an understudied family of genes whose role in cancer has 
not been fully explored.  The findings that NF1 is lost not only in neurofibromatosis type 1, but 
also in sporadic cancer, and that DAB2IP is a prostate cancer tumor and metastasis suppressor, 
support our hypothesis that other RasGAPs may also function as tumor suppressors in sporadic 
cancer.  In this Dissertation I identify the RasGAP RASAL2 as the newest tumor suppressor in 
this gene family.  Next, I discuss what was previously known about RASAL2. 
 
RASAL2 
The focus of this Dissertation is RASAL2 (RAS protein Activator Like 2), also called 
nGAP.  RASAL2 is in the SYNGAP subfamily of RasGAPs along with SYNGAP1, DAB2IP, and 
RASAL3, and, until this work, was one of the least studied of all RasGAP genes.  The sole 
publication focused on RASAL2 cloned the gene and indirectly determined the protein to be a 
functional RasGAP by its ability to rescue a heat-shock phenotype in yeast lacking the yeast 
RasGAP Ira2165. 
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The RASAL2 gene is located at chromosome 1q24.  Notably, the 1q chromosome arm 
often undergoes copy number gain in breast and other cancers166,167.  How this copy number 
gain relates to RASAL2 inactivation in cancer is an intriguing concept I discuss in Chapter 4 of 
this Dissertation.  There are two main isoforms of human RASAL2.  Isoform two is slightly 
longer than isoform one; it differs in its first few exons and hence has an entirely different 
proximal promoter region than isoform one (Figure 1-4A).  Our unpublished findings suggest 
that isoform two is the predominantly expressed isoform (data not shown).  Furthermore, the 
one main mouse Rasal2 isoform is orthologous to human isoform two.  Interestingly, the 
promoter of human RASAL2 isoform two contains a highly CpG dinucleotide rich “CpG island”, 
suggesting that this promoter could be subject to hypermethylation, a concept I address in 
Chapter 3 of this Dissertation.  The RASAL2 genomic locus also is predicted to contain a 
RASAL2 antisense RNA (RASAL2 AS1), but what biological function it may have remains 
unexplored (Figure 1-4A). 
The RASAL2 mRNA comprises 18 exons and yields an approximately 150-kilodalton 
protein (Figure 1-4B).  The RASAL2 protein contains pleckstrin homology (PH) and C2 
phospholipid/Ca2+ binding motif (C2) domains N-terminal to its RasGAP domain (Figure 1-4C).  
PH domains have been shown to facilitate a wide range of protein-protein interactions including 
binding phosphotyrosine- and polyproline-containing proteins, as well as interactions with 
phosphatidylinositol in membranes168; however, RASAL2 PH domain function and subcellular 
localization have not been explored.  Additionally, whether the C2 domain of RASAL2 confers 
calcium responsiveness like is true for some but not all C2 domain containing RasGAPs 
remains unknown.  Prior to this work, RASAL2 GAP activity had not been demonstrated in 
mammalian cells; however, as mentioned above, ectopic human RASAL2 had been shown to 
rescue a heat-shock phenotype in yeast lacking a yeast RasGAP, suggesting that RASAL2 is a 
functional RasGAP165.  The PH, C2, and RasGAP domains comprise approximately half of the 
RASAL2 protein; it remains unknown whether RASAL2 contains additional functional domains 
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or motifs.  In Chapter 3 of this Dissertation I identify and study a coiled-coil protein-protein 
interaction motif at the extreme C-terminus of RASAL2 (Figure 1-4C); this finding suggests that 
RASAL2 may have additional functions or at minimum additional regulatory domains. 
 
 
Figure 1-4: RASAL2 
(A) RASAL2 genomic locus on chromosome 1q.  RASAL2 isoforms 1 and 2 and RASAL2 
antisense RNA are indicated.  Image from NCBI (http://www.ncbi.nlm.nih.gov/gene/9462). 
(B) RASAL2 mRNA.  RASAL2 isoform 1 (top) and 2 (bottom) mRNAs are 16 and 18 exons long, 
respectively, with identical final 15 exons.  Un-shaded areas represent 5’ and 3’ UTRs.  Exons 
encoding PH, C2, and RasGAP domains are indicated. 
(C) The RASAL2 protein contains pleckstrin homology (PH), C2 phospholipid/Ca2+ binding (C2), 
and RasGAP domains.  The putative coiled-coil domain (C-C) discussed in Chapters 1 and 3 of 
this Dissertation also is indicated.  The 1280-amino acid long isoform 2 is shown (isoform 1 
contains the same domains but is 1139 amino acids long). 
 
 
RASAL2 is expressed in most tissues and developmental stages, indicating that it may 
function in multiple tissue types, unlike SYNGAP1, whose expression and function are restricted 
to neuronal tissues.  A few publications have identified potential RASAL2-interacting proteins.  
One study searching for protein partners of NF-κB family members found RASAL2 to co-
immunoprecipitate with the inhibitor of NF-κB, IκB-β, in HEK293 cells169.  Additionally, a study of 
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14-3-3-binding proteins reported that RASAL2 interacts with 14-3-3 γ in HEK293 cells170.  
However, the validity and biological significance of these interactions remain unknown.  
Nevertheless, these putative interactions imply potential additional functions for RASAL2, a 
concept addressed in Chapter 4 of this Dissertation. 
In summary, until the work presented in this Dissertation, RASAL2 was a completely 
uncharacterized RasGAP gene with no link to human cancer.  In the following chapters I present 
our findings, which show that RASAL2 is a tumor and metastasis suppressor gene in breast and 
possibly other cancers, and which begin to uncover its biological functions and regulation. 
  
THE MAMMARY GLAND 
The mammary gland is the organ responsible for lactation in mammals (the presence of 
a mammary gland defines mammals and gives the group its name).  The human mammary 
gland consists of a network of ducts that travel from the nipple to terminal ductal lobular units, 
which, interestingly, are where most breast cancers arise171,172.  Of note, the mouse mammary 
gland consists of alveolar buds that form with each estrous cycle instead of terminal ductal 
lobular units, and contains less fibrous tissue and more adipocytes than the human gland172.  
However, despite these structural differences, data suggest that the mouse and human 
mammary glands have similar cellular hierarchies and functions, supporting the utility of mouse 
models of mammary gland development and disease172. 
The mammary gland contains a number of cell types (Figure 1-5A)172.  Luminal epithelial 
cells surround mammary gland duct lumen and range from a single layer to a few layers thick, 
depending on the section of the ductal network.  Myoepithelial cells surround the luminal 
epithelial cells and contract to push milk through the ducts.  Finally, a basement membrane of 
cytoskeletal proteins surrounds the myoepithelial cell layer.  Adipocytes, fibroblasts, and 
macrophages surround the duct.  Although their precise location is not fully known, the vast 
expansion of the duct during puberty and pregnancy, along with other evidence, suggests that 
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mammary stem cells also reside within the mammary gland173.  Mammary stem cells are 
thought to differentiate into the luminal and myoepithelial cell lineages174.  Exactly what marks 
these cells remains an issue of debate and investigation.  Mammary stem cells are believed to 
lack expression of estrogen receptor, progesterone receptor, and HER2. 
 
 
Figure 1-5: The mammary gland in normal biology and malignant progression  
(A) The normal mammary gland comprises luminal epithelial cells that line the lumen of the 
ducts.  Myoepithelial cells and basement membrane surround the luminal epithelial cells.  The 
glad also contains adipocytes, fibroblasts, and macrophages (not shown).  Figure adapted 
from172. 
(B) The stages of breast cancer progression: normal duct, ductal carcinoma in situ (DCIS), 
invasive carcinoma, and metastatic disease.  Description of stages in text.  Figure from175. 
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Estrogen and the estrogen receptor 
The primary hormone that controls mammary gland structure and function is estrogen, a 
steroid hormone that is synthesized from cholesterol via a series of enzymatic reactions. 
Estrogen is critical for sexual and reproductive function, but also plays a significant role 
elsewhere in the body, including in the cardiovascular, musculoskeletal, and immune 
systems176,177. 
Estrogen exerts its effects via binding the estrogen receptor (ER).  There are two human 
estrogen receptors, ERα and ERβ, which are encoded by different genes (ESR1 and ESR2), 
and which data suggest have different activities178.  ERα is the predominant ER responsible for 
the canonical effects of estrogen and is the ER known to play a causal role in breast cancer; 
therefore, in this Dissertation I will not further discuss ERβ.  ERα is expressed in reproductive 
organs as well as in other tissue types including muscle, bone, adrenal gland, pituitary gland, 
and spleen, as might be expected given its role in many organ systems.  Within the mammary 
gland, ERα is expressed in many luminal mammary epithelial cells and is essential for 
mammary gland development: Esr1 (ERα) knockout mice fail to fully develop mammary gland 
ductal trees179-181. 
ERα is a nuclear hormone receptor that in the absence of ligand resides in the 
cytoplasm and at the cell membrane182.  Ligand binding induces a conformation change that 
leads to ERα dimerization and activation.  Activated ERα dimers travel to the nucleus and bind 
target DNA at estrogen response elements, which typically are in non-promoter (enhancer) 
genomic regions.  ERα regulates thousands of genes, the so-called ERα cistrome, and recruits 
a variety of co-factors to promote (or repress) transcription in a context-specific manner183,184.  
ERα also affects transcription through its interaction with other DNA-binding transcription factors, 
including NF-κB, AP1, and SP1185.  ERα-driven transcription promotes cell growth and survival, 
and ERα-positive cells are dependent on its activity for these properties.  
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In addition to its canonical activity as a ligand-activated transcription factor, ERα can be 
activated in a ligand-independent manner: activated ERK and AKT have been shown to 
phosphorylate and activate ERα, leading to ERα-driven transcription186-188.  Additionally, within 
minutes of estrogen stimulation, ERα elicits rapid “non-genomic” effects.  These effects include 
activation of receptor tyrosine kinases (HER2, EGFR, IGF1R, SRC), eNOS, MAPK, and PI3K, 
which drive additional transcriptional programs189-194.  The crosstalk between ERα and the 
MAPK and PI3K pathways is something I will discuss further in Chapters 3 and 4 of this 
Dissertation. 
 
BREAST CANCER 
Breast cancer is the most common cancer in women both worldwide and in the United 
States, where there were approximately 230,000 new cases in 2012 and 40,000 deaths195.  
Individuals with family members afflicted by the disease have an elevated risk, suggesting a 
genetic component.  Mutations in the breast cancer predisposition genes BRCA1, BRCA2, and 
TP53 account for less than one quarter of this elevated risk, pointing to additional contributions 
from other genes and pathways175. 
Breast cancer develops through a series of distinct stages, beginning with pre-malignant 
atypical ductal hyperplasia, or aberrant proliferation of cells in the mammary duct (Figure 1-
5B)175.  The first malignant stage of breast cancer is ductal carcinoma in situ (DCIS), which is 
characterized by ducts filled with abnormal-looking cells, but an intact myoepithelial layer and 
basement membrane.  Loss of the myoepithelial layer and basement membrane marks and is 
thought to contribute to progression from DCIS to invasive carcinoma.  Tumor cells that invade 
the stroma and travel to metastatic sites yield the most advanced stage, metastatic disease. 
Breast cancer is a heterogeneous disease, both in terms of molecular underpinnings and 
clinical outcome.  Histopathologically, breast cancers can be divided into a number of types, 
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including invasive ductal, invasive lobular, cribriform, mucinous, and medullary carcinomas196.  
Approximately 80% of tumors are invasive ductal carcinomas (IDC), a category comprised of 
tumors not otherwise specified to another histopathological group196.  Therefore, it is not 
surprising that IDCs themselves are heterogeneous.  Beginning in the early 2000s, a number of 
groups performed microarray analyses of primary IDCs197-202.  Hierarchical clustering of primary 
tumor expression profiles revealed four major IDC subtypes: luminal A, luminal B, HER2-
enriched, and basal-like (Table 1-3).  The tumor subtypes have distinct prognoses (Figure 1-
6)201,203; furthermore, our understanding of the biology underlying each subtype has led to 
separate treatment strategies, thus improving our management of the disease.  I will now briefly 
discuss each subtype. 
 
 
Figure 1-6: Outcomes of breast cancer subtypes 
Kaplan-meier curves showing metastasis-free survival (A) and overall survival (B) in two 
different cohorts of breast cancer patients (A – van’t Veer, B – Norway), divided by breast 
cancer subtype.  dark blue: luminal A, light blue: luminal B, pink: HER2-enriched (“ERBB2”), 
red: basal-like.  Breast cancer subtypes predict statistically significant differences in outcome.  
Figure adapted from201. 
 
 
Luminal breast cancers 
Hierarchical clustering of primary breast tumor mRNA expression profiles clusters 70% 
of tumors into the “luminal” subtype, named because many of the highly-expressed genes in 
these tumors are expressed in normal luminal epithelial cells in the mammary gland197,198.  
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Whether luminal tumors derive from normal luminal mammary epithelial cells, however, is a 
highly debated issue beyond the scope of this Dissertation.  Luminal tumors typically express 
ERα and ERα-driven gene expression is thought to drive the mRNA expression signature that 
defines this group197,203,204.  ERα-positive luminal tumors depend on ERα expression for growth.  
Further, human tumor and molecular biology data indicate that ERα activity plays a causal role 
in the development of ERα-positive breast tumors: sustained exposure to estrogen is a well-
established cause of breast cancer (its carcinogenic properties have been appreciated for over 
a century), and estrogen exerts its effects via the estrogen receptor, in particular ERα205.  As in 
the normal mammary gland, ERα in breast cancer cells regulates many genes206,207.  Its control 
of MYC (Myc) and CCND1 (Cyclin D1) in particular, however, are thought to contribute to breast 
tumorigenesis183.  
 
Table 1-3: Breast cancer subtypes 
Incidence, ER and HER2 status (ER-positivity, HER2-overexpression), mRNA signature, and 
therapeutic strategy for luminal A, luminal B, HER2-enriched, and basal-like breast cancer 
subtypes.  *: Data from56.  **: Data from208.  ***: for BRCA mutant patients only. 
 
The luminal tumor subtype itself is heterogeneous, and expression profiling sub-divides 
luminal tumors into A and B groups (Table 1-3).  The majority of luminal tumors are type A and 
overall have the best prognosis of breast cancer subtypes, with 5-year survival rates of over 
eighty percent198,201.  Luminal B tumors are more highly proliferative than luminal A tumors and 
have poorer prognoses198,201.  They also often overexpress the HER2 receptor tyrosine 
kinase203.  HER2-overexpressing luminal B tumors exhibit elevated ERα activity due to crosstalk 
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between the pathways; HER2 signaling is thought to promote ERα activity at least in part via 
ERK and AKT downstream of Ras186-188. 
For over a century, because of estrogen’s causal role in tumorigenesis, physicians have 
attempted to treat breast cancers by counteracting the effects of estrogen signaling.  Anti-
estrogen therapy has progressed from ovary removal in the early 1900s to the 1970s, when 
physicians began treating patients with drugs that specifically block estrogen action185.  In fact, 
anti-estrogen therapy was the first successful targeted therapy for cancer209.  Today, anti-
estrogen therapy remains the standard of care for patients with ERα-positive disease.  Most 
patients are treated with tamoxifen, a Selective Estrogen Receptor Modulator that competitively 
binds ER and acts as an estrogen antagonist210.  Aromatase inhibitors, which inhibit the final 
step in estrogen biosynthesis, are also used in the clinic.  Luminal B tumors generally respond 
less well to anti-estrogen therapies, likely because of HER2-driven ERα pathway activity211.  
Patients with luminal B disease typically receive chemotherapy in addition to anti-estrogen 
therapy because of the poorer response to anti-ER therapies and because the greater 
proliferative index leads to a better response to chemotherapy. 
Approximately one-third of women treated with the standard tamoxifen regimen relapse 
with endocrine resistant disease within 15 years210.  Given that ~70% of breast cancers are 
ERα-positive, the patients that develop anti-ER-resistant tumors represent nearly one-quarter of 
all breast cancer cases185.  Thus, much research has gone into identifying mechanisms of 
resistance to endocrine therapies, predicting which tumors will become resistant, and 
determining how to prevent resistance or treat resistant tumors.  Acquired resistance to 
tamoxifen often occurs at long latency, which presents unique challenges for determining 
mechanisms of resistance in patients185.  Current proposed mechanisms of acquired resistance 
fall into a few categories: alternative activation of ERα signaling, activation of receptor tyrosine 
kinase signaling pathways, and up-regulation of ERα transcriptional targets; each mechanism 
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would allow cells to promote proliferation and survival in an alternative or additional way than 
through ERα185,208,212,213.   
 
HER2-enriched breast cancers 
Ten to twenty percent of breast cancers overexpress the receptor tyrosine kinase (RTK) 
HER2 (also called ERBB2), but are ERα-negative.  These tumors group by molecular profile 
and comprise the “HER2-enriched” or “ERBB2” subtype (Table 1-3)197,198.  HER2 
overexpression not only defines the subtype, but also defines tumor biology, as these tumors 
are dependent on HER2 signaling.  HER2 amplification or transcriptional up-regulation drives 
overexpression (HER2 mutations occur less frequently214)65,215.  HER2 is an ERBB family 
receptor tyrosine kinase.  Generally, ligand binding of ERBB family RTKs triggers receptor 
dimerization, which in turn leads to activation of tyrosine kinase activity, phosphorylation, and 
downstream signal transduction216.  Ligands have been identified for the other ERBB RTKs; 
however, after much searching, researchers concluded that there is no ligand for HER2 and that 
unlike the other ERBBs, HER2 remains in a conformation open for dimerization217.  HER2 can 
dimerize with EGFR, ERBB3, or ERBB4.  Activated ERBB dimers trigger many downstream 
signaling cascades, including the Ras pathway (via the GRB2 adaptor and the RasGEF SOS), 
the Jak/STAT pathway, and direct activation of PI3K216,218.  HER2-induced Ras pathway 
activation in breast cancer will be discussed in more detail below. 
HER2 tumors are aggressive and have a poor prognosis198,201, although recent advances 
in targeted therapies have significantly improved patient outcomes219.  Today, the most widely 
used anti-HER2 therapies are trastuzumab and lapatinib.  Trastuzumab is a monoclonal 
antibody that binds the extracellular domain of HER2220; its mechanism of action remains 
unclear but may involve preventing dimerization with other ERBB family RTKs, antibody-
dependent cellular cytotoxicity, or induction of cell cycle arrest or apoptosis, among a number of 
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proposed mechanisms221,222.  Lapatinib is a reversible inhibitor of intracellular kinase activity of 
both HER2 and EGFR223-225.  Although lapatinib has more potent anti-HER2 effects in vitro226,227, 
trastuzumab has been more successful in vivo228, perhaps because of the anti-tumor immune 
response it elicits.  Both treatments are typically given in combination with chemotherapy.  Many 
new targeted therapies are in clinical trials or pre-clinical development, including 
trastuzumab/lapatinib combination therapy (which seems to outperform either drug alone)229, 
irreversible EGFR/HER2 inhibitors, and anti-HER2 antibodies tethered with toxins to deliver 
both the antibody and toxic agent specifically to HER2-overexpressing cells208,219. 
Although HER2 targeted therapies are highly successful, tumors typically relapse.  
Mechanisms of de novo and acquired resistance are thought to fall into a few broad 
categories219.  Overexpression or dependence on other ERBB RTKs, including overexpression 
of EGFR and ERBB3, overexpression of TGFα (an EGFR ligand), and expression of a fragment 
of HER2 that prevents trastuzumab binding, can cause resistance.  Second, increased signaling 
through pathways downstream of HER2 or other growth-promoting pathways may cause 
resistance, such as could occur via PIK3CA mutation or PTEN loss.  However, to date there is a 
lack of patient data showing that this mechanism occurs in human tumors.  Third, increased 
expression of ERα, via lapatinib-induced ERα transcription, can confer resistance (lapatinib 
treatment causes a decrease in phosphorylated AKT; as a result FOXO3 remains 
dephosphorylated and in the nucleus where it promotes ERα transcription)230.  In Chapter 4 of 
this Dissertation I discuss the hypothesis that RASAL2 inactivation may contribute to resistance 
to anti-HER2 and/or anti-estrogen therapies in breast cancer patients. 
 
Basal-like breast cancers 
Ten to twenty percent of breast cancers are categorized as “basal-like” because 
molecular profiling revealed that many highly expressed genes in these tumors are commonly 
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expressed in normal mammary myoepithelial cells197,198.  Again, whether basal-like tumors 
originate from basal cells remains an open question, beyond the scope of this Dissertation231.  
The basal-like subtype of breast cancers is morphologically and clinically heterogeneous232.  
The majority of basal-like tumors lack expression of ERα and the progesterone receptor, and do 
not overexpress HER2 (Table 1-3).  Therefore, they are often called “triple negative”.  Basal-like 
tumors also have a high rate of TP53 mutations56.  Due to the absence of therapeutic targets, 
basal-like disease is treated with chemotherapy203.  Basal-like tumors have a poor prognosis 
and are highly proliferative.  Likely due to their high proliferative index, tumors often respond 
well to chemotherapy, however, there is also a high rate of early relapse. 
Individuals who inherit (or somatically acquire) mutations in the breast cancer 
predisposition genes BRCA1 and BRCA2 develop basal-like tumors201,233.  A “targeted” therapy 
now exists for BRCA patients, taking advantage of the fact that BRCA1 and 2 are DNA repair 
proteins.  Patients are given PARP inhibitors; PARP inhibition induces cell death in the context 
of BRCA mutations because double-stranded breaks arise that the cell cannot repair208,232. 
 
Mouse models of breast cancer 
 Many genetically engineered mouse models (GEMM) have been generated to study 
breast cancer234, including GEMM that overexpress implicated breast cancer oncogenes, such 
as MYC or HER2, or lack implicated breast cancer tumor suppressor genes, such as TP53 or 
BRCA1.  These and other models have provided valuable in vivo insight into breast 
tumorigenesis.  Many transgenic models utilize the Wap (whey acidic protein) or MMTV (mouse 
mammary tumor virus) promoters, which drive transcription primarily, but not exclusively, in the 
mammary gland.  Wap and MMTV are hormonally regulated, so transgene expression levels 
increase with pregnancy and lactation.  It also should be noted that different inbred mouse 
strains have vastly different susceptibilities to breast cancer, from highly prone FVB and BALB/c 
	  31 
strains to highly resistant C57BL6/J235.  These and other factors significantly alter tumor 
phenotypes. 
 Most GEMM of luminal breast cancers are ERα-negative236.  Recently, however, GEMM 
of ERα-positive disease have been generated, including mice that ectopically express ERα, 
aromatase (the enzyme that catalyzes the final step in estrogen biosynthesis), or AIB1 (an ERα 
co-activator) in the mammary epithelium237. 
 
HER2 mouse models of breast cancer 
 The first of many GEMM of HER2-driven breast cancer, published in 1988, consisted of 
MMTV-driven expression of a constitutively active mutant version of the rat HER2, called Neu 
(MMTV-Neu-NT)238.  By three months of age, MMTV-Neu-NT mice develop multi-focal 
mammary tumors that involve the entire mammary gland.  This model demonstrated the ability 
of HER2-driven signaling to induce mammary tumors in mice.  However, HER2 is rarely 
mutated in human breast tumors; typically it is amplified and overexpressed239.  Therefore, a 
second Neu transgenic model was generated, also using the MMTV promoter, but ectopically 
expressing wildtype Neu (MMTV-Neu)240.  MMTV-Neu animals develop focal mammary tumors 
at a longer latency (median seven months on an FVB background), and a fraction of tumor-
bearing females develop lung metastases.  Interestingly, tumors from MMTV-Neu mice are 
luminal-like (but ERα-negative).  I utilize this GEMM to explore the role of Rasal2 loss in breast 
cancer, as will be discussed in Chapter 2 of this Dissertation. 
 
Models of breast cancer metastasis 
 Researchers have used a combination of cell culture, xenograft, and genetic mouse 
models to study mechanisms of breast cancer metastasis.  In Chapter 2 of this Dissertation I 
utilize a xenograft model of progression from DCIS to invasive carcinoma.  In this model, 
	  32 
injected cells form DCIS-like tumors that over time progress to invasive carcinoma241,242.  A 
number of orthotopic xenograft systems exist in which tumor cells preferentially metastasize to 
one distal site, such as bone243,244.  Xenograft models present certain advantages, such as the 
ease with which genetic manipulations can be made.  Genetically engineered mouse models 
(GEMM) present a rigorous and complementary approach to study the biology of tumor 
progression and metastasis in vivo.  Most metastatic breast cancer GEMM solely develop lung 
metastases245.  Lymph node metastases also have been reported in a few instances, as well as 
liver metastases (in mammary-specific Trp53 mutant mice)245.  Human breast cancers 
frequently metastasize to the lung; however, they also commonly metastasize to many other 
organs (Figure 1-7)196.  Clearly, the field is lacking GEMM of these metastases.  In Chapter 2 of 
this Dissertation I report a new GEMM of breast cancer that metastasizes to the lung as well as 
to brain, kidney, gastrointestinal tract, and ovary, all organs to which human tumors metastasize 
but which to date have not been reported as metastatic sites in breast cancer GEMM. 
 
 
 
 
 
 
 
 
 
 
 Figure 1-7: Sites of human breast cancer metastasis 
Percentage of cases with metastasis to indicated sites.  Figure adapted from196. 
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MOLECULAR BIOLOGY OF METASTASIS 
 Cancer metastasis accounts for up to 90% of cancer deaths246.  Thus, the imperative is 
high to better understand how metastasis occurs so that it can be prevented and effectively 
treated.  It is now appreciated that metastasis involves a series of steps: tumor cells must 
invade the local microenvironment, intravasate into the bloodstream or lymphatic system, 
survive in circulation, extravasate into a distant organ, and survive and grow from a 
micrometastasis to a frank metastatic lesion247.  In the field, researchers are working to identify 
properties of tumor cells that might allow the cells to undergo each of these steps.  Researchers 
have demonstrated that the initial phases of the metastatic process require tumor cells to detach 
from adjacent cells, acquire motility, and invade through the surrounding stroma to the 
bloodstream or lymphatic system247.  In Chapter 2 of this Dissertation I explore the contribution 
of RASAL2 inactivation to the acquisition of these pro-metastatic properties in the context of 
breast cancer metastasis.  Primary tumors of different organs preferentially metastasize to 
different sites; why this occurs is not known.  Developing models of metastasis to biologically 
relevant organs should help to answer this question and may lead to better preventative and 
therapeutic strategies.  As noted above, in Chapter 2 of this Dissertation I also develop a model 
of breast cancer metastasis that we expect will improve the field’s understanding of the disease. 
   
Breast cancer metastasis 
 Ten to fifteen percent of breast cancer patients develop metastatic disease within three 
years of diagnoses; many others develop metastases ten or more years later.  The median 
survival of breast cancer patients with metastatic disease is only two to four years; thus there is 
a clear need to improve our understanding and treatment of metastatic breast cancer203.  
Metastatic breast cancer develops following the progression from ductal carcinoma in situ 
(DCIS) to invasive carcinoma and the invasion of tumor cells through the stroma into 
circulation234.  Clinicians first can detect disseminated tumor cells in proximal lymph nodes, the 
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presence of which predicts increased risk for distant metastases196.  Breast cancers most often 
metastasize to lung, bone, and liver, but frequently metastasize to many other sites as well 
(Figure 1-7)196. 
 Breast cancer metastasis research efforts have implicated a number of genes and 
pathways in the metastatic process.  First, the different breast cancer subtypes have different 
metastatic propensities and outcomes (Figure 1-6); however, it is not fully understood what 
genes drive these biological differences203.  Expression profiling studies of primary tumors and 
paired metastases have identified poor prognosis or metastasis gene signatures248, although 
again, whether the identified genes and pathways merely mark or also drive metastatic disease 
remains unclear.  Some functional studies have implicated specific genes or pathways in driving 
breast cancer metastasis, such as the MYC oncogene.  Linkage analyses identified MYC as a 
driver of a breast cancer poor prognosis (metastasis) signature, and the authors further found 
that acute inactivation of MYC suppressed invasion and metastasis in MDA-MB-231 cells249.  
 Recent data also have pointed to a role for the tumor stroma and systemic 
microenvironment in progression and metastasis250,251.  Studies have found genetic alterations 
in breast cancer myoepithelial cells, including alterations in secreted factors250.  Functional 
studies also have shown that alterations in tumor stroma or systemic microenvironment can 
influence primary tumor progression242,252,253.  Thus it will be important to continue to study both 
the primary tumor as well as to consider the role of the local and systemic microenvironments in 
progression. 
 
The Ras pathway in metastasis 
The contribution of the Ras pathway to primary tumor development is well established.  
In contrast, the role of Ras signaling in tumor progression and metastasis is less clear254,255.  
Oncogenic Ras can confer some pro-metastatic properties on cells in vitro: oncogenic Ras has 
been shown to increase cell motility through alterations in actin organization and polymerization, 
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up-regulate mesenchymal proteins associated with enhanced migratory potential, and decrease 
cell-cell adhesion and E-Cadherin expression256-259.  Oncogenic Ras also has been shown to 
decrease cell attachment to extracellular matrix, enhance survival of cells detached from the 
extracellular matrix, and promote expression of extracellular matrix proteases, each of which 
could help cells invade surrounding normal tissue260,261.  Further, oncogenic Ras-expressing 
NIH3T3 fibroblasts metastasize to the lung when injected into the tail vein of nude mice262.  
Many other published studies that discuss the Ras pathway and metastasis focus on the Ras 
pathway promoting metastasis in combination with other signaling pathways that themselves 
are better appreciated for roles in metastatic progression, such as the TGF-β pathway, thus 
making it difficult to draw conclusions about what contribution the Ras pathway itself may be 
making263,264.   
Focusing on clinical data, one would expect to see enrichment for RAS mutations or Ras 
pathway activity in metastatic tumors, a correlation between Ras pathway activity and 
increasing tumor stage, and/or the ability of Ras pathway activity to predict outcome, if the Ras 
pathway contributes to tumor metastasis.  However, available clinical data show conflicting 
results, perhaps because of the methods used to call tumors RAS mutant or wildtype265.  
Furthermore, these studies focused on RAS mutations, and did not consider other mechanisms 
of Ras pathway activation.  Clearly, many questions remain regarding whether and how the Ras 
pathway drives metastasis.  As discussed below and in Chapter 2 of this Dissertation, our 
findings suggest that RASAL2 inactivation activates the Ras pathway and promotes metastasis 
in breast and other tumor types. 
 
THE RAS PATHWAY IN BREAST CANCER DEVELOPMENT AND METASTASIS 
Although RAS is one of the most commonly mutated genes across all human cancers, 
RAS is rarely mutated in breast cancer: RAS mutations are found in only 3.2% of breast cancers 
(1.8% KRAS, 0.5% HRAS, 0.9% NRAS) (Table 1-4)46.  Despite the dearth of RAS mutations, 
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the Ras pathway is frequently hyperactivated in breast cancer.  Common activation of the Ras 
pathway in breast cancer first was noted in the late 1990s, when researchers looked in primary 
breast tumor samples and found elevated phospho-ERK levels and ERK activity in over 50% of 
tumors analyzed, as compared to normal mammary tissue266-268.  Subsequently, von Lintig et al. 
directly assessed RasGTP levels, as well as phospho-ERK, and found both to be elevated in 
more than half of the tumor tissues analyzed269.  More recently, Loboda et al. derived a Ras 
pathway gene signature (across tumor types) and found that this signature was high in 30% of 
breast cancer cell lines, of which very few were RAS mutant, and that phospho-ERK and 
phospho-MEK levels correlated with the Ras-ON signature270. 
 
Table 1-4: Ras pathway aberrations in breast cancer 
 
 
 
 
 
 
 
 
 
 
Common aberrations in RAS genes, upstream regulators, and downstream effectors in human 
breast cancers.  Mutation frequencies as reported in the COSMIC database46.  *: Data from56.  
Note, mutation, amplification, and deletions frequencies vary across breast cancer subtypes; 
overall frequencies are reported here. 
 
 
 
Overexpression of oncogenic RAS transforms immortalized mammary epithelial cells 
and promotes anchorage-independent growth and xenograft tumor formation271.  Mouse 
modeling studies further have shown that Ras can drive mammary tumorigenesis: animals with 
mammary-specific expression of an oncogenic HRAS transgene develop mammary tumors272.  
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However, as RAS mutations are rare in breast cancer, overexpression of a RAS oncogene may 
not be an appropriate model to study Ras pathway driven breast tumorigenesis.  
The mechanism of Ras pathway activation in breast cancer remains an unanswered 
question.  Recent genomic studies have begun to identify some genetic alterations in tumors 
that would be expected to lead to Ras pathway activation or activation of downstream effector 
pathways (Table 1-4).  Wildtype KRAS is amplified in approximately 6% of human breast 
cancers (typically basal-like tumors)55,56.  Interestingly, NF1 is mutated in 2% of tumors as well56.  
Amplification of HER2 (ERBB2) occurs in 20-30% of breast cancers (HER2 mutations also are 
found, albeit infrequently); as a receptor tyrosine kinase upstream of Ras, HER2 amplification 
would be expected to promote Ras pathway activity.  The mouse model data presented in 
Chapter 2 of this Dissertation show that RASAL2 loss and HER2 gain cooperate in mammary 
tumorigenesis; in Chapter 4 of this Dissertation I explore the hypothesis that the positive HER2 
signal might need loss of the negative RASAL2 signal to fully drive Ras pathway activation.   
Downstream of Ras, mutations in MAPK and PI3K pathway members also have been 
identified in breast cancers (Table 1-4).  PIK3CA (which encodes PI3K p110α subunit) is 
mutated in approximately 25% of breast cancers46.  Mutations in PTEN, AKT1, PIK3R1, and 
BRAF also have been reported, although at frequencies of less than 5%46,55,273.  Based on our 
current knowledge, it seems that additional, currently un-described mechanisms likely contribute 
to Ras pathway activation in breast cancer.  In Chapter 2 of this Dissertation I show data 
supporting the hypothesis that RASAL2 inactivation is a major mechanism by which the Ras 
pathway is activated in breast cancer. 
The above studies focused on primary tumor development.  The connection between the 
Ras pathway and breast cancer metastasis remains poorly explored and fully unanswered (as 
mentioned previously, the contribution of Ras to metastasis across tumor types also remains 
unclear).  One of the initial studies that demonstrated MAPK pathway activation in breast tumors 
also noted trends of higher MAPK activity in lymph node positive breast cancers as compared to 
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node negative, and of higher MAPK activity in tumors from patients who relapsed versus those 
who did not268.  These findings suggest that the Ras pathway may contribute to metastasis.  
Oncogenic HRAS-mediated transformation of an immortalized mammary epithelial cell 
population promotes lung metastasis from orthotopic xenograft tumors274.  Additionally, the 
mammary tumors that develop in MMTV-Ha-Ras mice (described above) are locally invasive 
and occasionally metastasize to lung and liver272.  However, these studies utilize overexpression 
of the HRAS oncogene, and thus do not recapitulate biologically relevant mechanisms of Ras 
pathway activation in breast cancer.  Looking more generally, in the field, most xenograft 
studies investigating mechanisms of breast cancer metastasis utilize the metastatic MDA-MB-
231 cells275-277.  These cells harbor an oncogenic KRAS mutation; therefore, experiments using 
these cells are not designed to assess the contribution the Ras pathway may make to the 
metastatic process.  Thus, it remains an open question to what extent the Ras pathway drives 
breast cancer metastasis.  Our findings in Chapter 2 of this Dissertation suggest that Ras 
pathway activation, as mediated by loss of the RasGAP RASAL2 in conjunction with HER2 
overexpression, potently drives breast cancer metastasis. 
 
P53 
TP53 is a widely-known tumor suppressor gene278.  Under normal circumstances, 
ubiquitin-mediated proteasomal degradation keeps cellular levels of p53 protein low.  Under 
conditions of damage or stress, however, the mechanisms that normally keep p53 levels low 
subside and p53 levels spike.  p53 is a transcription factor, and accumulated p53 protein 
following stress or damage sets off the p53 transcriptional program, which can lead to cell cycle 
arrest, apoptosis, or senescence, depending on the context279.  These responses comprise a 
central component of a cell’s natural anti-cancer defense.  In fact, p53 is the most commonly 
altered gene in human cancer.  A variety of mechanisms, including mutation, deletion, and 
aberrant proteasomal degradation, disrupt p53 function in cancer280-283.  Additionally, germline 
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mutation of TP53 causes Li-Fraumeni syndrome, which is characterized by broad, early-onset 
tumorigenesis284,285.  
Trp53 mutant mice also are broadly tumor prone286,287.  Genetic strain background alters 
the tumor phenotype that Trp53 mutant mice develop286.  On a mixed B6/129 background, 
Trp53 homozygous mutant animals develop mostly lymphomas, but also sarcomas, and die at 
three to six months of age287.  Trp53 heterozygous mutant mice also are broadly tumor prone 
but their tumor spectrum differs from that of homozygotes287,288.  p53 heterozygotes develop 
lymphomas, osteo- and other sarcomas, and, at a low incidence, carcinomas, including of the 
lung and mammary gland.  p53 heterozygotes live ten to 24 months.  Notably, their tumors 
rarely metastasize289. 
RAS mutations and p53 inactivation both occur at a high frequency in human cancers, 
and are found in overlapping sets of tumors.  Numerous mouse models, including Kras/Trp53-
driven non-small cell lung cancer and pancreatic cancer models290,291, have demonstrated that 
Ras and p53 (loss-of-function) cooperate to promote tumorigenesis59.  In the mouse genome, 
Trp53 is located close to Nf1 on the same chromosome.  Cis deletion of Trp53 and Nf1 leads to 
the development of malignant peripheral nerve sheath tumors, the malignant tumor type 
neurofibromatosis type 1 patients develop (loss of heterozygosity of both Trp53 and Nf1 occurs 
in the tumors) 292,293.  This finding shows that loss of p53 also can cooperate with loss of a 
RasGAP to drive tumorigenesis.  In Chapter 2 of this Dissertation I investigate the broad role of 
RASAL2 loss in tumorigenesis and metastasis through the generation and analysis of Trp53, 
Rasal2 compound mutant mice. 
 
EPIGENETICS 
Epigenetics is the study of heritable changes in gene expression that do not result from 
alterations in the DNA sequence.  Multiple mechanisms of non-genetic gene regulation fall 
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under the category of epigenetics.  However, here I will focus only on those that are relevant to 
this Dissertation, namely histone modification by Polycomb group proteins and DNA methylation.  
 
Polycomb group protein-mediated gene silencing 
Covalent modification of specific histone residues by chromatin modifying enzymes 
contributes to epigenetic regulation by altering the chromatin state and consequently the ability 
of transcription factors to access DNA294,295.  Histone acetyltransferases acetylate lysine 
residues on histone proteins, a modification that generally opens chromatin, allows transcription 
factor access, and promotes gene expression.  Histone acetyl marks can be removed by 
histone deacetylases.  Additionally, histones lysine residues can be modified by methylation, 
carried out by histone methyltransferases, which attach one, two, or three methyl groups to a 
lysine, yielding a mono-, di-, or tri-methylated residue.  Depending on the lysine residue, 
methylation marks can have activating or repressing effects on gene expression.  For example, 
methylation of histone H3 lysines 4 and 36 positively regulates gene expression, whereas di- 
and tri-methylation of histone H3 lysine 27 has a repressive effect296.  Histone methyl marks can 
be removed by histone demethylases.  Additional histone modifications include ubiquitination 
and phosphorylation, which are attached to histone proteins by ubiquitin ligase enzymes and 
kinases, respectively294. 
Two multi-protein complexes carry out epigenetic silencing via histone modification, 
Polycomb Repressive Complexes (PRCs) 1 and 2.  The PRCs first were identified for their roles 
in homeobox gene silencing during differentiation297.  PRCs are essential for embryonic 
development and cell differentiation, and appear to play a role in the maintenance of stem cell-
like states298.  Today, it is well appreciated that aberrant PRC-mediated gene silencing plays a 
major role in cancer299; the cancer cell epigenome differs widely from that of normal cells and 
epigenetic changes alter expression of many genes that drive malignant transformation295.    
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PRC2 contains three core component proteins: EZH2, EED, and SUZ12.  Its catalytic 
member, EZH2, is a histone methyltransferase that tri-methylates histone H3 at lysine 27, 
suppressing gene expression.  EZH2 is found to be overexpressed in many cancers, including 
breast and prostate, where its expression positively correlates with more advanced disease and 
poorer prognosis122,300,301.  Thus, EZH2 is believed to play an oncogenic role in many tumor 
types.  EZH2/PRC2 is thought to have many target genes; perhaps up to 10% of the genome in 
embryonic stem cells302.  Identifying key direct targets, such as tumor suppressor genes whose 
suppression contributes to malignancy, is an important next step in our understanding of 
epigenetics and cancer.  Recently, our laboratory showed that the RasGAP DAB2IP is a key 
EZH2 target in prostate cancer: DAB2IP suppression mediates many of the tumorigenic effects 
of EZH2121.   
In breast cancer, however, the role of EZH2 in tumor development and progression and 
its mechanism of action in driving these processes are not fully understood.  As briefly 
mentioned above, EZH2 is overexpressed in breast tumors and higher expression correlates 
with more advanced disease, increased cellular proliferation, and other markers of aggressive 
disease301,303.  Overexpression of EZH2 in immortalized mammary epithelial cells promotes 
anchorage-independent growth and invasion in vitro300.  Mice genetically engineered to 
overexpress EZH2 in the mammary epithelium develop intraductal epithelial hyperplasia, albeit 
without a reported cancer phenotype304.  Additionally, overexpression of EZH2 in a primary 
breast cancer cell population enriched for tumor initiating cells inhibits DNA repair and leads to 
an increased number of genomic aberrations, tumor initiating cell expansion, and increased self-
renewal305.  Clearly, although current data point to a functional role for EZH2 in breast cancer 
progression, the precise biological effects of EZH2 overexpression and what key target genes 
mediate its function have yet to be elucidated. 
It is thought that PRC2-mediated histone lysine methylation promotes the recruitment of 
other chromatin modifying complexes, such as PRC1298.  One core component of PRC1 is BMI1, 
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a ubiquitin ligase enzyme that ubiquitinates lysines on histone H2A which in turn are thought to 
contribute to gene silencing306.  BMI1 is overexpressed in breast cancer cell lines and tumor 
samples and as such has been implicated as a breast cancer oncogene307,308.  Additionally, 
BMI1 has been implicated as an oncogene in other tumor types such as head and neck 
squamous cell carcinoma309.  Conflicting reports exist regarding a correlation between BMI1 
overexpression and disease outcome in breast cancer308,310.  Limited functional studies suggest 
that BMI1 may play a causal role in the disease: BMI1 can cooperate with oncogenic HRas to 
transform immortalized mammary epithelial cells (MCF10A), promote xenograft tumor growth, 
and enhance metastasis in a tail vein injection metastasis assay311,312.  However, precisely how 
BMI1 contributes to breast cancer remains unclear.  In Chapter 3 of this Dissertation I discuss 
our findings that identify RASAL2 as a target of EZH2 and BMI1 in breast cancer. 
 
DNA methylation 
PRC2-mediated methylation of histone proteins also is thought to promote the 
recruitment of DNA methyltransferase enzymes to the chromatin (additional data also support a 
role for DNA methylation in Polycomb protein recruitment and histone modification) 295,299.  DNA 
methyltransferases primarily methylate cytosine residues within CpG dinucleotides of genomic 
DNA, often within regions of high CpG density (CpG islands) near the 5’ end of genes295.  DNA 
methylation is a repressive mark and is thought to induce a more permanent suppression of 
gene expression than that of histone modification.  Normally, highly methylated DNA is 
restricted to heterochromatic regions of the genome that are not expressed.  In cancer, however, 
methylation patterns are greatly altered; in fact DNA methylation alterations were the first 
epigenetic changes identified in cancer cells313,314.  Studies have found that, in cancer cells, 
many previously methylated regions are hypomethylated, and many previously unmethylated 
regions are hypermethylated; both of these changes have been shown to contribute to 
tumorigenesis.  For example, hypomethylation of repeat sequences in the genome increases 
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chromosome instability and promotes genomic rearrangement315.  Aberrant hypermethylation 
has been found at many tumor suppressor gene promoters, such as RB1, where it prevents 
expression of the hypermethylated tumor suppressor gene and facilitates tumorigenesis316.  In 
Chapter 3 of this Dissertation I explore whether the RASAL2 promoter may be hypermethylated 
in breast cancer. 
 
MicroRNA-mediated suppression of gene expression 
MicroRNAs (miRNAs) are small non-coding RNAs that interact with target genes in a 
sequence specific manner and induce down-regulation of these targets via mRNA destruction 
and/or inhibition of protein translation317.  (Whether miRNA mediated regulation of gene 
expression is an epigenetic mechanism is an item of debate beyond the scope of this 
Dissertation.)  miRNA recognition sites typically reside within 3’-untranslated regions (3’UTRs) 
of genes and often are conserved, indicating their cross-species biological importance318.  
Today, miRNA misregulation occupies an increasingly large niche in cancer biology.  For 
example, one of the earliest identified miRNAs, let-7, today is a well established tumor 
suppressor miRNA.  Let-7 expression is lost in lung and in other cancers319,320.  Among many 
targets, let-7 has been show to target RAS, so its inactivation in cancer leads to Ras 
overexpression321.  Conversely, miRNAs can act as oncogenes.  For example, in breast cancer 
miR-10b is overexpressed and drives tumor progression and metastasis322.  Not surprisingly, 
many oncogenic miRNAs act by targeting important tumor suppressor genes.  For example, it 
recently was shown that the PTEN tumor suppressor gene is aberrantly suppressed in cancer 
by overexpressed miRNAs, including miR-22 and miR-2686,87.  Similarly, we wanted to explore 
whether RASAL2 is subject to aberrant miRNA-mediated suppression in cancer; I discuss our 
findings in Chapter 3 of this Dissertation. 
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OVERVIEW OF DISSERTATION 
Cancer is the second leading cause of death after heart disease and arises when cells 
acquire genomic, genetic, epigenetic, and other aberrations and become able to proliferate 
uncontrollably and avoid cell death323.  Understanding how cancer develops and progresses will 
enable us to prevent, detect, and treat the disease more effectively.  In this Dissertation I hope 
to contribute to this massive undertaking through the identification and analysis of a new tumor 
and metastasis suppressor gene, RASAL2.   
In Chapter 2 I identify RASAL2 as a candidate tumor suppressor based on its ability to 
transform immortalized cells and by the presence of RASAL2 mutations in human tumors.  
RASAL2 is a RasGAP gene.  Focusing on breast cancer, we show that RASAL2 inhibits Ras 
activity and that it functions as a tumor suppressor both in vitro and in vivo.  We also show that 
RASAL2 inactivation endows cells with migratory and invasive properties and accelerates the 
progression from ductal carcinoma in situ to invasive carcinoma in a xenograft breast cancer 
model.  We generate a Rasal2 mutant genetically engineered mouse model.  We establish 
Rasal2 mutant, mammary specific Her2 transgenic compound mice and find a striking increase 
in breast cancer metastasis in these animals.  Looking in primary human breast cancers we find 
loss of RASAL2 protein as compared to normal tissue, with a further decrease in metastatic 
samples.  Finally, we generate Rasal2, Trp53 double mutant compound mice, which exhibit 
increased tumorigenesis and widespread metastasis.  We conclude that RASAL2 is the newest 
tumor suppressor in the RasGAP family and that its inactivation contributes to primary 
tumorigenesis and more potently to metastasis. 
In Chapter 3 I delve into the regulation and function of RASAL2.  We investigate 
mechanisms of RASAL2 inactivation in breast cancer and present data to support a potential 
role for both epigenetic silencing and miRNA-mediated suppression.  We notice that RASAL2 is 
frequently inactivated in ERα-positive breast cancer cell lines, and discover that RASAL2 
inactivation and estrogen cooperate to promote proliferation in these cells.  Lastly, we find that 
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RASAL2 interacts with another tumor suppressor in the RasGAP family, DAB2IP, a finding that 
has broad implications for RASAL2 and DAB2IP function and for the RasGAP gene family 
overall. 
In Appendix A I detail the Rasal2 mutant genetically engineered mouse models I 
generated, including those analyzed in Chapter 2.  In Appendix B I reprint a publication from our 
laboratory in which we identify DAB2IP as a prostate tumor and metastasis suppressor.  Finally, 
in Appendix C I reprint a publication from Dr. Nancy Andrews’ laboratory (where I spent one 
year of graduate school), in which collaborators and I discover that the transcription factor 
STAT5 regulates expression of the transferrin receptor and that hematopoietic-specific loss of 
Stat5a/b causes microcytic, hypochromic anemia in mice. 
  
	  46 
 
 
 
 
 
 
 
 
 
 
 
 
Page intentionally left blank  
	  47 
 
 
 
 
 
Chapter 2 
 
The RasGAP Gene, RASAL2, Functions as a New Tumor and 
Metastasis Suppressor 
 
 
 
 
 
 
  
	  48 
The RasGAP Gene, RASAL2, Functions as a New Tumor and 
Metastasis Suppressor 
 
Sara Koenig McLaughlin1,2, Sarah Naomi Olsen1,2, Benjamin Dake3,4, Elgene Lim2,5, Junxia 
Min1,2, Charlotte Kuperwasser3,4, and Karen Cichowski1,2 
 
1: Genetics Division, Department of Medicine, Brigham and Women’s Hospital, Boston, MA 
02115 
2: Harvard Medical School, Boston, MA 02115 
3: Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111 
4: Department of Anatomy and Cellular Biology, Tufts University School of Medicine, Boston, 
MA 02111 
5: Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana-Farber 
Cancer Institute and Department of Medicine, Brigham and Women’s Hospital, Boston, MA 
02215 
 
Author attributions 
Sara Koenig McLaughlin: Performed all experiments not directly attributed to others and with KC 
planned the project and wrote the manuscript. 
Sarah Naomi Olsen: Performed the experiments shown in Figure 2-4 panels A and C. 
Benjamin Dake: Performed the experiment shown in Figure 2-3 panel C. 
Elgene Lim: Performed the experiment shown in Figure 2-2 panel D. 
Junxia Min: With SKM performed the experiment shown in Figure 2-1. 
Charlotte Kuperwasser: Performed the analyses shown in Figure 2-9 panels E-H. 
Karen Cichowski: Supervised and developed project and with SKM wrote the manuscript. 
	  49 
Figure 2-1 of this Chapter was published as supplemental data in the following manuscript: 
An oncogene–tumor suppressor cascade drives metastatic prostate cancer by 
coordinately activating Ras and nuclear factor-κB.   
Junxia Min, Alexander Zaslavsky, Giuseppe Fedele, Sara K McLaughlin, Elizabeth E Reczek, 
Thomas De Raedt, Isil Guney, David E Strochlic, Laura E MacConaill, Rameen Beroukhim, 
Roderick T Bronson, Sandra Ryeom, William C Hahn, Massimo Loda, and Karen Cichowski.   
Nature Medicine 16, pp. 286-294 (2010). 
 
 
The remainder of this Chapter has been submitted for publication as the following manuscript: 
The RasGAP Gene, RASAL2, Functions as a New Tumor and Metastasis Suppressor 
Sara Koenig McLaughlin, Sarah Naomi Olsen, Benjamin Dake, Elgene Lim, Roderick Terry 
Bronson, Thomas De Raedt, Rameen Beroukhim, Kornelia Polyak, Myles Brown, Charlotte 
Kuperwasser, and Karen Cichowski. 
Submitted (2013). 
 
 
 
 
  
	  50 
Introduction 
The Ras pathway is one of the most commonly deregulated pathways in human cancer7.  
Mutations in RAS genes occur in a variety of tumor types32,324; however the Ras pathway is also 
frequently activated as a consequence of alterations in upstream regulators and downstream 
effectors, underscoring the importance of this pathway in cancer7. 
Ras is negatively regulated by RasGAPs (Ras GTPase Activating Proteins), which 
catalyze the hydrolysis of Ras-GTP to Ras-GDP89.  As such, RasGAPs are poised to function as 
potential tumor suppressors.  Indeed, the NF1 tumor suppressor encodes a RasGAP and is 
mutated in the familial cancer syndrome neurofibromatosis type 195,96.  NF1 also is lost or 
suppressed in sporadic cancers, including glioblastoma110-112, non-small cell lung cancer113, 
neuroblastoma114, and melanoma107-109.  More recently the RasGAP gene, DAB2IP, has been 
shown to function as a potent tumor and metastasis suppressor in prostate cancer121.  In total 
there are 14 RasGAP genes in the human genome89.  All contain a RasGAP domain but exhibit 
little similarity elsewhere.  It is currently unknown whether any of these other genes may also 
function as human tumor suppressors.    
Breast cancer is the most common female cancer worldwide325.  K-, H-, and N-RAS 
mutations are relatively rare in this tumor type and together have been detected in only ~3.2% 
of all breast lesions46,326.  Nevertheless, the Ras/ERK pathway is hyperactivated in ≥50% of 
breast cancers and has been proposed to be involved in tumor progression and recurrence, 
suggesting that Ras may be more frequently activated by other mechanisms in these 
tumors266,268,327.  In this study we identify a new RasGAP tumor suppressor in breast cancer.  
Through the analysis of human tumor samples, human xenografts, and genetically engineered 
mouse models we show that RASAL2 loss plays a causal role in breast cancer development 
and metastasis.  Additional mouse modeling studies reveal a broader potential role for RASAL2 
in other tumor types.  Together these studies highlight the expanding role of RasGAP genes in 
cancer and reveal an important mechanism by which Ras becomes activated in breast tumors.   
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Results 
The RasGAP gene, RASAL2, is a candidate tumor suppressor  
We previously developed a cell-based screen to identify additional RasGAPs that might 
function as tumor suppressors121.  Briefly, distinct shRNAs that recognize individual RasGAP 
genes were introduced into immortalized mouse embryonic fibroblasts (MEFs) and cells were 
evaluated for the ability to grow in soft agar.  Three genes scored in this screen: Nf1, a well-
documented tumor suppressor gene, Dab2ip, which we have since shown is a tumor 
suppressor in prostate cancer, and a third uncharacterized RasGAP, Rasal2 (Figure 2-1)121.   
 
 
 
 
 
 
 
 
 
Figure 2-1. A screen for tumor suppressors in the RasGAP gene family 
All available shRNA lentiviral constructs recognizing murine RasGAP genes were collected from 
The RNAi Consortium (Broad Institute, MIT) and introduced into MEFs expressing dominant-
negative p53 and E1A.  Cells were plated in soft agar to assess anchorage-independent growth.   
Macroscopic colonies were counted and reported as relative number of colonies ± SD. 
 
Figure 2-2A demonstrates that distinct Rasal2-specific shRNA sequences promote colony 
growth in this assay and do so as well as Nf1-specific shRNAs.  Upon identifying RASAL2 as a 
candidate tumor suppressor, we searched publicly available databases and found mutations 
within the catalytic RasGAP domain in human breast cancers (Figure 2-2B and Table 2-
1A)328,329.  Current genomic mutation databases indicate that RASAL2 is also mutated in several  
 
 
 
Supplementary Figure 1 ShRNA screen to assess transforming effects of RasGAPs. 
 
(a) All available shRNA lentiviral constructs recognizing murine RasGAP genes were 
collected from the Broad TRC shRNA library and introduced into MEFs expressing 
DNp53 and E1a.  Knockdown was assessed by Western when possible (bolded genes) or 
Q-PCR.  shRNAs listed below represent those that were effective in knocking down the 
RasGAP gene specified. Relative number of colonies in soft agar are shown. (b) 
Efficiency of KD quantified by Q-PCR or quantification of Western blots using image j 
software. (c) We further confirmed that inactivation of DAB2IP and NF1, but not 
p120RasGAP also promoted the colony growth in MEFs only lacking p53 (with no E1a). 
Nature Medicine: doi:10.1038/nm.2100
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Figure 2-2: RASAL2 is a candidate tumor suppressor 
(A) Left: Mouse embryonic fibroblasts (MEFs) immortalized with dominant negative p53 and 
adenoviral E1A-encoded protein were infected with lentiviral shRNAs targeting Rasal2, Nf1, or 
control, and plated in soft agar.  Data are reported as relative number of colonies ± SEM.  
Inactivation of Nf1 or Rasal2 induced a statistically significant increase in anchorage-
independent growth (P ≤ 0.0001).  Right: Western blot confirming knockdown. 
(B) RASAL2 mutations in human tumor samples46.  Each triangle represents a non-synonymous 
mutation.  Red triangles indicate breast cancer mutations. 
(C) RASAL2 expression in a panel of human breast cancer cell lines in comparison to normal 
human mammary epithelial cells.  Cell lines with very low or no RASAL2 are starred and bolded. 
Breast cancer subtypes are indicated (Lu: luminal, Ba: basal). 
(D) Relative RASAL2 expression in subsets of sorted human mammary epithelial cells330.  
MaSC: mammary stem cell-enriched (CD49hi EpCAM-).  LP: luminal progenitor (CD49f+ 
EpCAM+).  ML: mature luminal (CD49f- EpCAM+). 
(E) Left: Western blot showing Ras-GTP and phospho-ERK (pERK) levels in MCF7 cells 
following expression of LacZ or RASAL2 cDNA.  Right: Western blot showing Ras-GTP and 
phospho-ERK (pERK) levels in MCF10A cells following shRNA-mediated inactivation of 
RASAL2 or control (non-targeting “Scramble” shRNA).  
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Figure 2-2 (Continued) 
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other cancers including colorectal, lung, and ovarian tumors (Figure 2-2B and Table 2-1B).  In 
total 42 non-synonymous mutations have been detected in RASAL2, 31% of which reside in the 
catalytic RasGAP domain, many of which are predicted to be deleterious (Table 2-1B and Table 
2-2).  Because the mechanism by which Ras becomes activated in breast cancer is largely 
unknown, and because mutations in breast tumors were among the first to be identified, we 
began by investigating a potential role for RASAL2 inactivation in breast cancer development. 
 
Table 2-1: RASAL2 mutations in human cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) Non-synonymous RASAL2 mutations in breast cancer samples328,329.  %:  
percent of samples in study in which RASAL2 mutations were identified. 
(B) Non-synonymous RASAL2 mutations in other tumor types.  Data from  
COSMIC46.  #: number of mutations.  %: percent of total samples in which  
RASAL2 mutations were identified. 
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Table 2-2: Human tumor mutations within the RasGAP domain of RASAL2 
 
 
 
 
 
 
 
 
 
 
 
Mutation: amino acid change.  Tissue: tumor tissue type.  Data from COSMIC46. 
 
 
Work from our laboratory and others have shown that the RasGAP genes NF1 and 
DAB2IP are inactivated in cancer by genetic, epigenetic, and proteasomal mechanisms110,116,121.  
Moreover, in many instances the non-genetic mechanisms of inactivation of these tumor 
suppressors appear to be more prevalent than mutational events in sporadic tumors107,110,121.  
Therefore we began by examining RASAL2 protein expression in a panel of breast cancer cell 
lines.  In comparison to normal mammary epithelial cells, RASAL2 was absent or minimally 
expressed in at least 5 out of 15 breast cancer cell lines, suggesting that RASAL2 may be 
frequently lost or suppressed in this tumor type (Figure 2-2C).  Notably, RASAL2 levels were 
high in MDA-MB-231 and SUM159PT cells, which are known to harbor a mutation in KRAS and 
HRAS, respectively331.  RASAL2 protein was frequently absent in cells derived from luminal 
cancers in this panel of lines.  Cell sorting studies indicate that there are no inherent differences 
in RASAL2 expression in any specific cell population within the mammary cell hierarchy: luminal 
progenitor, mature luminal, or mammary stem cell-enriched, indicating that the low RASAL2 
levels associated with luminal cancer cell lines were not inherently associated with a pre-
existing reduction in RASAL2 levels due to a specific cell of origin or cell fate, as has been 
Mutation Tissue
K417E Breast
E509D Breast
K567X Breast
N457S Colon
D477G Colon
D494N Colon
Y519N Colon
S507F Lung
G525W Lung
L637V Lung
A648S Lung
E526D Ovary
Q554H Urinary  Tract
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suggested for other genes (Figure 2-2D)330.  When RASAL2 was reconstituted in MCF7 cells, 
which express little to no endogenous RASAL2, Ras-GTP and phospho-ERK levels were 
suppressed (Figure 2-2E).  Conversely, acute inactivation of RASAL2 via shRNA sequences in 
immortalized mammary epithelial cells (MCF10A) increased Ras-GTP and phospho-ERK levels 
(Figure 2-2E).  These data confirm that RASAL2 is a functional RasGAP, and that its loss 
activates Ras in this tumor type. 
 
RASAL2 functions as a tumor suppressor in breast cancer 
We next investigated the biological consequences of reconstituting or suppressing 
RASAL2 in breast cancer cell lines.  When a RASAL2 cDNA was introduced into human breast 
cancer cells that lack endogenous RASAL2, proliferation was largely unaffected (Figure 2-3A); 
however RASAL2 reconstitution significantly inhibited anchorage-independent colony growth 
(Figure 2-3B).  Moreover, RASAL2 potently suppressed the growth of breast cancer xenografts 
in vivo (Figure 2-3C).  Conversely, RNAi-mediated suppression of endogenous RASAL2 in a 
breast cancer cell line that normally does not grow well as a xenograft promoted tumor growth in 
vivo (Figure 2-3D).  Finally, the biological effects of RASAL2 mutations identified in human 
breast cancer samples were evaluated.  Two of the three mutants (K417E and K567X) failed to 
suppress anchorage-independent growth, demonstrating that these two mutations result in a 
clear loss-of-function (Figure 2-3E).  The third mutation, which resulted in a more conservative 
amino acid change (E509D), still retained activity in this assay and therefore may not be 
pathogenic; however a number of additional non-conservative mutations have been detected in 
the RasGAP domain in other tumor types (Table 2-2).  Together, these gain- and loss-of 
function-studies, mutational analysis, and expression studies suggest that RASAL2 can function 
as a tumor suppressor in the mammary epithelium and that its inactivation or loss can contribute 
to breast tumor development. 
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Figure 2-3. RASAL2 functions as a tumor suppressor in breast cancer 
(A) Growth curves of MDA-MB-361 and MCF7 cells infected with RASAL2 or LacZ control cDNA.  
Data points shown triplicate averages ± SD.  There were no statistically significant differences in 
proliferation.  Western blot on right confirms ectopic RASAL2 expression. 
(B) Soft agar colony formation of MCF7, BT474, and MDA-MB-361 cells infected with RASAL2 
or LacZ control cDNA.  Data show relative number of colonies ± SD.  There was a statistically 
significant decrease in anchorage-independent growth upon ectopic RASAL2 expression (MCF7 
and BT474 P < 0.0001; MDA-MB-361 P = 0.002).  Western blots below confirm ectopic RASAL2 
expression. 
(C) Xenograft tumor formation of MDA-MB-361 cells infected with RASAL2 or LacZ control 
cDNA and injected orthotopically into female NOD/SCID mice.  Horizontal bar indicates mean 
tumor volume.  There was a statistically significant decrease in tumor growth upon ectopic 
RASAL2 expression (P < 0.0001).  Western blot on right confirms ectopic RASAL2 expression.  
(D) Xenograft tumor formation of CAMA1 cells infected with shRNAs targeting RASAL2 or non-
targeting control shRNA and injected subcutaneously into female NOD/SCID mice.  Horizontal 
bar indicates mean tumor volume.  There was a statistically significant increase in tumor growth 
upon RASAL2 inactivation (P = 0.0007).  Western blot on right confirms RASAL2 knockdown. 
(E) Soft agar colony formation of MCF7 cells infected with LacZ, RASAL2, or RASAL2 mutant 
cDNA.  Data show relative number of colonies ± SD.  * indicates P ≤ 0.05.  Western blot on right 
confirms expression of constructs (probed with anti-HA antibody to recognize N-terminal HA 
tag).  
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Figure 2-3 (Continued) 
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RASAL2 inactivation promotes migration, invasion, and tumor progression 
To fully characterize the oncogenic effects of RASAL2 loss we investigated whether 
RASAL2 suppression might also promote migration, invasion, and tumor progression.  We 
found that RASAL2 suppression promoted the migration of MCF10A cells in a wound-healing 
assay (Figure 2-4A,B), and significantly enhanced invasion through Matrigel (Figure 2-4C, P = 
0.002).  Moreover, using a xenograft model of breast cancer progression that mimics the 
progression of ductal carcinoma in situ (DCIS) to invasive carcinoma241,242, we found that 
RASAL2 inactivation accelerated tumor progression, resulting in a rapid disruption of the 
myoepithelium and basement membrane, and the development of invasive adenocarcinoma 
(Figure 2-4D).  Taken together these results suggest that RASAL2 inactivation may also play a 
role in breast cancer progression. 
 
Loss of Rasal2 promotes metastasis and Ras activation in a genetically engineered 
mouse model of luminal breast cancer 
As a rigorous and complementary means of investigating the biological consequences of 
Rasal2 inactivation in vivo we generated genetically engineered mice that lack Rasal2.  Mouse 
embryonic stem cells that contain a gene-trap cassette within the third intron of Rasal2 were 
obtained from Toronto Centre for Phenogenomics (Figure 2-5A).  These cells were used to 
generate gene-trap positive mice and appropriate integration as well as loss of Rasal2 
expression were confirmed in mutant animals (Figure 2-5B,C).  Rasal2 -/- mice were viable and 
fertile and born at Mendelian ratios.  We found that mutant animals did have a slightly shorter 
overall survival as compared to control animals (77.8 compared to 95.6 weeks; P = 0.007, 
Figure 2-6A).  However there was no obvious difference in phenotype between wildtype and 
Rasal2 -/- mice.  A subset of animals from both cohorts developed tumors associated with old 
age.  While Rasal2 mutant mice developed these tumors earlier the tumor spectrum was similar 
to wildtype animals and they did not develop mammary lesions (Figure 2-6B).  These results  
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Figure 2-4. RASAL2 inactivation promotes migration, invasion, and tumor progression 
(A) Cell migration assay (wound healing).  MCF10A cells infected with shRNAs targeting 
RASAL2 or a non-targeting control were grown to confluence, scratched to create a wound, and 
imaged after indicated number of hours to monitor cell migration to close the wound.  
Representative images are shown. 
(B) Western blot confirming RASAL2 knockdown in MCF10A cells used in (A) and (C). 
(C) Transwell invasion assay.  MCF10A cells infected with an shRNA targeting RASAL2 or a 
non-targeting control were plated in triplicate on a Matrigel invasion chamber.  Invasion was 
measured after 24 hours and reported as average ± SD (P = 0.002). 
(D) Xenograft tumor progression.  MCF10ADCIS cells were infected with shRNAs targeting 
RASAL2 or a non-targeting control and injected subcutaneously into female nude mice.  Top: 
Representative H&E images of xenograft tumors.  Bottom left: Quantification of xenograft tumor 
progression.  Bottom right: Western blot confirming RASAL2 knockdown. 
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Figure 2-5. Loss of Rasal2 promotes metastasis and Ras activation in a genetically 
engineered mouse model of breast cancer   
(A) Schematic of Rasal2 genomic locus and pNMDi4 genetrap cassette.  Rasal2 comprises 18 
exons (numbered).  Un-shaded regions in exons 1 and 18 mark 5’ and 3’ UTRs, respectively.  
ATG indicates Rasal2 translation start site.  Known domains of Rasal2 are noted (PH, C2, and 
RasGAP).  See Materials and Methods for detailed description of pNMDi4.  The genetrap 
cassette targets the third intron of Rasal2. 
(B) Genotyping of Rasal2 mice to distinguish wildtype, heterozygous mutant (het), and 
homozygous mutant (hom). 
(C) Western blot confirming loss of Rasal2 protein in genetrap animals (mammary gland tissue).  
wt: wildtype, het: heterozygous, hom: homozygous mutant. 
(D) Top: Representative H&E images of primary mammary adenocarcinomas from MMTVneu; 
Rasal2 +/+ and MMTVneu; Rasal2 -/- animals.  Bottom: Representative H&E images of lung 
metastases from MMTVneu; Rasal2 +/+ and MMTVneu; Rasal2 -/- animals.  M indicates 
metastases. 
(E) Lung metastasis burden in MMTVneu; Rasal2 +/+ and MMTVneu; Rasal2 -/- animals.  Lung 
metastasis incidence: percent of tumor-bearing females with lung metastases at sacrifice (P = 
0.05; n=24 MMTVneu; Rasal2 +/+, n=23 MMTVneu; Rasal2 -/-).  Average number of lung 
metastases per animal: counted per representative section of lungs for each tumor-bearing 
female (P = 0.04).  Average metastasis burden per animal: average total area of metastasis in a 
representative section of lung for each tumor-bearing female (arbitrary units; P = 0.04). 
(F) H&E images of metastases to brain (a), gut (b), ovary (c), and kidney (d) in compound 
tumor-bearing females.  M indicates regions of metastasis. 
(G) Western blot analysis of phospho-ERK (pERK) and phospho-AKT (pAKT) levels in primary 
mammary tumors from MMTVneu; Rasal2 +/+ animals (numbers 1-9) and MMTVneu; Rasal2 -/- 
animals (numbers 10-18). 
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Figure 2-5 (Continued)  
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Figure 2-6. Survival and phenotypes of Rasal2 mutant mice 
(A) Kaplan-Meier survival curves of Rasal2 +/+ (n=17) and Rasal2 -/- (n=20) animals (P = 
0.007). 
(B) Phenotypes observed in Rasal2 +/+ (n=17), Rasal2 +/- (n=11), and Rasal2 -/- (n=20) 
animals. 
 
 
 
indicate that Rasal2 loss is not sufficient to drive breast cancer in mice, but may play a more 
general role in enhancing the development of other spontaneous tumors. 
To examine the effects of RASAL2 loss on mammary tumorigenesis, we crossed Rasal2 
-/- mice to animals that constitutively overexpress a wildtype Her2 (Erbb2) transgene in the 
mammary epithelium (MMTVneu mice)240, which is a model of luminal breast cancers in mice236.  
Female MMTVneu mice have been reported to develop focal luminal mammary tumors and a 
fraction of tumor-bearing females develop lung metastases240.  As expected, MMTVneu and 
MMTVneu; Rasal2 -/- compound mice developed mammary adenocarcinomas, and did so at a 
similar high frequency (Figure 2-5D, top panels, and Figure 2-7).  Strikingly however, we found 
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compared to MMTVneu mice (Figure 2-5E, P = 0.04).  Interestingly, a subset of compound 
mutant mice also developed metastases to other organs, including brain, kidney, ovary, and 
gastrointestinal tract, something not observed in MMTVneu animals historically or in our cohort 
(Figure 2-5F).  It should be noted that in most autochthonous mouse models of mammary 
adenocarcinoma, metastasis is typically limited to the lung and occasionally lymph nodes245.  
However, human breast cancers do frequently metastasize to the brain and these other distal 
sites, underscoring the significance of these observations and the potential utility of this mouse 
model196.  Despite the dramatic increase in metastasis, no differences in primary tumor  
 
 
Figure 2-7: Tumor incidence and survival of MMTVneu; Rasal2 compound mutant mice 
(A) Kaplan-Meier curve showing tumor-free survival of MMTVneu; Rasal2 +/+ (n=24) and 
MMTVneu; Rasal2 -/- (n=25) females.  There is no difference in tumor-free survival (P = 0.98). 
(B) Kaplan-Meier curve showing overall survival of MMTVneu; Rasal2 +/+ (n=27) and 
MMTVneu; Rasal2 -/- (n=30) females.  There is no difference in survival (P = 0.90). 
(C) Mammary tumor incidence in MMTVneu; Rasal2 +/+ and MMTVneu; Rasal2 -/- females.  
There is no difference in mammary tumor incidence (P = 0.41). 
(D) Final mammary tumor volumes from tumor-bearing MMTVneu; Rasal2 +/+ and MMTVneu; 
Rasal2 -/- females.  Horizontal bars indicate mean tumor volume.  There is no difference in 
tumor volume (P = 0.41). 
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incidence, growth rate, or tumor size were observed in MMTVneu versus MMTVneu; Rasal2 -/- 
mice, indicating that the differences in metastatic burden were not due to underlying differences 
in primary tumor onset or growth (Figure 2-7).  Importantly, when we examined primary tumors 
from MMTVneu; Rasal2 -/- mice and MMTVneu animals, high levels of phospho-ERK and 
phospho-AKT were more consistently observed in MMTVneu; Rasal2 -/- lesions (Figure 2-5G).  
Moreover, we found that Rasal2 was spontaneously lost or suppressed in a subset of MMTVneu 
tumors and that this was accompanied by a substantial increase in phospho-ERK and phospho-
AKT levels (Figure 2-5G).  Finally, the primary tumor that spontaneously lost/suppressed Rasal2 
and exhibited the most robust activation of the Ras pathway was a metastatic outlier within the 
MMTVneu cohort (Tumor 6, Figure 2-5G, and Figure 2-8).  Taken together these findings 
indicate that Rasal2 loss enhances Ras activity in mammary tumors and that its loss promotes 
tumor progression, invasion and metastasis in both autochthonous mouse models of breast 
cancer and human xenografts.   
 
 
 
 
 
 
 
 
Figure 2-8. Metastasis burden in MMTVneu and MMTVneu; Rasal2 -/- mice 
Metastasis burden in MMTVneu; Rasal2 +/+ and MMTVneu; Rasal2 -/- tumor-bearing 
females.  Metastasis burden measures total area of metastasis within a representative 
section of lung (arbitrary units, AU).  Red data point: metastatic outlier within MMTVneu; 
Rasal2 +/+ cohort (Figure 2-5G, animal 6).  Horizontal lines: mean metastasis burden 
(MMTVneu; Rasal2 +/+ = 100, MMTVneu; Rasal2 -/- = 471; P = 0.04). 
 
 
M
et
as
ta
si
s  
B
ur
de
n
(A
U
)
MMTVneu;;
Rasal2  +/+
MMTVneu;;
Rasal2  -­/-­
0
150
1000
2000
3000
4000
	  66 
RASAL2 in primary human breast cancers 
Genomic analyses indicated that RASAL2 mutations do occur in human breast cancer 
but are relatively rare (Table 2-1A)46.  However, the two other known RasGAP tumor 
suppressors appear to be more frequently inactivated in cancer via multiple non-genetic 
mechanisms.  To more accurately determine how frequently RASAL2 is lost or suppressed in 
human breast cancers we directly examined RASAL2 protein levels in primary human tumors. 
Existing RASAL2 antibodies cannot be used for immunohistochemistry; therefore we obtained 
breast cancer arrays comprised of 55 sets of protein lysates (in triplicate) from matched primary 
breast tumors and adjacent normal mammary tissue taken from naïve patients332,333.  These 
tumor samples have been histologically verified to contain at least 80% cancer cells and the 
normal tissue is cancer cell-free.  We first validated our purified RASAL2 antibody in this assay 
and found that dot blots from RASAL2-expressing and non-expressing human breast cancer cell 
lines exhibited the expected pattern of expression (Figure 2-9A, top).  RASAL2-specific shRNA 
sequences also successfully ablated expression in this assay (Figure 2-9A, bottom).  Using the 
tumor arrays we found that RASAL2 expression was decreased by 75%-100% in 20% of human 
breast tumors as compared to adjacent normal mammary tissue (Figure 2-9B,C).  These results 
confirm our finding in breast cancer cell lines, suggesting that RASAL2 expression is lost or 
suppressed in a significant fraction of human breast cancers at a frequency that is much greater 
than indicated by mutation analysis alone.  More importantly, however, low RASAL2 protein 
levels were significantly associated with metastasis (Figure 2-9D; P = 0.006). 
 Because our cell line analysis showed that RASAL2 expression is low or undetectable 
in a subset of luminal breast cancer cell lines (Figure 2-2), and mouse modeling studies further 
demonstrated that RASAL2 loss promotes the metastasis of luminal tumors, we wanted to 
evaluate RASAL2 expression in the context of different breast cancer subtypes.  Human breast 
cancers can be molecularly classified into distinct subtypes: basal-like, HER2-positive, luminal A, 
luminal B, and normal breast-like197,198,334,335.   Notably, molecular subtype association analysis 
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Figure 2-9. RASAL2 expression is lost/low in primary human breast cancers and low 
levels are associated with metastasis and recurrence  
(A) Test dot blot of RASAL2 antibody.  RIPA whole cell extracts from human breast cancer cell 
lines with high or low RASAL2 expression (MDA-MB-231 “231” and T47D, respectively) (top) or 
MCF10ADCIS cells infected with control or RASAL2-targeting shRNAs (bottom) were spotted 
on a nitrocellulose membrane and probed with the RASAL2 antibody. 
(B) Sample images from human breast tumor lysate array.  Six sets of RASAL2 and total protein 
stains are shown.  Each set contains triplicate spots of tumor lysate (right) and triplicate spots of 
paired normal tissue lysate (left). 
(C) Tumor lysate microarray results.  Each bar marks the change in RASAL2 expression in one 
tumor sample as compared to its matched normal control.  RASAL2 levels in each spot were 
quantified, normalized to total protein in the same spot, and averaged among the triplicate, 
yielding the “normalized value”.  Fold change in RASAL2 expression was determined by taking 
the Log2 of the ratio of the normalized tumor value over the normalized control tissue value.  
Shaded bars indicate metastatic samples.  RASAL2 expression decreased by 75%-100% in 
20% of tumors on the array, as compared to matched normal controls. 
(D) The decrease in RASAL2 protein expression in tumor versus normal in non-metastatic 
(Stages I, II, III) versus metastatic (Stage IV) tumors.  Graph shows the Log2 fold change in 
RASAL2 expression in tumor versus normal.  Data are reported as average ± 95% CI.  P = 
0.006. 
(E) Heatmap of RASAL2 gene expression as a function of robust molecular subtype predictor 
classification, which is based on patients classified in the same tumor subtype.  Percentages of 
tumors with high, intermediate and low RASAL2 expression per molecular subtype are given in 
the gene expression table  
(F) RASAL2 expression table.  For each breast cancer subtype, the number of samples and 
percentage of samples with low, intermediate, or high RASAL2 mRNA expression are indicated. 
(G) Kaplan-Meier curve showing recurrence-free survival of luminal B tumors with high or low 
RASAL2 expression.  logrank P = 0.013. 
(H) Kaplan-Meier curve showing overall survival of luminal B tumors with high or low RASAL2 
expression.  logrank P = 0.013.  
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Figure 2-9 (Continued) 
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of transcriptional profiles from primary breast cancers revealed that RASAL2 expression was 
low in luminal B breast cancers; 50% of luminal B tumors expressed the lowest levels of 
RASAL2, consistent with a potential role for RASAL2 loss in this subtype (Figure 2-9E,F).  
Moreover, low RASAL2 expression was also associated with both increased tumor recurrence 
(Figure 2-9G, logrank P = 0.0133) and decreased overall survival (Figure 2-9H, logrank P = 
0.0131) in patients with luminal B cancers.  Taken altogether cellular, xenograft, mouse 
modeling, and human tumor studies suggest that RASAL2 loss promotes breast cancer 
development and metastasis, and may play a particularly important role in the progression of 
luminal B tumors. 
 
Rasal2 mutations promote tumor development and widespread metastasis in p53 mutant 
mice  
To determine whether RASAL2 inactivation might also contribute to the development of 
other sporadic tumors, Rasal2 -/- mice were crossed to mice mutant for p53, one of the most 
commonly inactivated tumor suppressors in human cancer278,336.  Trp53 mutant mice develop a 
spectrum of lymphomas and sarcomas and some carcinomas arise in heterozygotes286,287.  In 
addition to the classical tumors observed in Trp53 mutant mice, Rasal2/Trp53 compound 
mutant mice developed several other lesions that were not found in Trp53 mutant controls, 
historically or in our cohort (Figure 2-10A)287,288.  Specifically, Rasal2/Trp53 mutant mice 
developed hepatocellular carcinomas and other liver tumors, colonic adenomas, and oral and 
stomach tumors (Figure 2-10A).  These findings are of particular interest because RASAL2 
mutations have been found in related human cancers, namely hepatocellular carcinoma, 
colorectal carcinoma, head and neck squamous cell carcinoma, and stomach cancer (Table 2-
1B).  Together, these data suggest that RASAL2 loss may play a broader role in the 
development of these tumor types.   
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Figure 2-10. Rasal2, Trp53 compound mutant mice develop highly metastatic tumors 
(A) Phenotypes in Rasal2/Trp53 compound mutant mice.  Pie charts display the array of 
phenotypes in each genotype.  New phenotypes in Rasal2 mutant compound mice are shown in 
color.  n=21 Rasal2 +/+; Trp53 -/-, 18 Rasal2 +/-; Trp53 -/-, 31 Rasal2 -/-; Trp53 -/-, 16 Rasal2 
+/+; Trp53 +/-, 21 Rasal2 +/-; Trp53 +/-, 21 Rasal2 -/-; Trp53 +/-. 
(B) Percentage of metastatic solid tumors in Rasal2 +/+, +/-, and -/-; Trp53 +/- compound mice.  
Increased metastasis in compound animals is statistically significant (P = 0.003).  The paucity of 
metastatic solid tumors in Trp53 +/- mice is supported by historical data on a similar strain 
background in which 3/44 animals (7%) developed metastases289. 
(C) Representative images of metastatic lesions (bottom) and their primary tumors (top).  From 
left to right: mammary adenocarcinoma and lung metastasis, osteosarcoma and liver metastasis, 
hepatocellular carcinoma and lung metastasis, and lung adenocarcinoma and liver metastasis.  
M: metastasis, Lu: lung, Liv: liver. 
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However the most striking phenotype in Rasal2/Trp53 mutant mice was that Rasal2 loss 
potently promoted metastasis.  The Trp53 -/- mice, either with or without functional Rasal2, 
typically died from the primary tumor, which was frequently lymphoma.  Nevertheless 60% of 
the solid tumors that developed in Rasal2 +/-; Trp53 +/- mice and 83% of the solid tumors from 
Rasal2 -/-; Trp53 +/- mice were metastatic, as compared to 18% of tumors in Trp53 +/- mice 
(Figure 2-10B, P = 0.003).  Specifically, Rasal2/Trp53 mutant animals developed highly 
metastatic mammary adenocarcinomas, hepatocellular carcinomas, lung adenocarcinomas, and 
various sarcomas, again tumor types in which RASAL2 mutations have been detected in 
humans (Figure 2-10C).  Thus these findings further underscore the role of RASAL2 loss as a 
driver of metastasis and suggest that its inactivation may play a role in the progression of breast 
and other human cancers.   
 
Discussion 
The Ras pathway plays a well-established role in cancer7.  However the primary 
mechanism(s) by which Ras becomes activated in breast cancers has remained elusive.  Here 
we report that RASAL2, which encodes a previously uncharacterized RasGAP, functions as a 
tumor and metastasis suppressor in breast and other cancers.  First, we have shown that loss-
of-function mutations in RASAL2 are found in human breast cancers and other tumor types.  
However, like other RasGAP genes RASAL2 appears to be more frequently inactivated by non-
genetic mechanisms and it is substantially repressed in at least 20% of primary human breast 
cancers.  Second, RASAL2 ablation promotes tumor growth and progression in two different 
human xenograft models, while RASAL2 reconstitution suppresses breast tumor growth.  Third, 
RASAL2 mutations activate Ras and significantly promote metastasis in a genetically 
engineered mouse model of luminal mammary cancer.  Fourth, RASAL2 mutations cooperate 
with p53 mutations in tumor development and promote the metastasis of several tumor types, 
including mammary tumors, in the mouse.  Finally, RASAL2 is lost or suppressed in a significant 
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fraction of human breast cancers and low RASAL2 protein levels are associated with metastasis.  
Notably, the lowest RASAL2 mRNA expression levels were most frequently observed in luminal 
B human breast cancers and also were associated with recurrence and reduced survival of 
patients with this tumor subtype.  Collectively, these data suggest that RASAL2 loss plays a 
causal role in breast cancer pathogenesis, and may be particularly important for progression 
and metastasis.   
It should be noted that while RAS mutations are rare in breast cancer, they do occur.  
Moreover amplifications of wildtype RAS are frequently observed in basal-like breast cancers, 
the most aggressive subtype of human breast cancer, underscoring the connection between 
Ras activation and breast cancer progression55,56,270,337.  Our data suggest that overall RASAL2 
is suppressed or lost in at least 20% of human breast cancers.  However expression analysis of 
different breast cancer subtypes suggests that RASAL2 may play a particularly important role in 
the progression of luminal B tumors.  The observation that RASAL2 loss promotes metastasis in 
a mouse model of luminal tumors further supports this possibility.  In this respect it is notable 
that luminal B tumors have poorer outcomes than luminal A tumors, however the mechanism(s) 
that drive the progression of these tumors are largely unknown.  Our data suggest that RASAL2 
loss/suppression may play a causal role in the progression of this subtype, although these 
observations do not preclude its potential involvement in other subtypes.  
Finally while RASAL2 is mutated in breast cancer and in other human tumors, it appears 
to be more commonly inactivated via non-mutational mechanisms.  Notably, the other RasGAP 
tumor suppressors, NF1 and DAB2IP, are also inactivated in cancer by both genetic and several 
non-genetic mechanisms110,121.  Similarly, PTEN and INPP4B, two other tumor suppressors that 
negatively regulate an overlapping set of signals, are also suppressed by multiple mechanisms 
in cancer, some of which have not yet been elucidated338-340.  As such, loss of PTEN protein 
expression, rather than mutational status or copy number, is often evaluated in clinical samples 
during clinical trials and for pathological staging341,342.  The observation that RASAL2 loss plays 
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a causal role in breast cancer progression and metastasis in animal models and that its 
expression is lowest in primary human tumors that ultimately progress or recur, suggests that 
RASAL2 may ultimately be useful as a prognostic biomarker, in at least a subset of breast 
cancers, such as luminal B tumors.  Regardless, these studies have identified a new gene 
involved in breast cancer progression and have revealed a mechanism by which Ras becomes 
activated in this disease.   
 
Materials and Methods 
Cell Culture and DNA Constructs 
Mouse embryonic fibroblasts (MEFs) were isolated and immortalized with dominant-
negative P53 and adenoviral E1A-encoded protein102.  MCF7 and MCF10A cells were 
purchased from ATCC.  BT549, HS578T, MDA-MB-231, MDA-MB-453, MDA-MB-468, SKBR3, 
T47D, and ZR-75-1 cells were obtained from Dr. William Hahn (Dana-Farber Cancer Institute).  
SUM149PT, SUM159PT, SUM1315MO, and BT474 cells were obtained from Dr. Frank 
McCormick (University of California San Francisco).  MCF10A.DCIS cells were obtained from Dr. 
Kornelia Polyak (Dana-Farber Cancer Institute), MDA-MB-361 cells were obtained from Dr. 
Charlotte Kuperwasser (Tufts University), and CAMA1 cells were obtained from Dr. Marcia 
Haigis (Harvard Medical School).  Cell lines were cultured according to published protocols. 
Endogenous proteins were inactivated using short-hairpin RNAs (shRNAs) from The 
RNAi Consortium (Broad Institute, MIT) with the following target 21-mer sequences: NF1 
shRNA (5’-TTATAAATAGCCTGGAAAAGG-3’), RASAL2 shRNA1 (5’-
CCCTCGTGTTCTTGCTGATAT-3’), and RASAL2 shRNA2 (Figure 2-4 shRNA3) (5’-
GCCTTCCACCTCTTCATAGTA-3’).  A scrambled non-silencing shRNA was purchased from 
Addgene (5’-CCTAAGGTTAAGTCGCCCTCG-3’)343.  A RASAL2-targeting shRNA was cloned 
into the pLKO vector (Figure 2-4 shRNA2) (5’-ATGGAGTGCAATAGGACATTG-3’).  The 
Mammalian Gene Collection fully sequenced human RASAL2 cDNA was purchased from Open 
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Biosystems (cat. # MHS4426-99623118) and cloned it into the pHAGE-N-Flag-HA lentiviral 
expression vector (Dr. J. Wade Harper, Harvard Medical School) for expression in cell lines.  
The RASAL2 cDNA was mutagenized using QuikChange II Site-Directed Mutagenesis kit, 
according to the manufacturer’s instructions (Agilent).  shRNA or cDNA vectors along with viral 
packaging plasmids delta 8.2 and VSVG were transfected into 293T cells using Fugene6 
(Roche), following the manufacturer’s instructions.  Virus supernatant was harvested after 48 
hours, filtered through a 0.45µm filter, and incubated on target cells for 6 hours at a 1:2-1:10 
dilution with 8µg/ml polybrene.  Infected cells were selected in 0.5-2.0µg/ml puromycin, as 
optimized for each cell line. 
 
Proliferation Curves 
150,000 cells were plated in triplicate in 6-well dishes.  The following day cells were 
counted for day 0, and then triplicate sets of cells were counted on subsequent days as 
indicated. 
 
Soft Agar and Xenograft Assays 
Soft agar assays were plated in triplicate in 6-well dishes using the appropriate growth 
media for each cell line and SeaPlaque GTG low melting point agarose (Lonza).  Plating 
conditions were as follows.  MEFs: 10,000 cells, 0.5% agar base, 0.35% agar top.  MCF7 cells: 
5,000 cells, 0.5% agar base, 0.35% agar top.  BT474 cells: 10,000 cells, 0.6% agar base, 
0.35% agar top.  MDA-MB-361 cells: 50,000 cells, 0.5% agar base, 0.35% agar top.  
Macroscopic colonies were counted after 2-6 weeks in 5 representative fields per well. 
Female nude and NOD/SCID mice were purchased from Charles River Laboratories (cat. 
#s 088 and 394, respectively) for subcutaneous xenograft experiments.  Cells were injected with 
matrigel (BD Biosciences cat. # 354234) as follows: MCF10A.DCIS (1x105 cells, 50% matrigel, 
nude mice), CAMA1 (2x106 cells, 50% matrigel, NOD/SCID mice).  For mammary fat pad 
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orthotopic xenograft experiments, 1x106 MDA-MB-361 cells were injected in 50% matrigel 
bilaterally into the 4th mammary glands of female NOD/SCID mice (Jackson Laboratories).  
Tumor size was measured by caliper and tumor volume was calculated using the formula 
volume = (length x width2) x π/6. 
 
Migration and Invasion Assays 
For migration assays, MCF10A cells were grown to 95-100% confluence and treated 
with mitomycin C to inhibit cell division.  Wounds were generated with a pipette tip and images 
of wound healing (migration) were taken at indicated time intervals.  For invasion assays, 
100,000 MCF10A cells were plated per well on BioCoat Matrigel Invasion Chambers (BD cat. # 
354480) and after 24 hours invaded cells were fixed, stained, and counted, following the 
manufacturer’s instructions.   
 
Rasal2 Mutant Mice 
All animal procedures were approved by the Center for Animal and Comparative 
Medicine at Harvard Medical School in accordance with the NIH Guildlines for the Care and Use 
of Laboratory Animals and the Animal Welfare Act.  A mouse embryonic stem cell line in which 
the pNMDi4 genetrap cassette targets Rasal2 was purchased from the Toronto Centre for 
Phenogenomics / Canadian Mouse Mutant Repository (clone CMHD 463C12).  The pNMDi4 
genetrap cassette contains the following elements as depicted in Figure 3A: HA 3/5 SA (splice 
acceptor), FL (flexible linker), Venus (enhanced yellow fluorescent gene) with stop codon, loxP 
sites, pA (polyadenylation signal), PGK (promoter), neo (neomycin resistance gene) with stop 
codon, HPRT SD (splice donor).  The neomycin resistance gene stop codon prevents 
translation of 3’ exons.  The presence of the genetrap cassette within the third intron of Rasal2 
was confirmed using cDNA PCR.  The Brigham and Women’s Hospital Transgenic Mouse 
Facility injected ES cells into blastocysts and implanted them into pseudo-pregnant recipients to 
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generate chimeric pups.  Chimeras were crossed to Black 6 animals (C57BL/6-E, Charles River 
Laboratories cat. # 475) and pups were tested for presence of the genetrap.  Two additional 
copies of the genetrap cassette elsewhere in the genome were discovered in the mouse ES cell 
line and genetrap mice.  Genetrap-positive mice were crossed to wildtype animals and Southern 
blotting was used to identify pups that had the genetrap cassette only within the Rasal2 locus 
(data not shown).  These animals were used as founders for all cohorts and subsequent 
crosses.   
 
Rasal2 Genotyping 
Primers for PCR of the genetrap cassette were NMD.F (5’-
CATGGTCCTGCTGGAGTTC-3’) and NMD.R (5’-TGCCTTTAGACCTTTTTGTGG-3’).  Total 
RNA was extracted from homogenized tails using QiaShredder and RNeasy kits (Qiagen), and 
cDNA was synthesized using qScript cDNA Synthesis Kit (Quanta), following the manufacturer’s 
instructions.  PCR was performed on cDNA with primers NeoL (5’-
GCTATCAGGACATAGCGTTGGCTAC-3’), GT463C12_F3 (5’-TCGGATCCTTCTGGAGTCAG-
3’), and GT463C12_R1 (5’-CTCTCTCGGAGGCAGAGCTA-3’) to detect wild type (F3/R1) and 
mutant (NeoL/R1) transcripts.   
 
Compound Mutant Mice 
Rasal2 genetrap mice were crossed to FVB/N-Tg(MMTVneu)202Mul/J mice (Jackson 
Laboratories cat. # 002376)240 or to B6.129S2-Trp53Tm1Tyj/J mice (Jackson Laboratories cat. # 
002101)287 to generate the following compound strains for analysis: MMTVneu; Rasal2 +/+, 
MMTVneu; Rasal2 +/-, MMTVneu; Rasal2 -/-, Trp53 +/-; Rasal2 +/+, Trp53 +/-; Rasal2 +/-, 
Trp53 +/-; Rasal2 -/-, Trp53 -/-; Rasal2 +/+, Trp53 -/-; Rasal2 +/-, and Trp53 -/-; Rasal2 -/-.  
Genotyping of the neu transgene and Trp53 was performed following published protocols.  
Cohorts of Rasal2 mutant mice and controls were on a 129-enriched background (75% 
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129SvImJ, 25% C57BL6).  Cohorts of Trp53; Rasal2 compound mice and controls were on a 
mixed 129/B6 background (62.5% C57BL6, 37.5% 129SvImJ).  Cohorts of MMTVneu; Rasal2 
compound mice and controls were on a background of 56% 129SvImJ, 25% FVB, and 19% 
C57BL6. 
 
Protein Lysates and Western Blot Analyses 
Protein extracts were isolated from cells or homogenized tissue in 1% SDS boiling lysis 
buffer.  Ras-GTP levels were determined using a Ras Activation Assay kit, following the 
manufacturer’s instructions (EMD Millipore).  Protein lysates were quantified and separated on 
polyacrylamide gels.  Western blots were probed following validated procedures using the 
following antibodies: Actin (Sigma cat. # A2066), phospho-AKT (Ser473, Cell Signaling cat. # 
4060), AKT (Cell Signaling cat. # 9272), ER (Thermo cat. # R9101-SO), phospho-ERK 
(Thr202/Thr204, Cell Signaling cat. # 4370), ERK (Cell Signaling cat. # 9102), GAPDH (Cell 
Signaling cat. # 2118), HA (Covance cat. # MMS-101P), HER2 (Cell Signaling cat. # 2242), NF1 
(UP69 C-terminal polyclonal antibody)110, p120RasGAP (BD Transduction Laboratories cat. # 
610040), Ras (Upstate cat. # 05-516), α-Tubulin (Sigma cat. # T5168), β-Tubulin (Sigma cat. # 
T4026), and Vinculin (Cell Signaling cat. # 4650).  A peptide antigen (NP_773793 amino acids 
1111-1130) was used to generate and affinity purify an anti-RASAL2 rabbit polyclonal antibody 
(Covance ImmunoTechnologies). 
 
Tumor and Tissue Analysis 
Tumors and tissues were fixed in buffered formalin, stored in 70% ethanol, paraffin 
embedded, and sectioned.  Sections were stained with hematoxylin and eosin and analyzed by 
the rodent pathologist, Dr. Roderick Bronson. 
 
Tumor Lysate Array Analysis 
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The RASAL2 antibody was tested for use on tumor lysate arrays by probing 
nitrocellulose membranes that had been spotted with 1µg/µl RIPA lysates from human breast 
cancer cell lines with high or low RASAL2 levels or from MCF10ADCIS cells infected with 
shRNA sequences targeting RASAL2 or control. 
Qualitative breast cancer tumor lysate arrays were purchased from Protein 
Biotechnologies (cat. # PMA2-001-L).  Arrays were probed with the affinity purified RASAL2 
antibody.  Developed film was scanned and quantified using ImageJ software.  Arrays were 
then stained with Colloidal Gold, scanned, and total protein was quantified using ImageJ.  
RASAL2 levels in each spot were normalized to the Colloidal Gold level in the same spot.  
Triplicate spots were then averaged, and the ratio between the tumor normalized triplicate and 
normal normalized triplicate was calculated and reported as a Log2 fold change value. 
 
Molecular Subtype Association and Survival Analysis  
 Gene expression correlations targeted analysis was applied on published genomic data 
on patients classified in the same molecular subtype with the six molecular subtype 
predictors201,334,335 using GenExMiner as previously described344.  A gene expression map was 
determined by molecular subtype predictors (single sample predictors (SSPs) and/or subtype 
clustering models (SCMs)).  A gene expression table was also provided for robust 
classifications, indicating for each subtype the proportion of patient with low, intermediate and 
high gene expression; gene expression values being split in order to form three equal groups. 
 Gene expression data and relapse free and overall survival information were analyzed 
as previously described345.  Data were downloaded from GEO (Affymetrix HGU133A and 
HGU133+2 microarrays), EGA and TCGA.  The background database integrates gene 
expression and clinical data simultaneously.  To analyze the prognostic value of RASAL2, the 
patient samples are split into two groups according to median expression of RASAL2. 
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Introduction 
In Chapter 2 of this Dissertation I identify RASAL2 as a putative tumor suppressor 
RasGAP gene, and show in vitro and in vivo data that support a role for RASAL2 inactivation in 
breast cancer development and metastasis.  Additionally, I demonstrate that RASAL2 
inactivation promotes the development and progression of other sporadic tumor types.  These 
findings raise a number of new questions as to the biology, regulation, and function of RASAL2.  
In this Chapter I present our current efforts at addressing these questions.  These unpublished 
findings represent several avenues the laboratory could further explore.  First, we investigate 
the mechanisms by which RASAL2 is inactivated in breast cancer.  Second, we assess whether 
RASAL2 inactivation has an augmented effect on specific breast cancer subtypes.  Finally, we 
determine that RASAL2 interacts with another RasGAP, DAB2IP, and consider the biological 
consequences of this interaction.  We believe that the data presented in this Chapter represent 
the beginning of the next, exciting phase of RASAL2 exploration and will lead to a better 
understanding of the role of RasGAPs in cancer. 
 
MECHANISMS OF RASAL2 INACTIVATION IN BREAST CANCER 
Currently available data suggest that RASAL2 is mutated in approximately 1-4% of 
breast cancers46,328,329.  However, as shown in Chapter 2 of this Dissertation, we found that 
RASAL2 expression is absent or low in at least 30% of breast cancer cell lines and is reduced 
by 75-100% in 20% of primary breast tumors samples.  Therefore, we believe that the RASAL2 
mutation frequency underrepresents the actual number of cases in which RASAL2 is inactivated 
in breast cancer, and that RASAL2 is likely inactivated via additional mechanisms.  RASAL2 
resides on chromosome 1q, a region of the genome that often undergoes copy number gain in 
breast and other cancers166,167, and focal deletions of RASAL2 have not been reported.  Thus, 
we believe that genomic deletion of RASAL2 does not contribute to its inactivation in cancer.  
Instead, we hypothesize that RASAL2 inactivation might more commonly occur via non-genetic 
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mechanisms.  A precedent exists for non-genetic mechanisms of RasGAP inactivation in 
cancer: both NF1 and DAB2IP are commonly inactivated in cancer via non-genetic mechanisms, 
NF1 by aberrant proteasomal degradation110, and DAB2IP by epigenetic silencing121.  In this 
Chapter I explore the roles of epigenetic silencing and miRNA suppression in RASAL2 
inactivation in breast cancer. 
 
Epigenetic silencing 
The Polycomb Repressive Complexes (PRCs) 1 and 2 are critical mediators of 
epigenetic gene regulation.  PRCs 1 and 2 affect gene transcription by modifying chromatin-
associated histones at specific genetic loci299.  Multiple PRC members have been implicated as 
oncogenes in human cancer.  The PRC2 member EZH2, a histone methyltransferase, is 
overexpressed in many tumor types, including breast and prostate cancer.  In prostate cancer, 
EZH2 expression has been shown to increase with increasing tumor grade and stage122.  Work 
from our laboratory demonstrated a causal role for EZH2 in driving both prostate primary tumor 
formation and metastasis121.  Importantly, this study also revealed the RasGAP DAB2IP as a 
critical target of EZH2, and led us to hypothesize that epigenetics may more broadly contribute 
to RasGAP inactivation in cancer.  Studies have reported that, in breast cancer, EZH2 is 
overexpressed and its overexpression correlates with more aggressive disease and poor 
prognosis300,301,303; however, key target genes of EZH2 have not yet been identified.  In this 
Chapter we test the hypothesis that RASAL2 is a target of EZH2 in breast cancer.  We also 
investigate whether the PRC1 member BMI1 targets RASAL2, as BMI1 also has been 
implicated as a breast cancer oncogene307,346.  Hypermethylation of promoter DNA can follow 
histone modification and induce a permanent suppression of target genes295.  Therefore, in this 
Chapter we also explore whether the RASAL2 promoter may be hypermethylated in breast 
cancer. 
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MicroRNA-mediated gene regulation 
MicroRNAs (miRNAs) are small non-coding RNAs that down-regulate expression of 
target genes through inhibition of protein translation and/or degradation of mRNA318.  It is 
becoming clear that miRNAs play an important role driving gene expression alterations that 
contribute to human cancer317.  In this Chapter we explore whether miRNA-mediated 
suppression of RASAL2 contributes to its inactivation in breast cancer.  We identify a list of 
candidate miRNAs predicted to target RASAL2 and perform experiments to functionally validate 
one candidate, miR-135b, a miRNA that had been implicated as an oncogene in breast and 
colon cancers due to its overexpression in these tumor types, but whose target genes and 
functional effects had not been explored347,348. 
 
RASAL2 AND ESTROGEN RECEPTOR POSITIVE BREAST CANCERS 
Breast cancer is a heterogeneous disease, comprising distinct tumor types that can be 
grouped based on gene expression signatures197,198.  Seventy percent of breast cancers belong 
to the luminal subtype; these tumors typically express the estrogen receptor alpha (ERα)183,185.  
ERα is a nuclear hormone receptor and is the major receptor for estrogen, the steroid hormone 
responsible for mammary gland development and function.  Estrogen binding induces ERα 
dimerization and activation followed by nuclear translocation and activation of a vast 
transcriptional program that promotes cell growth and survival.  ERα also elicits “non-genomic” 
responses within minutes of ligand binding that occur in the cytoplasm in the absence of gene 
transcription.  These effects include activation of receptor tyrosine kinases, eNOS, PI3K, and 
MAPK178. 
For over a century it has been appreciated that extended exposure to estrogen plays a 
cause role in breast cancer; throughout this period physicians and scientists have made 
eliminating estrogens or ERα function a therapeutic strategy185.  Since the 1970s, the standard 
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of care for patients with ERα-positive breast cancer has been targeted anti-estrogen therapy, 
typically tamoxifen, which acts as an estrogen antagonist, or an aromatase inhibitor, which 
inhibits the final step of estrogen biosynthesis185.  These therapies are widely successful, at 
least initially, underscoring the central role estrogen and ERα play in driving these tumors.  It is 
thought that both the canonical transcriptional effects of ERα, as well as its non-genomic effects, 
contribute to tumorigenesis185. 
Data suggest that significant crosstalk exists between ERα signaling and the Ras 
pathway.  Upon estrogen stimulation, non-genomic activities of ERα include activation of the 
PI3K and MAPK Ras effector pathways349.  Conversely, both AKT and ERK also have been 
shown to phosphorylate and activate ERα186-188.  We hypothesized that, in ERα-positive tumors 
and cell lines, inactivation of the RasGAP RASAL2 might enhance ERα signaling, such as via 
AKT and ERK, and thus confer a proliferative advantage upon ERα-positive breast cancer cells 
that had lost RASAL2 expression.  Interestingly, in Chapter 2 of this Dissertation we discovered 
that RASAL2 expression is lost in many ERα positive breast cancer primary tumor samples and 
cell lines.  Further, RAS mutations are rare in breast cancer and KRAS amplification occurs 
predominantly in basal-like tumors55,56, so neither genetic alteration is likely to exist in ERα-
positive tumors to generate a similar cooperative effect.  In this Chapter we investigate the 
hypothesis that RASAL2 inactivation and estrogen signaling cooperate to drive proliferation of 
ERα-positive luminal breast cancer cells. 
 
RASGAP DIMERIZATION 
There are fourteen RasGAPs in the human genome.  Emerging data suggest that 
multiple RasGAPs may function as human tumor suppressors.  It remains unknown whether 
RasGAPs play critical tumor suppressive roles in mutually exclusive settings, whether any 
RasGAPs might exhibit overlapping or redundant functions, and/or whether any RasGAPs might 
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cooperate within one cell or tissue type.  Recent evidence of RasGAP dimerization suggests 
that at least the last of these three possibilities might occur.  Dai et al. determined that the 
RasGAP CAPRI (RASA4) homodimerizes and that its status as a homodimer or monomer 
differentially affects its RasGAP and RapGAP activities147.  Dai et al. also showed that CAPRI 
homodimerization occurs via a C-terminal coiled-coil domain, a finding we will return to below147.  
Additionally, p120RasGAP (RASA1) has been shown to dimerize with the RhoGAP DLC1 
(Deleted in Liver Cancer 1), a tumor suppressor gene commonly deleted in liver cancer350.  The 
authors determined that p120RasGAP-DLC1 dimerization occurs via the SH3 domains of 
p120RasGAP and the RhoGAP domain of DLC1; the authors’ in vitro data further suggested 
that the interaction inhibits DLC1’s RhoGAP activity350. 
The fourteen human RasGAPs share a GAP domain but otherwise differ widely; 
RasGAPs with similar overall domain architectures can be grouped into subfamilies.  Two 
RasGAP genes recently identified as tumor suppressors, RASAL2 and DAB2IP, fall in the same 
RasGAP subfamily.  Interestingly, published and unpublished data implicate inactivation of both 
RASAL2 and DAB2IP in some of the same tumor types, including in breast cancer.  RASAL2 
inactivation in breast cancer has been discussed at length in this Dissertation; the DAB2IP 
promoter has been shown to be hypermethylated and protein levels suppressed in breast 
cancer cell lines116.  Therefore we hypothesized that RASAL2 and DAB2IP might have 
overlapping functions or cooperate to carry out their functions.  To begin addressing this 
possibility we chose to investigate whether RASAL2 and DAB2IP interact in mammary epithelial 
cells.  These data are presented in this Chapter.  
 
Results and Discussion 
MECHANISMS OF RASAL2 INACTIVATION IN BREAST CANCER 
Epigenetic silencing of RASAL2 
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To begin to investigate whether epigenetic silencing contributes to RASAL2 inactivation 
in breast cancer, we assessed the effects of the Polycomb group proteins EZH2 and BMI1 on 
RASAL2 expression.  We ectopically expressed EZH2 or BMI1 in MCF10A cells and found that 
RASAL2 protein expression decreased by approximately 55% and 40%, respectively, showing 
that both EZH2 and BMI1 can suppress RASAL2 in mammary epithelial cells (Figure 3-1A).  To 
elucidate whether Polycomb proteins are responsible for the low expression of RASAL2 in 
breast cancer, we acutely inactivated EZH2 or BMI1 in a number of breast cancer cell lines with 
low RASAL2 levels.  We found that inactivation of either EZH2 or BMI1 resulted in an increase 
in RASAL2 expression, further supporting our hypothesis that epigenetic silencing contributes to 
RASAL2 inactivation in breast cancer (Figure 3-1B). 
DNA methylation often follows histone modification and further suppresses gene 
expression.  DNA methylation occurs at CpG islands, often near gene promoter regions.  
Notably, the RASAL2 promoter contains a CpG island and thus could be subject to 
hypermethylation, which also may contribute to gene silencing (Figure 3-1C). 
 
These data show that the Polycomb group proteins EZH2 and BMI1 can repress 
RASAL2 expression, and that acute inactivation of either EZH2 or BMI1 can partially reverse 
this effect, suggesting that EZH2 and BMI1 may contribute to RASAL2 inactivation in breast 
cancer.  It would be interesting to follow these studies with more detailed biochemical analyses, 
and with biological studies to explore how central a role RASAL2 inactivation plays in the 
oncogenic effects of EZH2 or BMI1 overexpression in breast cancer.  We also found that the 
RASAL2 promoter contains a CpG island and could be subject to DNA hypermethylation.  It 
would be interesting to determine if the RASAL2 promoter is hypermethylated in breast cancer 
tumor tissues and cell lines.  Together these studies would deepen our understanding of 
epigenetic silencing of RASAL2 in breast cancer, and more broadly how epigenetic regulators 
act as oncogenes through repression of tumor suppressors. 
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Figure 3-1: Epigenetic silencing of RASAL2 
(A) Effect of ectopic EZH2 or BMI1 on RASAL2 expression.  MCF10A cells were infected with 
EZH2 or BMI1 cDNA or a control; MCF7 cells are a negative control for RASAL2 expression. 
Western blot shows RASAL2 levels and confirms EZH2 and BMI1 ectopic expression; Arrow 
marks ectopic (tagged) EZH2.  Graph quantifies RASAL2 levels in Western blot. 
(B) Effect of EZH2 or BMI1 inactivation on RASAL2 expression.  Western blot showing RASAL2 
levels in BT549, Hs578T, and T47D breast cancer cell lines following acute inactivation of EZH2 
(E) or BMI1 (B) as compared to a non-targeting “Scramble” shRNA (S).  Human mammary 
epithelial cells (hMEC) are a positive control for RASAL2 expression.  Western blot confirms 
EZH2 and BMI1 knockdown. 
(C) RASAL2 genomic locus (image from UCSC Genome Browser).  Red box highlights a CpG-
rich region (CpG island) in the RASAL2 proximal promoter and exon 1.  Trans S.S. indicates 
transcription start site. 
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However, Polycomb group proteins silence genes by inhibiting transcription; therefore 
we would expect to see changes in RASAL2 mRNA expression in breast cancer samples in 
which RASAL2 was silenced by this mechanism.  We looked extensively at mRNA microarray 
expression databases (Oncomine, TCGA – The Cancer Genome Atlas), but did not see a 
decrease in RASAL2 mRNA expression in breast cancer samples in these databases (nor an 
inverse correlation between RASAL2 and EZH2 or BMI1) (data not shown).  Therefore we 
concluded that although epigenetics may play a role in RASAL2 suppression, as of yet there is 
no definite link.  Many possibilities exist that could explain why we do not see loss of RASAL2 
mRNA expression in publicly available databases.  Importantly, as described in Chapter 2 of this 
Dissertation, we do see loss of RASAL2 protein in breast cancer primary tumors and cell lines.  
Therefore we chose to explore additional hypotheses of how RASAL2 might be inactivated and, 
based on the above observations, hypothesized that RASAL2 may be commonly inactivated in 
cancer via post-transcriptional (specifically post mRNA) mechanisms.  We began to pursue this 
possibility by investigating miRNA-mediated suppression (data suggest that miRNAs may 
repress expression of target genes through mRNA degradation and suppression of protein 
translation318) and proteasomal degradation.  We will next discuss miRNA-mediated 
suppression of RASAL2 in breast cancer; in Chapter 4 of this Dissertation we discuss 
proteasomal degradation. 
 
miRNA-mediated suppression of RASAL2 
We used publicly available miRNA prediction algorithms to identify miRNAs predicted to 
target RASAL2, focusing on miRNAs that multiple algorithms predict to target RASAL2 (to 
reduce the number of false positives) and on miRNAs that the prediction algorithm TargetScan 
ranks highly (our unpublished observations suggest that TargetScan predictions are most often 
accurate351) (Figure 3-2A).  We then queried the literature to identify miRNAs implicated as 
breast cancer oncogenes.  The intersection of these searches resulted in miRNA candidates  
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Figure 3-2: miRNA-mediated suppression of RASAL2 
(A) Table of miRNAs predicted to target RASAL2.  Number of miRNA prediction databases that 
predict each miRNA to target RASAL2 is indicated.  Databases searched were TargetScan, 
miRanda, PicTar, and microcosm.  TargetScan Rank: where within the top 20 miRNAs 
predicted to target RASAL2 each miRNA on this list falls.  --: not ranked. 
(B) Top: Western blot showing RASAL2 expression following transfection of a miR control or 
miR-135b mimic into MCF10A cells.  Bottom: Quantification of Western blot results. 
(C) Luciferase reporter system and results.  Top: schematic of luciferase reporter construct in 
which the RASAL2 3’UTR follows the Renilla luciferase gene.  Bottom: Results of luciferase 
assay, shown as the ratio of renilla to firefly (internal control) luciferase in cells transfected with 
a miR-135b mimic versus a miR mimic control.  EV: empty vector 3’UTR.  The RASAL2 3’UTR 
was subcloned into the luciferase reporter vector in two pieces, as diagrammed.  Black 
horizontal bars mark predicted miR-135b consensus recognition sites.  RASAL2-1: construct 
with the 5’ half of the RASAL2 3’UTR (3 miR-135b consensus sites).  RASAL2-2: construct with 
the 3’ half of the RASAL2 3’UTR (2 miR-135b consensus sites). 
(D) Top: Relative expression of miR-135b in a panel of breast cancer cell lines and normal 
mammary epithelial cells, as determined by quantitative real-time PCR.  Data are shown as 
average ± SD.  Bottom: Western blot showing RASAL2 expression in panel of breast cancer cell 
lines.  Cell lines with relatively high miR-135b and low RASAL2 levels are circled (MCF7, MDA-
MB-361). 
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Figure 3-2 (Continued)
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implicated as breast cancer oncogenes and predicted to target RASAL2.  We hypothesized that 
some of these miRNAs may aberrantly down-regulate RASAL2 in breast cancer, explaining at 
least in part how RASAL2 is inactivated and how the miRNA(s) drive breast cancer.  We first 
focused on miR-135b; miR-135b was predicted to target RASAL2 by multiple prediction 
algorithms and TargetScan ranked it highly, and miR-135b had been linked to breast cancer but 
its important target genes were not known.  We ectopically expressed a miR-135b or control 
miRNA mimic in MCF10A cells, and found that ectopic miR-135b decreased endogenous 
RASAL2 expression by over 50%, demonstrating that miR-135b can suppress RASAL2 (Figure 
3-2B). 
We next wanted to confirm that miR-135b directly targets RASAL2.  The RASAL2 3’UTR 
contains five predicted miR-135b target sites.  We cloned the RASAL2 3’UTR, in two 
approximately 3kb pieces, into a luciferase reporter vector (Figure 3-2C).  We transfected the 
luciferase-RASAL2-3’UTR construct (or a control 3’UTR construct) into HeLa cells along with 
either a miR-135b or control miRNA mimic.  We assessed luciferase expression and found that 
miR-135b specifically decreased expression of luciferase from each luciferase-RASAL2-3’UTR 
construct (interestingly, the second half of the RASAL2 3’UTR had a more potent effect) (Figure 
3-2C).  Based on these data we concluded that miR-135b directly targets the RASAL2 3’UTR. 
Having shown that miR-135b down-regulates RASAL2 in mammary epithelial cells, we 
wanted to explore whether miR-135b contributes to RASAL2 inactivation in breast cancer.  To 
this end we assessed miR-135b expression in our panel of breast cancer cell lines to determine 
whether miR-135b and RASAL2 expression levels inversely correlate overall or in a particular 
subset of samples.  miR-135b expression was high in some cell lines with low RASAL2 (MCF7, 
MDA-MB-361), suggesting that in these lines miR-135b may contribute to RASAL2 suppression 
(Figure 3-2D, circled).  Overall, however, there was not a strong inverse correlation between 
miR-135b and RASAL2 expression.  Thus, although miR-135b may contribute to RASAL2 
inactivation in some cases, at this point it is unclear the role it may play in vivo; to determine this 
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we would need tumor samples where we could assess miRNA and protein levels.  It also would 
be interesting to pursue other putative RASAL2-targeting miRNAs and to identify which miRNAs 
might play significant roles in RASAL2 inactivation in breast cancer. 
 
Prior to the studies presented here, it was unknown how RASAL2 was inactivated in 
breast cancer.  In this Chapter we demonstrated a possible role for two non-genetic 
mechanisms.  We believe that both mechanisms, and possibly others, may contribute to 
RASAL2 inactivation in breast cancer.  Precedent exists for tumor suppressor genes to be 
inactivated in cancer via multiple mechanisms.  The RasGAP gene NF1 is inactivated in 
glioblastoma via mutation, deletion, and aberrant proteasomal degradation110, and the RasGAP 
gene DAB2IP is inactivated in prostate cancer via multiple, mainly non-genetic mechanisms 
118,121.  Further, we believe that the biology of tumor evolution might promote multiple, 
particularly non-genetic mechanisms of gene inactivation.  I explore these concepts in Chapter 4 
of this Dissertation.  Finally, we believe that understanding how RASAL2 is inactivated in breast 
cancer will allow us to explore potential prognostic indicators or therapeutic avenues. 
 
RASAL2 INACTIVATION COOPERATES WITH ESTROGEN SIGNALING 
At least 20% of breast cancer tumor samples and cell lines we have interrogated 
express significantly reduced RASAL2 levels.  Many of these tumors and cell lines are luminal 
and ERα-positive (Figure 3-3A and Chapter 2).  We decided to investigate whether RASAL2 
inactivation might specifically contribute to the biology of ERα-positive breast tumors.  However, 
we first wanted to address the possibility that low RASAL2 in luminal breast cancers simply 
reflects an absence of RASAL2 expression in all luminal mammary epithelial cells (and not a 
specific inactivation of RASAL2 in cancer).  All normal mammary epithelial cell lines in culture  
are basal-like, so we were not able to look at RASAL2 protein expression in this manner.   
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Figure 3-3: RASAL2 inactivation cooperates with estrogen signaling 
(A) RASAL2 expression, breast cancer subtype (lu – luminal, ba – basal), and ERα status in a 
panel of breast cancer cell lines. 
(B) Relative RASAL2 expression in subsets of sorted human mammary epithelial cells.  MaSC: 
mammary stem cell-enriched (CD49hi EpCAM-).  LP: luminal progenitor (CD49f+ EpCAM+).  
ML: mature luminal (CD49f- EpCAM+)330. 
(C) Growth curve of CAMA1 cells following acute inactivation of RASAL2 or control (Scramble 
shRNA).  Cells were plated, treated with 10nM β-estradiol, and counted on indicated days.  Data 
are shown as relative cell number ± SD.  Western blot below confirms RASAL2 knockdown. 
(D) Growth curve of MCF7 cells following ectopic expression of RASAL2 or LacZ cDNA.  Cells 
were plated, treated with 0, 1, or 10nM β-estradiol, and counted on day 5.  Data are shown as 
relative cell number ± SD.  Western blot below confirms ectopic RASAL2 expression. 
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Instead, we assessed RASAL2 mRNA expression in sorted human mammary epithelial cells 
and found similar levels of RASAL2 in a mammary stem cell-enriched population of cells, 
luminal progenitor cells, and mature luminal cells (Figure 3-3B)330.  These data suggest that 
RASAL2 is expressed to a similar level in different types of mammary epithelial cells; thus we 
think it is unlikely that RASAL2 is not expressed in luminal cells, and believe that this finding 
supports our hypothesis that instead RASAL2 is inactivated in luminal mammary tumors. 
We next asked whether RASAL2 inactivation cooperates with ERα-driven signaling.  We 
acutely inactivated RASAL2 in CAMA1 cells (which are ERα-positive) and assessed estrogen-
driven proliferation.  Indeed, we found that RASAL2 inactivation accelerated estrogen-driven 
proliferation (Figure 3-3C).  We then ectopically expressed RASAL2 in MCF7 cells (which are 
ERα-positive and lack RASAL2) and found that ectopic RASAL2 interfered with estrogen-driven 
proliferation (Figure 3-3D).  Notably, RASAL2 does not affect cell proliferation under normal 
growth conditions (Figure 2-3A).  Together these data suggest that RASAL2 inactivation 
enhances ERα-driven proliferation in breast cancer cells. 
 
Within the last decade molecular profiling has divided breast cancers into distinct 
subtypes197-199.  An important next step for the field is to understand the biology of each subtype 
and what drives them.  What pathways are most important and how can we use this information 
to better design therapeutic strategies? 
RASAL2 is a RasGAP, a negative regulator of Ras.  We believe that RASAL2 
inactivation contributes broadly to breast cancer at least in part via its promotion of Ras 
signaling.  Here we showed that RASAL2 expression is low in many ERα-positive breast cancer 
cell lines and that RASAL2 inactivation cooperates with estrogen to promote proliferation in 
these cells.  This cooperation could occur via ERK and AKT phosphorylation and activation of 
ERα, events that have been shown to occur186-188, which would lead to increased ERα-driven 
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transcription and proliferation.  This also could occur via a novel mechanism, either downstream 
of Ras or independently.  These findings imply that RASAL2 inactivation may have a particularly 
potent impact in ERα-positive tumors due to the dual effects of RASAL2 inactivation on the Ras 
pathway and ERα signaling.  It would be very interesting to delve further into these possibilities, 
in part because of potential implications for resistance to endocrine therapy, a concept that will 
be discussed in more detail in Chapter 4 of this Dissertation. 
 
THE RASGAPS RASAL2 AND DAB2IP INTERACT 
The RasGAPs RASAL2 and DAB2IP share the same domain organization and thus are 
in the same RasGAP subfamily.  We noticed that in addition to their homologous PH, C2, and 
RasGAP domains, the extreme C-termini of RASAL2 and DAB2IP are highly homologous (71%, 
Figure 3-4A).  This region does not comprise a previously annotated domain, however, we 
discovered that it is predicted to form hydrophobic coiled-coils (Figure 3-4B).  Interestingly, the 
RasGAP CAPRI homodimerizes via a similar C-terminal coiled-coil domain147.  Thus, we 
hypothesized that the RasGAPs RASAL2 and DAB2IP might heterodimerize via their 
homologous C-terminal coiled-coil domains in mammary epithelial cells, and that this could be 
important for protein function.  We immunoprecipitated endogenous RASAL2 from MCF10A 
cells and found that it co-immunoprecipitated endogenous DAB2IP, whereas control 
immunoprecipitations (p120RasGAP, pre-immune serum) did not (Figure 3-4C).  The same 
immunoprecipitation performed on MCF10A cells in which RASAL2 had been acutely 
inactivated largely failed to co-immunoprecipitate DAB2IP, showing that DAB2IP 
immunoprecipitates with RASAL2 and not non-specifically (Figure 3-4C).  We performed a 
reciprocal co-immunoprecipitation and confirmed that endogenous DAB2IP pulls down 
endogenous RASAL2 (Figure 3-4D).  Together these data show that endogenous RASAL2 and 
DAB2IP interact in mammary epithelial cells.   
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Figure 3-4: RASAL2 and DAB2IP interact 
(A) Top: Schematic of RASAL2 and DAB2IP domain organization.  Each contains a pleckstrin 
homology (PH) domain, a C2 domain, and a RasGAP domain, as indicated.  DAB2IP also has a 
Period-like domain (Per).  The extreme C-termini of RASAL2 and DAB2IP are highly 
homologous (checkered box).  Bottom: Alignment of RASAL2 and DAB2IP extreme C-termini 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). * - identical amino acid, : - highly similar amino acid. 
(B) Extreme C-termini of RASAL2 (and DAB2IP, data not shown) are predicated to form coiled-
coils.  Data from http://embnet.vital-it.ch/software/COILS_form.html 
(C) Co-immunoprecipitation of RASAL2 and DAB2IP from MCF10A cells.  Left: Western blot of 
co-immunoprecipitation.  Top indicates antibody used for immunoprecipitation (IP), left indicates 
antibodies used to probe Western blot.  Right: Western blot of whole cell extracts.  Two right-
most lanes of both IP (left panel) and whole cell extract (right panel) Western blots are from 
MCF10A cells infected with shRNAs targeting RASAL2 (shR2) or control “Scrambled” shRNA 
(shScr).   
(D) Reverse co-immunoprecipitation in MCF10A cells.  IP antibody listed on top, Western blot 
antibody listed on left.  RASAL2 and DAB2IP co-immunoprecipitate each other; p120RasGAP 
does not. 
(E) Truncation of RASAL2 abolishes the RASAL2-DAB2IP interaction. N-terminal HA-tagged 
LacZ, RASAL2 or RASAL2 truncation mutant (Y1180X) cDNAs were expressed in MCF10A 
cells.  Left: Western blots probed for HA and DAB2IP following immunoprecipitation with an HA 
antibody.  Right: whole cell extracts confirming expression of constructs. endog: endogenous 
RASAL2; FL: full length (wildtype) cDNA; Y1180X: RASAL2 truncation mutant cDNA. 
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Figure 3-4 (Continued) 
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We next tested our hypothesis that dimerization occurs via the homologous C-terminal 
coiled-coil region.  We generated a truncation mutant of RASAL2 that terminates immediately 
preceding this region.  We expressed wildtype or truncated RASAL2 cDNAs in MCF10A cells 
and immunoprecipitated exogenous RASAL2 by its N-terminal HA tag.  We found that while 
wildtype RASAL2 co-immunoprecipitated DAB2IP, the RASAL2 truncation completely abolished 
DAB2IP co-immunoprecipitation (Figure 3-4E).  These data show that RASAL2 interacts with 
DAB2IP via its C-terminal hydrophobic coiled-coil domain. 
 
Together, these data strongly suggest that RASAL2 and DAB2IP interact in mammary 
epithelial cells.  To our knowledge this is the first example of RasGAP-RasGAP 
heterodimerization.  This finding raises many exciting questions about RASAL2 and DAB2IP, 
with potential implications for the whole gene family. 
With the knowledge that RASAL2 and DAB2IP interact, it would be interesting to explore 
the biochemistry of the interaction: What is the stoichiometry of the interaction?  Does either 
protein also homodimerize?  Under what conditions do they heterodimerize?  It also would be 
very interesting and important to explore the biology of the interaction: Is the interaction 
necessary or sufficient for RasGAP activity?  For tumor suppressor function?  DAB2IP inhibits 
NF-κB as well as Ras121; might RASAL2 inactivation also increases NF-κB signaling, perhaps 
through DAB2IP?  Given the strong connection between DAB2IP inactivation and metastasis via 
NF-κB, the RASAL2-DAB2IP interaction suggests that RASAL2 loss might promote metastasis 
via DAB2IP and NF-κB.  We return to this hypothesis in Chapter 4 of this Dissertation.  Finally, 
in this Chapter we also identified the RASAL2-DAB2IP interaction domain.  This will provide a 
useful tool to address the above-stated questions.   
Increasing evidence indicates that the RasGAPs are an important class of human tumor 
suppressor genes.  There are fourteen human RasGAP genes, many of which are expressed in 
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the majority of tissue types.  One important question is if and how RasGAPs cooperate in their 
functions.  In this Chapter we showed that the RasGAPs RASAL2 and DAB2IP do indeed 
interact.  These findings have clear implications for RASAL2 and DAB2IP biology, as mentioned 
above, and imply a potential role for RasGAP dimerization throughout the gene family.  It will be 
important to consider potential RasGAP-RasGAP interactions and their functional 
consequences as we expand our studies of RasGAPs in cancer. 
 
Materials and Methods 
Cell Culture 
MCF7 and MCF10A cells were purchased from ATCC.  BT549, Hs578T, and T47D cells 
were obtained from Dr. William Hahn (Dana-Farber Cancer Institute), and CAMA1 cells from Dr. 
Marcia Haigis (Harvard Medical School).  Cell lines were cultured according to published 
protocols.  For estrogen-driven proliferation assays, cells were cultured in phenol red-free media 
with charcoal/dextran-treated Fetal Bovine Serum (HyClone).  Cells were plated in triplicate in 6-
well plates and treated the following day with indicated concentrations of β-estradiol (Sigma) or 
ethanol for the indicated number of days. 
 
DNA Constructs, Transfections, and Infections 
Endogenous proteins were inactivated using short-hairpin RNAs (shRNAs) from The 
RNAi Consortium (Broad Institute, MIT) with the following target 21-mer sequences: RASAL2 5’-
CCCTCGTGTTCTTGCTGATAT-3’, EZH2 5’-TATTGCCTTCTCACCAGCTGC-3’, and BMI1 5’-
CGGAAAGTAAACAAAGACAAA-3’.  A scrambled non-silencing shRNA was purchased from 
Addgene 5’-CCTAAGGTTAAGTCGCCCTCG-3’ 343.  The Mammalian Gene Collection fully 
sequenced human RASAL2 cDNA was purchased from Open Biosystems (cat. # MHS4426-
99623118) and cloned into the pHAGE-N-Flag-HA lentiviral expression vector (Dr. J. Wade 
Harper, Harvard Medical School) for expression in cell lines.  The RASAL2 cDNA was 
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mutagenized using QuikChange II Site-Directed Mutagenesis kit, according to the 
manufacturer’s instructions (Agilent).  The EZH2 cDNA was cloned into the pBabe-myc 
retroviral vector for expression in cell lines121.  The BMI1 cDNA was obtained from the Orfeome 
collection and cloned into the pBabe retroviral vector for expression in cell lines.   
shRNA or cDNA vectors along with viral packaging plasmids delta 8.2 and VSVG were 
transfected into 293T cells using Fugene6 (Roche), following the manufacturer’s instructions.  
Virus supernatant was harvested after 48 hours, filtered through a 0.45µm filter, and incubated 
on target cells for 6 hours at a 1:2-1:10 dilution with 8µg/ml polybrene.  Infected cells were 
selected in 0.5-2.0µg/ml puromycin, as optimized for each cell line. 
miRNAs mimics and U6 snRNA control were purchased from Dharmacon and 
transfected into MCF10A cells using Dharmafect 1 transfection reagent.  Dharmafect 1 was 
incubated in OptiMEM and then incubated with 50nM miRNA mimic or U6 control.  The 
miRNA/Dharmafect mixture was added to a suspension of MCF10A cells and plated at 400,000 
cells per well in 6-well plates.  Protein was harvested 48-72 hours post transfection. 
 
Luciferase Assays 
The psicheck-2 vector (Promega) was modified by replacing the SV40 promoter with the 
mouse PGK promoter using the BglII and NheI sites, in order to reduce Renilla mRNA 
expression to more physiological levels.  The RASAL2 3’UTR was divided into two overlapping 
fragments, covering base pairs 1-2899 (RASAL2.1) and base pairs 2875-6268 (RASAL2.2) and 
amplified by RT-PCR, then cloned into the Renilla 3’UTR using the NotI and XhoI sites. The 
plasmids were co-transfected with miR-135b or control miRNA mimics into HeLa cells using 
Lipofectamine, and luciferase activity was tested 48 hours post transfection with the Dual-
Luciferase Reporter Assay System (Promega) as per the manufacturer's instructions. Renilla 
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luminescence was normalized to an internal control (Firefly) and test transfections were 
normalized to the control mimic transfections. 
 
TaqMan Analysis of miRNA Levels 
Total RNA was isolated from breast cancer cell lines using Trizol reagent, following the 
manufacturer’s instructions (Invitrogen).  Reverse transcription and real-time PCR were carried 
out using TaqMan MicroRNA Reverse Transcription Kit and TaqMan MicroRNA Assays, 
according to the manufacturer’s instructions (Applied Biosystems). 
 
Immunoprecipitation, Protein Lysates, and Western Blot Analyses 
For immunoprecipitations (IP), MCF10A cells were lysed in ice-cold CHAPS buffer with 
protease inhibitor tablets (Roche).  Lysates were normalized and an aliquot removed for whole 
cell lysate analysis.  Lysates were pre-cleared with protein A beads and incubated with pre-
mixed IP antibody and protein A beads overnight at 4°C.  Beads were pelleted and washed 
before separating by polyacrylamide gel electrophoresis. 
Whole cell protein extracts were isolated from cells in 1% SDS boiling lysis buffer.  
Protein lysates were quantified and separated on polyacrylamide gels.  Western blots were 
probed following validated procedures using the following antibodies: Actin (Sigma cat. # 
A2066), BMI1 (Millipore cat. # 05-637), DAB2IP (Abcam cat. # 87811), EZH2 (BD cat. # 
612666), GAPDH (Cell Signaling cat. # 2118), HA (Covance cat. # MMS-101P), p120RasGAP 
(BD Transduction Laboratories cat. # 610040), and β-Tubulin (Sigma cat. # T4026).  A peptide 
antigen (NP_773793 amino acids 1111-1130) was used to generate and affinity purify an anti-
RASAL2 rabbit polyclonal antibody (Covance ImmunoTechnologies). 
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Conclusion 
The goal of this Dissertation was to elucidate whether any additional RasGAP genes 
function as tumor suppressors in sporadic cancer.  Indeed, we discovered that a previously 
uncharacterized RasGAP gene, RASAL2, is a tumor and metastasis suppressor in breast and 
possibly other cancers.  We identified RASAL2 as a candidate tumor suppressor gene through a 
cell-based screen, and chose to focus on its role in breast cancer based on the lack of RAS 
mutations in this tumor type, the potential importance of the Ras pathway in breast cancer, and 
the presence of RasGAP domain mutations in RASAL2 in breast tumors.   
We confirmed that RASAL2 is a functional RasGAP and showed that it acts as a tumor 
suppressor: ectopic RASAL2 suppresses anchorage-independent growth in vitro and tumor 
formation in vivo and, conversely, inactivation of RASAL2 promotes anchorage-independent 
growth in vitro, xenograft tumor formation in vivo, and tumorigenesis in Rasal2-null genetically 
engineered mouse models.  We also discovered that inactivation of RASAL2 promotes cell 
migration, invasion, tumor progression, and, strikingly, widespread metastasis in multiple 
genetically engineered mouse models, including a mammary tumor model.  We found that 
RASAL2 expression is lost in primary human breast tumors, with greatest loss in metastatic 
lesions, providing strong support that RASAL2 loss contributes to human breast cancer 
development and metastasis.  Additionally, we discovered that the Ras pathway is 
hyperactivated in mammary tumors that lost Rasal2 through genetic deletion or spontaneous 
loss; these findings suggest that RASAL2 loss activates the Ras pathway and represents one 
mechanism by which the pathway is activated in, and contributes to, breast tumorigenesis and 
metastasis.   
Although mutations in RASAL2 do occur at a low frequency in human breast tumors, our 
human tumor and cell line data suggest that RASAL2 is inactivated more frequently than 
indicated by mutation analysis alone, implying that RASAL2 may be inactivated more commonly 
by non-genetic mechanisms.  Indeed, we found that both epigenetic silencing and miRNA-
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mediated suppression may contribute to RASAL2 inactivation in breast cancer.  These findings 
support our broader hypothesis that tumor suppressor RasGAPs are commonly inactivated in 
human cancer via non-genetic mechanisms. 
Finally, we discovered that RASAL2 interacts with another tumor suppressor RasGAP, 
DAB2IP, in mammary epithelial cells.  This finding suggests that RASAL2 and DAB2IP may act 
in concert in their tumor and metastasis suppressor functions. 
Together, our human tumor, mouse modeling, and cell culture data strongly support our 
conclusion that RASAL2 is the newest tumor and metastasis suppressor in the RasGAP gene 
family.  Our findings further provide support to what we view as three important, emerging 
concepts.  First, that the Ras pathway plays a key role in breast tumorigenesis and metastasis, 
and becomes hyperactivated as a result of RASAL2 inactivation.  Second, that epigenetic and 
non-genetic repression of tumor suppressor genes is a common mechanism of their inactivation 
in cancer.  And third, that multiple RasGAPs are human tumor suppressors and may function 
together to carry out their tumor suppressive activities. 
 
Future Directions 
Mechanisms of RASAL2 inactivation in breast cancer 
Currently available data suggest that RASAL2 mutations occur in 1-4% of breast 
cancers46,328,329.  However, as reported in Chapter 2 of this Dissertation, we found that RASAL2 
protein is lost in at least 20% of breast cancer primary tumor tissues and cell lines.  Thus, we 
believe that the RASAL2 mutation rate underrepresents the frequency with which RASAL2 is 
inactivated in breast cancer, and raises the question of how RASAL2 is commonly inactivated.  
In Chapter 3 of this Dissertation we began to investigate two possible mechanisms of 
inactivation.  First, we explored epigenetic silencing; we found that EZH2 and BMI1 can 
suppress RASAL2 expression and that inactivation of EZH2 or BMI1 increases RASAL2 
expression.  Among possible next steps, it would be important to determine whether EZH2 or 
	  108 
BMI1 can be found at the RASAL2 promoter, and to determine whether re-expression of 
RASAL2 can rescue phenotypes induced by EZH2 or BMI1.  However, as noted in Chapter 3 of 
this Dissertation, in contrast to our finding of RASAL2 protein loss in at least 20% of breast 
cancer samples, publicly available mRNA expression databases do not indicate loss of RASAL2 
mRNA in breast tumor samples as compared to normal mammary tissue.  We would expect 
mRNA and protein levels to be suppressed by EZH2 or BMI1-mediated silencing; thus it 
remains unclear how significant a role Polycomb group protein mediated silencing may play in 
RASAL2 suppression in human tumors.  We therefore began to explore additional possible 
mechanisms of RASAL2 inactivation in breast cancer. 
In Chapter 3 of this Dissertation we initiated an investigation into whether miRNAs might 
suppress RASAL2 in breast cancer, and presented preliminary data on one miRNA, miR-135b.  
Many miRNAs are predicted to target RASAL2 and have been implicated as breast cancer 
oncogenes; it would be important to functionally test more candidate miRNAs to more 
thoroughly explore how miRNA regulation contributes to RASAL2 inactivation in breast cancer.  
Furthermore, it will be important to obtain human tissue samples in which we can assess 
expression levels of RASAL2 (protein) and miRNAs. 
It also will be important to consider additional mechanisms of inactivation, in particular 
proteasomal degradation.  The RasGAP neurofibromin is aberrantly degraded by the 
proteasome in glioblastoma110.  Additionally, many other well-known tumor suppressor genes, 
including TP53, PTEN, and CDKN1B (p27), are inactivated in cancer partially via proteasomal 
degradation88,280,352.  We hypothesize that RASAL2 also could be subject to aberrant 
proteasomal degradation in sporadic cancer.  Our preliminary analysis in breast cancer cell lines 
indicates that proteasomal degradation may play a role in RASAL2 inactivation in some cases 
(data not shown), and warrants further investigation into this hypothesis. 
The RASAL2 gene is located on chromosome 1q (1q24).  The 1q chromosome arm 
often undergoes copy number gain in breast and other cancers166,167, and there is no evidence 
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of focal deletion of RASAL2.  Thus, genomic loss is not likely to contribute to RASAL2 
inactivation in breast cancer.  Further, the copy number gain of 1q raises an intriguing 
hypothesis.  Perhaps in tumors cells with 1q gain, only cells that evolve a means to suppress or 
at least not overexpress RASAL2 are able to grow and progress as a tumor.  In order to test this 
hypothesis we would want to determine whether RASAL2 is specifically suppressed or not 
overexpressed in tumors with 1q gain, for example in comparison to other genes on the 1q 
amplicon.   
Our hypothesis of 1q copy number gain and subsequent suppression of RASAL2 fits 
well with the potential mechanisms of inactivation suggested by our preliminary data 
(epigenetics, miRNAs, proteasomal destruction), and with our understanding of how tumor cells 
avoid or escape a phenomenon called oncogene induced senescence.  Oncogene induced 
senescence is a natural tumor suppressive mechanism that exists within cells353.  Upon 
expression of an oncogene, such as mutant Ras, cells undergo a burst of proliferation followed 
by an irreversible growth arrest354.  Importantly, the signals that activate oncogene induced 
senescence are sensitive to levels of the oncogenic stimulus.  For example, overexpression of 
oncogenic Ras in mammary epithelial cells triggers oncogene induced senescence, whereas 
low-level expression of the same oncogene does not trigger senescence and instead drives 
proliferation355.  Thus, a gradual increase in Ras signaling as a result of a gradual suppression 
of RASAL2, such as in response to gradually increasing EZH2 levels (which data has shown 
occurs in breast and other tumors122,300), might allow the tumor to grow and evade oncogene 
induced senescence.  It would be very interesting to explore this hypothesis.  Notably, this 
hypothesis could be true whether or not RASAL2 is specifically suppressed in tumors with 1q 
copy number gain, and vice versa. 
 
Biochemical analysis of RASAL2 
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Before the work presented in this Dissertation, RASAL2 was a completely 
uncharacterized gene beyond its indirectly determined activity as a RasGAP165.  We have 
confirmed that RASAL2 is a functional RasGAP and have demonstrated its biological 
importance in suppressing tumorigenesis and metastasis.  Many questions remain regarding 
RASAL2 structure and function, a more detailed understanding of which will aid our 
understanding of RASAL2 biology.  We know that RASAL2 is a functional RasGAP, however, it 
will be important to determine which Ras isoform(s) RASAL2 most potently regulates.  Our 
preliminary data suggest that RASAL2 may regulate both H- and K-Ras (data not shown).  Data 
suggest that a number of RasGAPs (SYNGAP1, RASAL1, CAPRI, and GAP1IP4BP) also 
function as RapGAPs127,146.  It would be interesting to explore whether RASAL2 also has activity 
against Rap.   
RASAL2 contains pleckstrin homology (PH) and C2 domains.  It would be informative to 
determine the function of these domains, in particular whether RASAL2 is a calcium-regulated 
RasGAP.  Many RasGAPs contain C2 domains; some but not all C2-domain containing 
RasGAPs are calcium-sensitive126,148,149.  It also will be important to determine RASAL2’s 
subcellular localization, which may be determined in part by its PH domain; this may help 
answer questions about protein function and protein-protein interactions.   
Finally, it would be interesting to investigate whether RASAL2 expression and function 
are cell cycle regulated.  The RasGAP neurofibromin is cell cycle regulated via proteasomal 
degradation; neurofibromin destruction plays a key role in Ras pathway activation and entry into 
the G1 phase of the cell cycle25.  It remains an open question whether RASAL2 (or any other 
RasGAP) also is regulated by the cell cycle. 
 
Novel functions of RASAL2 
In this Dissertation we showed that RASAL2 is a functional RasGAP.  An exciting and as 
of yet unexplored possibility is that RASAL2 also possesses non-RasGAP activities.  
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Suggestions in the literature, our unpublished findings, and precedent from other RasGAPs all 
support this hypothesis.  Two published large-scale co-immunoprecipitation/mass-spectrometry 
studies have identified putative RASAL2-interacting proteins.  Bouwmeester et al. found 
RASAL2 to co-immunoprecipitate with the inhibitor of NF-κB, IκB-β169.  We find this putative 
interaction especially intriguing because precedent exists for tumor suppressor RasGAPs to co-
regulate the Ras and NF-κB pathways: DAB2IP suppresses both Ras and NF-κB and both 
functions are critical for the potent tumor suppressive effects of DAB2IP in the prostate121.  It will 
be exciting to pursue Bouwmeester et al.’s finding, and if the interaction between RASAL2 and 
IκB-β is confirmed, to characterize the interaction and elucidate its biological effects.  Second, 
Jin et al. reported that RASAL2 co-immunoprecipitates with 14-3-3 γ170.  14-3-3 proteins are 
abundant cellular proteins with diverse roles to facilitate protein-protein interactions, affect 
protein subcellular localization, and stabilize phospho-protein conformations170.  The 14-3-3 γ-
RASAL2 interaction was reported in HEK293 cells.  We would want to determine whether these 
proteins interact in mammary epithelial cells, and to assess the impact of 14-3-3 γ binding on 
RASAL2 subcellular localization, other protein-protein interactions, and function.  
A collaborator’s unpublished findings suggest that RASAL2 also may interact with the 
proteins MCC and USHBP1356.  MCC (mutated in colorectal cancer) and USHBP1 (Usher 
syndrome 1C binding protein 1, also called MCC2) are related proteins thought to have tumor 
suppressive functions in the colon, perhaps via negative regulation of the cell cycle357,358.  Using 
a combination of proteomics and bioinformatics approaches, our collaborators sought to identify 
proteins that interacted with both MCC and USHBP1.  One of their top hits was RASAL2, 
indicating that RASAL2 interacts with MCC and USHBP1, either together or separately.  
Surprisingly, another top hit was DAB2IP, suggesting that RASAL2 and DAB2IP may complex 
together with these proteins, or that RASAL2 and DAB2IP could substitute for each other in 
binding MCC and USHBP1.  In light of our findings that RASAL2 and DAB2IP interact with each 
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other (Chapter 3), we hypothesize that a complex may form containing RASAL2, DAB2IP, MCC, 
and USHBP1.  Whether this complex exists and what function it has are exciting questions 
waiting to be answered. 
As a complementary means to interrogate novel functions of RASAL2, it could be 
revealing to take an unbiased approach, namely via microarray analysis and 
immunoprecipitation/mass-spectrometry.  Microarray analyses comparing control and RASAL2 
knockdown cells would uncover signaling pathways altered upon RASAL2 inactivation.  We 
would expect to see up-regulation of the Ras pathway, but anticipate that other pathways might 
also be up- or down- regulated.  In parallel we also could immunoprecipitate RASAL2 from cells 
(particularly from mammary epithelial cells where we know RASAL2 functions) and use mass 
spectrometry to identify novel RASAL2-interacting proteins, possibly confirm the above-
mentioned putative RASAL2-interacting proteins, and point to potential signaling pathways that 
RASAL2 affects. 
We anticipate that RASAL2 possesses non-RasGAP activities, and expect that the 
targeted and unbiased approaches described above will uncover new function(s).  Importantly, a 
precedent exists for RasGAPs to act as signaling scaffolds, controlling multiple pathways.  Our 
laboratory showed that the RasGAP DAB2IP negatively regulates both Ras and NF-κB 
signaling and that DAB2IP is a potent tumor and metastasis suppressor in the prostate because 
of its ability to critically regulate both pathways121.  The NF1 gene encodes a nearly 3000-amino 
acid protein, only 10% of which comprises annotated domains.  However, neurofibromatosis 
type I patients present with mutations that span the NF1 gene105.  Together these data suggest 
that NF1 also has non-RasGAP functions, a hypothesis supported by our laboratory’s 
unpublished findings.  Notably, NF1 and DAB2IP are the only RasGAPs confirmed to be human 
tumor suppressors (before our identification of RASAL2).  However, as detailed in Chapter 1 of 
this Dissertation, most of the 14 human RasGAPs possess catalytic GAP activity; why certain 
RasGAPs are tumor suppressors and others are not remains an open and very interesting 
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question.  Many factors could contribute, including RasGAP expression pattern, subcellular 
localization, and target Ras protein(s).  However, we hypothesize that another important factor 
may be whether a RasGAP gene possesses additional non-RasGAP activities such that it 
coordinately regulates Ras as well as another critical signaling pathway in the cell.  We expect 
that future studies of RASAL2 and NF1 non-RasGAP functions as well as further 
characterization of other RasGAPs, will help test this hypothesis and elucidate what makes a 
RasGAP a tumor suppressor.  
 
RASAL2-DAB2IP interaction and function 
In this Dissertation we report for the first time that the RasGAPs RASAL2 and DAB2IP 
interact.  This exciting finding raises many questions regarding how RASAL2 and DAB2IP each 
function, with implications for the RasGAP gene family as a whole; I will discuss a selection of 
these questions here.  The most important next step in studying this interaction will be to 
investigate its biological consequences.  Is the interaction necessary and/or sufficient for the 
tumor suppressive functions of each protein?  Does heterodimerization impact the RasGAP 
activity of either RASAL2 or DAB2IP?  DAB2IP also inhibits the NF-κB pathway, therefore it also 
will be important to assess whether heterodimerization impacts DAB2IP’s effects on NF-κB 
signaling (and potentially on metastasis, as discussed further below).  In this Dissertation we 
determined that RASAL2 and DAB2IP interact via a highly homologous coiled-coil region at the 
proteins’ C-termini, and generated a truncation mutation in RASAL2 that abolishes 
heterodimerization.  The heterodimerization mutant should prove to be a useful tool for future 
dissection of the biochemistry and biology of the interaction. 
RASAL2 and DAB2IP both have been implicated as tumor suppressors in breast cancer 
(our work presented in this Dissertation – RASAL2, Dote et al. – DAB2IP116).  This, in 
combination with knowledge of the RASAL2-DAB2IP interaction in mammary epithelial cells, 
	  114 
evokes many possible scenarios for how the proteins might function.  Does loss of either 
RASAL2 or DAB2IP promote tumorigenesis?  Metastasis?  Is loss of both proteins required for 
either process?  It will be exciting to answer these questions.  Further, lessons learned 
regarding how RASAL2 and DAB2IP function together in breast cancer may be applicable to 
RASAL2 and DAB2IP in other tumor types, and possibly to other RasGAPs whose functions 
might be affected by heterodimerization. 
Lastly, it also is important to note that future experiments assessing novel functions of 
RASAL2 (discussed above) will need to consider that novel functions may result from direct 
actions of RASAL2 or indirectly via RASAL2 binding to DAB2IP. 
 
Signaling in MMTVneu; Rasal2 compound mutant mice 
Neu (HER2) is a receptor tyrosine kinase that signals through the Ras pathway.  A very 
simplified model might suggest, therefore, that HER2 overexpression and RASAL2 loss might 
be redundant and together might have the same phenotype as either alteration individually.  
However, our mouse model data presented in Chapter 2 of this Dissertation clearly show that 
this is not true, as double mutant compound mice are subject to a significantly greater 
metastasis burden than MMTVneu controls.  Many possibilities exist as to how HER2 
overexpression and RASAL2 loss cooperate.  First, both HER2 and RASAL2 likely have 
functions that are non-redundant.  HER2 does signal through the MAPK and PI3K pathways; 
however, it also activates other downstream effectors, such as the Jak/STAT pathway218.  
Further, as discussed in this Chapter, we hypothesize that RASAL2 may have non-RasGAP 
activities, such as activating the NF-κB pathway.  Second, even within the same signal cascade, 
we believe that HER2 overexpression and RASAL2 loss might cooperate.  HER2 
overexpression drives signaling through the pathway; however, negative regulators of the 
pathway, such as RASAL2, still could lessen pathway throughput, and many studies have 
demonstrated that flux through the pathway affects biological outcome359,360.  Thus, losing 
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RASAL2 might be necessary for HER2 to fully activate the MAPK and PI3K pathways.  We 
expect that this may be particularly important for promoting metastasis, as MMTVneu; Rasal2 
compound mutant mice specifically develop a more severe metastatic phenotype. 
 
Mechanism of metastasis potentiation upon RASAL2 loss 
The mouse models presented in this Dissertation revealed a striking increase in 
metastasis upon Rasal2 loss.  It would be interesting to determine the mechanism(s) by which 
Rasal2 loss drives metastasis.  The contribution of the Ras pathway to cancer metastasis 
remains an open question; moreover, RASAL2 may or may not have additional, non-RasGAP 
functions.  Therefore, it will be very interesting to determine whether RASAL2 inactivation drives 
metastasis through its activation of the Ras pathway and/or via other mechanisms.  The NF-κB 
pathway is a known driver of metastasis361.  One hypothesis is that RASAL2 loss drives 
metastasis via activation of NF-κB, either directly such as via binding of IκB-β, or indirectly, via 
DAB2IP and its well-established regulation of NF-κB signaling121. 
If the Ras pathway contributes to metastasis following Rasal2 loss, it would be 
interesting to determine which effector pathways downstream of Ras play a critical role in this 
process.  Such insights would have potential therapeutic benefits as well.  Ras itself is not 
currently druggable32, but many drugs exist that target Ras effector pathways, such as 
rapamycin which inhibits mTOR (PI3K pathway), and PD-901 which inhibits MEK (MAPK 
pathway).  It would be important to identify the downstream effectors that drive metastasis in 
order to design a therapeutic strategy to target the key pathway(s); notably, our laboratory has 
used this strategy successfully: our laboratory identified mTOR as the critical Ras effector 
pathway in MPNST development and used this knowledge to design what proved to be a 
successful therapeutic strategy of rapamycin treatment102,103.  In this Dissertation I showed that 
Rasal2 loss drives metastasis not only of breast tumors but also from numerous sporadic 
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tumors that Trp53 +/-; Rasal2 compound mutant mice develop.  It would be interesting to 
assess whether the same or different pathways drive metastasis in these settings.  
 
RASAL2 loss and resistance to anti-estrogen or anti-HER2 therapies 
Resistance to targeted therapy for breast cancer remains a major outstanding problem in 
the clinic.  Nearly one-third of women who present with ERα-positive breast cancer and are 
treated with the standard five years of tamoxifen therapy relapse with endocrine-resistant 
disease185.  Importantly, given the high fraction of breast cancers that are ERα-positive, patients 
with endocrine resistant disease represent nearly one-quarter of all breast cancer cases.  
Mechanisms of resistance are not well understood, but one proposed mechanism involves up-
regulation of receptor tyrosine kinases or activation of the Ras, MAPK, and PI3K pathways362.  
Cell culture studies suggest that PI3K and MAPK signaling can confer resistance to endocrine 
therapy through ligand-independent activation of ERα (AKT and ERK each can phosphorylate 
and activate ERα and can do so in the absence of estrogen186-188) and/or through activation of 
canonical PI3K and MAPK transcriptional targets that promote proliferation and survival 
independently of ERα185,363.  However, whether these proposed mechanisms cause resistance 
in patients remains unclear185.  Given that RASAL2 inactivation stimulates the MAPK and PI3K 
pathways, and that RASAL2 inactivation contributes to ERα-driven proliferation (perhaps via 
AKT or ERK-mediated phosphorylation of ERα, or via a novel mechanism) as shown in Chapter 
3 of this Dissertation, we hypothesize that RASAL2 inactivation in ERα-positive breast cancers 
may be a mechanism by which endocrine resistance develops.  It would be exciting to explore 
this possibility; clarifying mechanisms of endocrine resistance that occur in women with ERα-
positive breast cancer could help suggest ways to treat endocrine resistant disease more 
effectively. 
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HER2-overexpressing breast cancers are aggressive and have poor prognoses203.  Anti-
HER2 targeted therapies currently used in the clinic include trastuzumab, a monoclonal 
antibody that binds HER2220-222, and lapatinib, an dual EGFR/HER2 kinase inhibitor223-225.  
Although tumors generally respond well to these therapies, the majority of tumors relapse within 
one year of treatment, and 15% are de novo resistant364,365.  Proposed mechanisms of 
resistance to anti-HER2 breast cancer therapy include signaling through other ERBB receptor 
tyrosine kinases and alternative mechanisms that activate signaling pathways downstream of 
HER2208,219. (ERα expression and signaling is another major proposed mechanism of 
resistance.)  In particular, studies have implicated Ras, MAPK, and PI3K signaling in anti-HER2 
resistance.  The PI3K pathway has been shown to confer resistance to both lapatinib and 
trastuzumab, and it has been proposed (but not proven) that the PI3K pathway may become 
activated in human tumors via PIK3CA mutation or PTEN loss366-368.  Further, unpublished data 
from a collaborator demonstrated that oncogenic Ras confers resistance to lapatinib in HER2-
overexpressing breast cancer cell lines369.  Oncogenic Ras also confers resistance to anti-
EGFR therapies in a number of tumors types370.  Based on these findings, the dearth of RAS 
mutations in breast cancer, and the role that we believe RASAL2 inactivation plays in this tumor 
type, we hypothesize that RASAL2 inactivation may be a mechanism by which HER2-
overexpressing breast cancers acquire resistance or are de novo resistant to anti-HER2 
therapies.  Notably, our MMTVneu; Rasal2 -/- mouse model provides a unique tool to study 
HER2 resistance and to test this hypothesis.  Finally, it is important to mention that mechanisms 
of resistance to anti-HER2 therapies could differ depending on the specific therapy227. 
 
RASAL2 inactivation in other sporadic cancers 
The majority of the work presented in this Dissertation focuses on RASAL2 inactivation 
in breast cancer.  However, our data suggest that RASAL2 inactivation might also contribute to 
other sporadic cancers.  First, RASAL2 mutations have been found in a number of tumor types, 
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including lung, liver, ovarian, and head and neck cancers.  Second, in the context of Trp53 
homozygous or heterozygous loss, Rasal2 loss promotes the development and metastasis of a 
range of tumor types.  Notably, many of the tumor types observed in Trp53/Rasal2 double 
mutant compound mice also are tumor types in which RASAL2 mutations have been found in 
human tumor samples (head and neck, colon, liver).  Thus, in would be interesting to expand 
our studies of RASAL2 to these tumor types, via additional mouse crosses, the generation of a 
conditional Rasal2 knockout mouse model, and cell and xenograft studies similar to those we 
have performed for our analyses of RASAL2 in breast cancer.  Furthermore, many of the breast 
cancer-related future directions described in this Chapter may be applicable to RASAL2 in other 
tumor types as well, such as differential effects on primary tumorigenesis versus metastasis and 
the interaction of RASAL2 and DAB2IP.  
 
Additional tumor suppressor RasGAP genes 
The work presented in this Dissertation highlights the RasGAPs as an expanding class 
of human tumor suppressor genes.  In addition to the future studies described above which will 
deepen our understanding of RASAL2, the newest tumor suppressor in the RasGAP gene 
family, it also could be interesting to broaden our studies and explore whether there are 
additional tumor suppressors within the family.  Our initial screen for tumor suppressors in the 
RasGAP gene family identified three genes, NF1, DAB2IP, and RASAL2, each of which we now 
know is indeed a tumor suppressor121.  It is possible, however, that additional RasGAPs also 
may have tumor suppressive roles in sporadic cancer.  In particular, suggestions in the literature 
point to RASAL1 and CAPRI as possible tumor suppressor genes150,152.  Perhaps notably, our 
screen was unable to assess the transforming properties of RASAL1 or CAPRI inactivation: 
RASAL1 is not expressed in the cells in which we conducted our screen, so our negative result 
was uninformative.  Additionally, shRNAs targeting CAPRI were not available at the time we 
performed the screen so we were unable to include CAPRI in the experiment.  Therefore, future 
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research efforts to identify additional RasGAP tumor suppressor genes might want to focus first 
on these two RasGAPs. 
 
 All together, we believe that the Future Directions described here layered atop the 
findings presented in this Dissertation will expand and develop our understanding of RasGAPs 
as tumor suppressor genes inactivated in sporadic cancer, the Ras pathway in primary 
tumorigenesis and metastasis, mechanisms of breast cancer primary tumorigenesis and 
metastasis, and mechanisms of resistance in breast cancer patients; and ultimately, we hope, 
improve outcomes for cancer patients.  
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Generation of Rasal2 Mutant Genetically Engineered Mouse 
Models 
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In this Appendix I detail the methods used to generate Rasal2 mutant genetically engineered 
mouse models. 
 
Generation of the Rasal2 genetically engineered mouse model described in Chapter 2 
As noted in Chapter 2 of this Dissertation, we generated Rasal2 mutant mice using a 
genetrap targeting strategy.  We purchased a mouse embryonic stem (ES) cell line in which the 
pNMDi4 genetrap cassette targets the third intron of Rasal2, which importantly is upstream of all 
known domains (Toronto Centre for Phenogenomics / Canadian Mouse Mutant Repository 
embryonic stem cell clone CMHD 463C12) (Figure 2-5A).  We confirmed the presence of the 
genetrap cassette within the third intron of Rasal2 using PCR from cDNA (Figure 2-5B).  The 
Brigham and Women’s Hospital Transgenic Mouse Facility injected the ES cells into blastocysts 
and implanted them into pseudo-pregnant recipients to generate chimeric pups.  We crossed 
chimeras to wildtype Black 6 animals (C57BL/6-E, Charles River Laboratories cat. # 475) and 
tested agouti pups (those whose chimeric parent-derived germ cell was genetrap ES cell line 
based) for presence of the genetrap.  We noticed that too high a fraction of agouti pups were 
genetrap-positive.  We would expect 50% of agouti pups to be genetrap positive: 50% of ES cell 
derived germ cells should be genetrap positive since the parental ES cell line should be 
monoallelic for the genetrap.  However, 100% of agouti pups (13/13) were genetrap positive.  
We hypothesized that this resulted from the presence of multiple insertions of the genetrap 
cassette within the genome of the original mouse ES cell line.   
To determine the number of genetrap copies in the mouse ES cell line and F1 pups, we 
performed Southern blot analyses of genomic DNA, probing for the genetrap cassette.  We 
found that the ES cell line had three copies of the genetrap cassette, and that F1 pups had two 
or three of these copies (Figure A-1A).  These findings suggested that the ES cell line has two 
extra copies of the genetrap.  We outcrossed F1 pups to wildtype mice and performed Southern 
blot analyses of genomic DNA from pups.  By cross referencing the Southern blot results with 
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cDNA PCR analyses that tested for the presence of the genetrap cassette within the Rasal2 
locus, we identified animals with the genetrap cassette only within the Rasal2 locus (Figure A-
1B).  These animals were used as founders for all cohorts described in this Dissertation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-1: Southern blot analysis of genetrap-positive mice 
(A) Southern blot probed for genetrap cassette.  Mouse embryonic stem cell line genomic DNA 
has 3 copies of the genetrap cassette (ES, far right lane).  Genomic DNA from wildtype mice is 
a negative control and has no bands (wt, next to right most lane).  Each other lane has genomic 
DNA from a mouse that has the genetrap cassette at least within the Rasal2 locus, as 
determined by PCR of cDNA.  The top band is present in all lanes, and therefore must be the 
band that recognizes the genetrap cassette in the Rasal2 locus (red arrow).  Black arrows 
indicate copies of the genetrap elsewhere in the genome. 
(B) Confirmation of Southern blot results.  Top panel: Southern blot for genetrap cassette.  Red 
arrow indicates copy of the genetrap cassette within the Rasal2 locus.  Animals 91 and 96 have 
this band and no other bands.  Middle panel: genomic DNA (gDNA) PCR is positive in all 
animals that have any copy of the genetrap cassette.  All animals with a band on the Southern 
blot are gDNA PCR positive.  Bottom panel: cDNA PCR for the genetrap cassette within the 
Rasal2 locus.  Animals 91 and 96 are positive, whereas 92 and 94 are negative (92 and 94 
have the genetrap cassette within a different locus).  Animals 91 and 96 were among those 
used to generate all cohorts and crosses. 
 
Backcrossing Rasal2 genetrap mice onto a pure background 
The Rasal2 genetrap animals described above and in Chapter 2 are on a 129-enriched 
background of 75% 129S1/SvImJ (129) and 25% C57BL6/J.  We backcrossed the Rasal2 
genetrap line onto a pure 129 background through ten generations of backcrossing genetrap-
Rasal2-trapped 
A wt 
(-) 
ES 
(+) 88   89   90   91   92    93    94   95    96 
gDNA PCR: 
(genetrap +) 
91  92   94   96  ES(+) 
cDNA PCR: 
(Rasal2-trapped) 
B 
88   89  90   91   92  93   94  95   96 
 148 
positive animals to wildtype 129S1/SvImJ animals and selecting genetrap-positive pups at each 
generation (Table A-1). 
Table A-1: Genetically engineered mouse model backcrossing 
 
Percent contribution of destination 129 genome to animals at each generation.   
Ten generations of backcrossing produces animals on a pure 129 background. 
 
Generation of a second Rasal2 genetrap mouse line 
We obtained from the Texas Institute for Genomic Medicine a second mouse ES cell line 
with a genetrap cassette targeting Rasal2, mouse ES cell line IST11848D8 (Figure A-2A).  The 
genetrap cassette is localized within intron 1 of Rasal2 (Figure A-2B).  We generated genetrap-
positive animals, bred them onto a 129-enriched background, and generated a cohort of mice, 
which we have maintained within the laboratory but which we have not used for analyses 
described in this Dissertation. 
Figure A-2: Second 
Rasal2 genetrap line 
(A) Mouse ES 
genetrap cell line 
IST11848D8 targets 
intron 1 of Rasal2. 
(B) Precise location 
of the genetrap 
cassette as 
determined by the 
Texas Institute of 
Genomic Medicine.  
Asterisk indicates site 
of genetrap insertion.  
Generation 129 
contribution 
F1 50.00% 
N2 75.00% 
N3 87.50% 
N4 93.75% 
N5 96.88% 
N6 98.44% 
N7 99.22% 
N8 99.61% 
N9 99.81% 
N10 99.90% 
5’TAGAATCATACAATATTTATCTTTTTATATTTAGGTTATTTCCCTCTGTAAAATGTTTTCAGGGTTT
ATTCATATTGAAGCAAGTATCTAATTCTAGTCATTATAAGACTGAATAATATTCCTTTGTATGCGTT
GGTCATAATTTTTTAGACATTGATTTTCTGGTGAATGCTTTGGGTATTAACACTTTTTGGCTCTTG
TACGTCTTGCTGCTATCAAATTTGGTACACAAATAATCTTTCAATCCTTG*CTTGGAGTTTTTGGG
GGTATACCCAGGAGTAGAATTGCTGGGTCATATATTTTATTTTACTTTATTTTATTTTATTTATTTATT
TTTTTTTTTGGTTTTTCACACAGGGTTTCTCTGTGTAGCCCTAGCTGTCCTGGAACACACTCTGT
AGACCAGGCTGCCCTCGAACTCAGAAATCAGCCTGCCTCTGCCTCCCAAGTGCAAGGCATGC
GCCACCACTGCCCGACTCATATAATTTATTTTTAAGAGA-3’ 
 
ATG STOP  
IST11848D8 
SA 
BGEO 
A 
B 
 149 
 
 
 
 
 
Appendix B 
 
Reprint: An oncogene-tumor suppressor cascade drives 
metastatic prostate cancer by coordinately regulating Ras 
and nuclear factor-κB 
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This Appendix consists of the following publication, in which I performed the experiments shown 
in Figure 4B and C, and, with Junxia Min, performed the shRNA screen described in the 
publication (Supplementary Figure 1) and shown as Figure 2-1 of this Dissertation. 
 
An oncogene–tumor suppressor cascade drives metastatic prostate cancer by 
coordinately activating Ras and nuclear factor-κB.  
Junxia Min, Alexander Zaslavsky, Giuseppe Fedele, Sara K McLaughlin, Elizabeth E Reczek, 
Thomas De Raedt, Isil Guney, David E Strochlic, Laura E MacConaill, Rameen Beroukhim, 
Roderick T Bronson, Sandra Ryeom, William C Hahn, Massimo Loda, and Karen Cichowski.  
Nature Medicine 16, pp. 286-294 (2010). 
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Although early detection has reduced mortality from prostate cancer, 
there is no curative treatment for advanced disease1. Consequently, 
one in 30 men is expected to die from metastatic prostate cancer1,2. 
Nevertheless, our current understanding of the mechanisms that drive 
progression and metastasis is limited. Hyperactivation of Ras effector 
pathways (the extracellular signal-regulated kinase (ERK) and AKT 
kinase pathways) have been proposed to promote prostate cancer 
progression3–6. However, whereas AKT is activated by loss of the gene 
encoding phosphatase and tensin homolog, it is unclear how ERK is 
activated in this tumor type. KRAS and BRAF mutations are present 
in a subset of tumors from Japanese and Korean individuals, but are 
rare in American and European populations7–9.
Ras is regulated positively by guanine nucleotide exchange factors 
(GEFs) and negatively by GAPs10,11. It is unknown whether GEFs have a 
role in cancer; however, one RasGAP, neurofibromin (encoded by NF1), is a 
known tumor suppressor12–15. Notably, there are 14 human RasGAPs, few 
of which have been studied in detail. Therefore, we investigated whether 
other RasGAP genes might also function as tumor suppressors. Here we 
identify a new tumor and metastasis suppressor within this gene family, 
define the mechanism by which its loss promotes metastatic prostate 
cancer and demonstrate that its epigenetic suppression is a key mechanism 
by which the polycomb-group protein EZH2 triggers metastasis.
RESULTS
DAB2IP suppression drives transformation
To identify tumor suppressors within the RasGAP family, we per-
formed a cell-based screen, originally designed to quantify transfor-
mation caused by NF1 loss16. As shown previously16, NF1 ablation 
promoted anchorage-independent growth (Fig. 1a). However, sup-
pression of another RasGAP, DAB2IP, induced colonies that were 
larger than NF1-deficient colonies (Fig. 1b). Of note, transformation 
was not generally promoted by the loss of most RasGAPs, including 
p120RasGAP (Fig. 1a and Supplementary Fig. 1).
We then investigated whether there was evidence linking DAB2IP 
loss to human cancer. DAB2IP expression seems to be selectively sup-
pressed in AML cell lines and in one case was disrupted by a transloca-
tion17. DAB2IP has also been reported to be epigenetically suppressed 
in advanced lung, breast and gastrointestinal tumors18–20. It is among 
the list of genes repressed by EZH2 in prostate cancer cell lines, a 
polycomb-group protein thought to promote advanced prostate 
cancer21,22. Nevertheless, the potential tumorigenic consequences of 
DAB2IP loss have not been investigated.
Given the proposed importance of the Ras-ERK pathway in prostate 
cancer progression and the lack of a mechanism by which it becomes 
activated3–5,14, we explored a role for DAB2IP loss in this process. 
An oncogene–tumor suppressor cascade drives metastatic 
prostate cancer by coordinately activating Ras and  
nuclear factor-KB
Junxia Min1,2, Alexander Zaslavsky3, Giuseppe Fedele2,4, Sara K McLaughlin1,2, Elizabeth E Reczek1,2,  
Thomas De Raedt1,2, Isil Guney2,4, David E Strochlic2,4, Laura E MacConaill5, Rameen Beroukhim2,4,6,7,  
Roderick T Bronson2, Sandra Ryeom3, William C Hahn2,4,5,7, Massimo Loda2,4,7–9 & Karen Cichowski1,2,10
Metastasis is responsible for the majority of prostate cancer–related deaths; however, little is known about the molecular 
mechanisms that underlie this process. Here we identify an oncogene–tumor suppressor cascade that promotes prostate cancer 
growth and metastasis by coordinately activating the small GTPase Ras and nuclear factor-KB (NF-KB). Specifically, we show 
that loss of the Ras GTPase-activating protein (RasGAP) gene DAB2IP induces metastatic prostate cancer in an orthotopic mouse 
tumor model. Notably, DAB2IP functions as a signaling scaffold that coordinately regulates Ras and NF-KB through distinct 
domains to promote tumor growth and metastasis, respectively. DAB2IP is suppressed in human prostate cancer, where its 
expression inversely correlates with tumor grade and predicts prognosis. Moreover, we report that epigenetic silencing of DAB2IP 
is a key mechanism by which the polycomb-group protein histone-lysine N-methyltransferase EZH2 activates Ras and NF-KB 
and triggers metastasis. These studies define the mechanism by which two major pathways can be simultaneously activated in 
metastatic prostate cancer and establish EZH2 as a driver of metastasis.
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Primary human prostate epithelial cells (PrECs) are immortalized by 
introducing Simian virus 40 (SV40) large T (LgT) and small t proteins 
and androgen receptor, but these cells are unable to form anchorage-
independent colonies23. However, the addition of H-RasV12 promotes 
colony growth and adenocarcinoma when such cells are injected into 
mice23. DAB2IP ablation also promoted colony growth, indicating 
that DAB2IP loss transforms human prostate cells (Fig. 1c). Notably, 
DAB2IP loss also triggered Ras, ERK and AKT activation (Fig. 1d). 
These phenotypes were reversed by rescuing cells with a DAB2IP com-
plementary DNA (Fig. 1e,f).
DAB2IP loss promotes metastatic prostate cancer
When we orthotopically injected immortalized PrECs into mouse 
prostates, well-circumscribed, benign growths in the prostate devel-
oped (Fig. 1g), as previously described23. The lesions had a low pro-
liferative index, showed considerable apoptosis and regressed (9 of 15 
regressed completely) (Fig. 1g and Supplementary Fig. 2a,b). 
However, mice injected with PrECs expressing oncogenic H-RasV12 (15 
of 15) or DAB2IP-specific short hairpin RNAs (15 of 15), developed 
prostate adenocarcinomas that expressed cytokeratin-8, prostate- 
specific antigen (PSA) and little tumor protein p63, similar to high-
grade human tumors (Fig. 1g,h). H-RasV12–expressing and DAB2IP-
deficient tumors were highly proliferative, showed little apoptosis and 
grew with similar kinetics and to a similar maximum size (Fig. 1g,i,j 
and Supplementary Fig. 2b,c). Mice injected with DAB2IP- 
reconstituted cells were similar to controls; most lesions regressed in 
45 d, were small in size, or both (Fig. 1g and Supplementary Fig. 2c).
However, whereas H-RasV12-driven tumors remained noninvasive 
and never disseminated, all DAB2IP-deficient tumors were invasive and 
metastatic (Fig. 2 and Supplementary Fig. 2d). These tumors invaded 
the hip, lumbar muscle and bladder (Fig. 2b)24. We observed metastases 
starting at 45 d after injection in liver, proximal and distal lymph nodes, 
Figure 1 DAB2IP suppression induces prostate 
tumor development. (a) Left, immunoblots 
showing expression of NF1, DAB2IP and 
p120 RasGAP in mouse embryonic fibroblasts 
(MEFs) expressing the adenoviral E1A protein 
and a dominant-negative p53, after lentiviral 
expression of shRNAs targeting each protein. 
Right, colony formation in soft agar (right). 
Significance determined by Student’s t test  
(P = 3.7 × 10−8 (DAB2IP shRNA1 versus 
control); P = 8.6 × 10−9 (DAB2IP shRNA2  
versus control)). (b) Relative size of colonies  
resulting from loss of Dab2ip versus Nf1.  
A significant difference in colony size conferred 
by Nf1 versus Dab2ip loss was determined by 
Student’s t test (P = 0.046). n = 3. Scale bars, 
1 mm. (c) Colony formation of immortalized 
PrEC cells infected with lentiviruses expressing 
DAB2IP-specific shRNA sequences. n = 3. 
Error bars refer to s.d. (d) Immunoblots of  
cells from c to assess DAB2IP knockdown  
and activation of Ras, ERK and AKT, as 
described in the Online Methods. (e) Colony 
growth induced by DAB2IP suppression with an 
shRNA directed to the 3` untranslated region 
(UTR), or rescued with wild-type DAB2IP.  
(f) Immunoblots of cells in e to assess DAB2IP 
expression and activation of Ras, ERK and 
AKT. (g) Histological micrographs of tumors 
resulting from orthotopic injection of PrECs. 
Ki67 staining shows the proliferative index 
(quantified in Supplementary Fig. 2). The first 
column of images represents prostate tissue 
from a mouse in which a control lesion had 
regressed. The second column of images is 
from a small control lesion. The last column is 
from a prostate in which a ‘rescued’ lesion had 
regressed. (h) Immunohistochemical staining 
of H-RasV12–expressing and DAB2IP-deficient 
tumors with antibodies to cytokeratin-8 (CK8), 
p63 and PSA. (i) Volume of orthotopic tumors 
over time, calculated by Xenogen imaging. 
A Student’s t test was used to compare the 
growth rates of H-RasV12–expressing and 
DAB2IP-deficient tumors (P = 0.13). n = 10 
each. (j) Final weight of orthotopic tumors at 
H-RasV12–expressing and DAB2IP-deficient 
tumors (Student’s t test (P = 0.34)). n = 5 each. 
All scale bars, 200 Mm. Error bars refer to s.d.
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seminal vesicles, testes and vas deferens (Fig. 2c and Supplementary 
Fig. 2d). The metastases were derived from PrECs, as confirmed by 
SV40 LgT antigen immunostaining and sequenome-based single nucleo-
tide polymorphism genotyping (Fig. 2c,d and Supplementary Fig. 3a), 
and we never observed metastases from cells rescued with DAB2IP. 
We could readily detect DAB2IP-deficient tumor cells throughout the 
lymphatic and blood vessels, implicating both vessel systems in meta-
stasis (Fig. 2d). Mice also developed thromboemboli, a life-threatening 
complication observed in a subset of individuals with prostate cancer 
(Supplementary Fig. 3b)25. The metastatic potential of these tumors 
can be best appreciated by Xenogen imaging (Fig. 2e). Mice harboring 
DAB2IP-deficient tumors showed reduced survival compared to those 
with H-RasV12–expressing tumors (Fig. 2f; P = 0.03, Mann-Whitney 
U test). Thus, DAB2IP suppression promotes prostate tumorigenesis 
and uniquely triggers metastasis.
RasGAP activity partially underlies DAB2IP function
Because DAB2IP is a RasGAP, we investigated whether aberrant Ras 
activation was responsible for these phenotypes. We expanded our 
analysis to include metastatic human prostate cancer cells in which 
DAB2IP is epigenetically silenced (PC-3 cells), to more directly assess 
the effects of DAB2IP loss in human cancer21. PC-3 and DAB2IP- 
deficient PrEC cells were reconstituted with wild-type DAB2IP or a 
GAP activity–deficient point mutant. Wild-type DAB2IP had subtle 
effects on the proliferation of these cell lines in vitro, indicating that 
the re-introduction of physiological amounts of DAB2IP does not, by 
itself, induce a growth arrest (Supplementary Fig. 4). DAB2IP proteins 
were equivalently expressed and recapitulated endogenous expression 
(Fig. 3a,b). Wild-type DAB2IP reduced Ras-GTP, phosphorylated ERK 
(pERK) and pAKT amounts, whereas the catalytically inactive RasGAP 
mutant (DAB2IP-R289L) did not suppress these effectors (Fig. 3b).
Mice injected with PC-3 cells developed metastatic prostate cancer 
(Fig. 3c–e). Wild-type DAB2IP significantly suppressed tumor devel-
opment (Fig. 3d; P = 3 × 10−8, Mann-Whitney U test) and metastasis 
(Fig. 3c,e); however, DAB2IP-R289L was unable to suppress tumor 
growth, indicating that RasGAP activity is essential for its tumor-
suppressive function (Fig. 3c,d; P = 0.71). Nevertheless, this mutant 
partially suppressed metastasis; only three of six mice developed 
metastases, and those that did had fewer metastases than mice injected 
with PC-3 cells lacking DAB2IP (Fig. 3e; P = 0.0083). We confirmed 
these findings with PrECs (Fig. 3f,g). These results suggest that other 
regions of DAB2IP harbor metastasis-suppressing activity.
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Figure 2 DAB2IP loss, but not H-RasV12 
expression, promotes invasion and widespread 
metastasis. (a) Histological micrographs of 
primary tumors from mice injected with  
H-RasV12-expressing PrEC cells. Scale bar,  
5 mm. (b) Histological micrographs of primary 
tumors from mice injected with DAB2IP-
deficient PrEC cells. Immunohistochemistry 
with an LgT-specific antibody is shown in the 
second image. Scale bar, 5 mm, except for 
lumbar muscle and bladder (scale bar, 1 mm). 
T, tumor; H, hipbone; LM, lumbar muscle.  
(c) Histological micrographs of metastases 
from mice injected with DAB2IP-deficient 
PrEC cells. Immunohistochemistry with an 
LgT-specific antibody on an adjacent section 
is shown at a higher power below each 
metastasis, with the exception of the lymph 
node, where H&E staining is shown. Scale bars: 
liver and seminal vesicle, 5 mm; lymph node, 
testis and vas deferens (VD), 1 nm. The first 
image in the top row was enlarged by 8.5-fold, 
the second image in the top row was enlarged 
by 4.5-fold, the third and fourth images in 
the top row were enlarged by 3.8-fold, and 
the fifth image in the top row was enlarged by 
6.2-fold in Photoshop; all enlarged images are 
shown directly below the originals. (d) H&E-
stained sections of tissues containing tumor 
cells (T) within blood vessels (BV and arrows) 
and lymphatic vessels (LV). When specified by 
lines, higher magnification images are shown. 
LgT antigen, which marks injected tumor cells, 
was expressed in cells found within both BV 
and LV (last two images, bottom row). Scale 
bars: first, second and fourth images in top 
row, 1 mm; third image in top row and second 
and third images on bottom row: 200 Mm. 
The first panel in the top row was enlarged 
by 4.8-fold and the fourth image in the top 
row was enlarged by 6.2-fold in Photoshop; 
the enlarged images are shown directly below the originals. (e) Xenogen images of mice orthotopically injected with luciferase-expressing control, 
DAB2IP-deficient or H-RasV12-expressing cells. (f) Survival curves of mice with DAB2IP-deficient versus H-RasV12-expressing tumors.©
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DAB2IP regulates epithelial-to-mesenchymal transition
Notably, DAB2IP ablation in PrECs also induced an epithelial-to-
mesenchymal transition (EMT), a dynamic cellular process thought 
to underlie metastasis by promoting invasion, intravasation and 
extravasation26–28.  DAB2IP loss promoted an increase in the expres-
sion of the mesenchymal markers vimentin, twist and fibronectin 
and a concomitant reduction in the expression of membrane-bound 
E-cadherin (Fig. 3h and Supplementary Fig. 5)29. DAB2IP suppression 
also enhanced invasion (Supplementary Fig. 5a). EMT occurred 
synchronously within 96 h and was not caused by the outgrowth 
of a specialized subset of cells (Supplementary Fig. 6). In contrast, 
H-RasV12 was a much weaker regulator of EMT (Fig. 3h).
We also observed EMT in vivo, as indicated by vimentin expres-
sion, which we observed in cells at the edge of these highly metastatic 
lesions (Fig. 3i). We observed this expression pattern in every tumor 
examined (n = 12), and the vimentin was present in tumor cells, not 
stroma, as the antibody that we used exclusively recognizes human 
protein. Similar findings have been described in a metastatic breast 
cancer model and support the hypothesis that environmental cues 
contribute to EMT and metastasis28,30. H-RasV12-expressing tumors 
never showed evidence of EMT (Fig. 3i), supporting the hypothesis 
that distinct effects of DAB2IP loss on EMT underlie metastasis.
DAB2IP loss promotes metastasis via NF-KB
Although Ras can promote EMT in some settings, a plethora of signals 
regulates this transition27. Of note, DAB2IP, in addition to its RasGAP 
activity, can suppress NF-KB in endothelial cells through a direct inter- 
action  with TRAF2, via a region distinct from the RasGAP domain31. Notably, 
NF-KB has a crucial role in EMT, and many EMT-associated genes, 
including TWIST1, are NF-KB targets32. NF-KB also promotes tumor 
progression and metastasis in other model systems33. Thus, we asked 
whether DAB2IP loss triggers EMT and metastasis by activating NF-KB.
Ectopic DAB2IP expression suppresses NF-KB in endothelial 
cells, but it was unknown whether DAB2IP loss would activate NF-
KB in prostate cells31. DAB2IP ablation activated NF-KB (Fig. 4a) 
and increased expression of NF-KB transcriptional targets in PrECs 
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Figure 3 The RasGAP activity of DAB2IP underlies 
some but not all of its tumor and metastasis suppressor 
function. (a) Immunoblots comparing DAB2IP expression 
in PrEC cells, PC-3 cells and PC-3 cells expressing wild-
type (WT) DAB2IP or DAB2IP-R289L. (b) Immunoblots 
assessing the effects of DAB2IP and DAB2IP-R289L 
on Ras, ERK and AKT activation in PC-3 cells, as 
described in the Online Methods. (c) Xenogen images of 
mice injected with PC-3 cells from a and b. (d) Volume 
of PC-3–derived tumors calculated by values derived 
from Xenogen images. (e) Dot plot depicting the number of metastases per mouse in mice injected with PC-3 cells expressing wild-type DAB2IP or 
DAB2IP-R289L. (f) DAB2IP immunoblot corresponding to e. (g) Left, bar graph showing final weight of tumors from PrECs. Right, dot plot depicting 
the number of metastases per mouse in mice injected with PrEC cells expressing DAB2IP-specific shRNAs 1 or 2 alone or with wild-type DAB2IP or 
DAB2IP-R289L. A Mann-Whitney U test (P = 0.0030) was used to illustrate a significant difference between the number of metastases that developed 
in mice injected with control PC-3 cells (expressing a LacZ contol) versus PC-3 cells expressing DAB2IP-R289L. (h) Left, phase-contrast images (top), 
immunofluorescence staining of the mesenchymal marker vimentin (middle) and immunofluorescence staining of the epithelial marker E-cadherin 
(bottom) of immortalized PrEC cells expressing a lentiviral vector control, a DAB2IP-specific shRNA or an activated Ras variant. Right, expression of 
DAB2IP, ectopic Ras, fibronectin, vimentin and E-cadherin, as detected by immunoblotting. Bottom, real-time PCR quantification of vimentin,  
E-cadherin and twist expression in response to DAB2IP loss or an activated Ras variant. (i) Confocal images of immunofluorescence staining of vimentin 
(green) and E-cadherin (red) in DAB2IP-deficient or H-RasV12-expressing tumors. All scale bars, 100 Mm. Error bars reflect s.d.
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(Fig. 4b)34. Conversely, DAB2IP reconstitution suppressed NF-KB and target 
genes in PC-3 cells (Fig. 4a,c). A point mutant in the period-like domain of 
DAB2IP that prevents TRAF2 binding (S604A) is defective in suppressing NF-
KB activity in endothelial cells31. DAB2IP-S604A did not effectively inhibit 
NF-KB, but it still suppressed Ras (Supplementary Fig. 7a,b). This mutant 
was also defective in suppressing invasion and EMT, suggesting that NF-KB 
mediates these phenotypes in response to DAB2IP loss (Supplementary 
Fig. 7). We confirmed this hypothesis by introducing a dominant-negative 
inhibitor of KBA protein, referred to as the IKBA super repressor (IKBASR), 
which suppressed NF-KB activity, invasion and EMT in both model 
systems (Supplementary Fig. 5 and data not shown). However, consistent 
with the notion that Ras feeds into the NF-KB pathway35, the DAB2IP double 
mutant (R289L and S604A) was more defective in suppressing invasion, 
EMT and NF-KB, illustrating cooperativity between these two domains and 
downstream signals (Supplementary Fig. 7).
Notably, the DAB2IP-S604A mutant, which effectively suppressed 
Ras but not NF-KB, inhibited primary tumor growth, supporting the 
conclusion that Ras has a key role in tumor initiation (Fig. 4d–g; 
P = 1.65 × 10−7, Mann-Whitney U test). However, although the tumors 
were small, five of ten mice developed metastases, suggesting that aber-
rant NF-KB activity promoted dissemination (Fig. 4f,g). Accordingly, 
the IKBASR had no effect on primary tumor development (Fig. 4e,g) 
but significantly suppressed metastasis (Fig. 4f,g; P = 0.005). The 
DAB2IP double mutant (R289L and S604A) did not suppress primary 
tumor development (P = 0.48) or metastasis (P = 0.31) (Fig. 4e–g). We 
observed similar results in the PrEC model (Fig. 4h,i).
We conclude that DAB2IP loss induces the activation of Ras and 
NF-KB in prostate cancer. Ras is essential in primary tumor growth, 
whereas NF-KB drives metastasis. Notably, we found that whereas 
both H-RasV12 expression and DAB2IP loss activated ERK and 
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Figure 4 DAB2IP loss promotes tumorigenesis 
and metastasis via concomitant effects on 
Ras and NF-KB. (a) Left, NF-KB activity 
reported as relative light units (RLU) in 
response to DAB2IP suppression in PrEC 
cells. Middle, NF-KB activity in response to 
DAB2IP reconstitution in PC-3 cells. Right, 
DAB2IP immunoblot. Control (C) represents 
a control lentiviral shRNA or control cDNA 
plasmid where appropriate. (b) Expression of 
NF-KB targets as determined by quantitative 
PCR (qPCR) in PrEC cells with and without 
the DAB2IP shRNA even in the absence of 
the NF-KB–activating factor, tumor necrosis 
factor-A. BCL-2, B cell lymphoma-2; BCL-XL, 
BCL2-like-1; C-FLIP, CASP8 and FADD-like 
apoptosis regulator; C-IAP1, baculoviral IAP 
repeat-containing-2; C-IAP2, baculoviral IAP 
repeat-containing-3; IL-1, interleukin-1;  
IL-6, interleukin-6; IL-8, interleukin-8;  
MMP-9, matrix metallopeptidase-9; MYC, v-myc 
myelocytomatosis viral oncogene homolog; 
VEGF, vascular endothelial growth factor; 
INOS, inducible nitric oxide synthase.  
(c) Expression of the same NF-KB targets as 
determined by qPCR in PC-3 cells with and 
without the DAB2IP cDNA, in the presence 
of tumor necrosis factor-A. (d) DAB2IP 
immunoblots of reconstituted PC-3 cells. 
Double DAB2IP mutant, R289L + S604A. 
IKBASR expression is shown in Supplementary 
Figure 7b. (e) Tumor volumes derived from  
PC-3 cells calculated from Xenogen images.  
(f) A dot plot depicting the number of 
metastases detected in each mouse injected 
with PC-3 cells. (g) Xenogen images of mice 
injected with PC-3 cells from d–f. The Ras 
and NF-KB status noted above each image 
summarizes the biochemical effects of the 
expressed mutants. The numbers below the 
images represent the number of mice that 
developed metastases over the number of mice 
injected. (h) Final weight of tumors derived 
from control PrEC cells, PrEC cells with the 
3` UTR shRNA (3` UTR cells), 3` UTR cells 
reconstituted with DAB2IP or the S604A 
mutant. Expression of proteins was determined 
to be equivalent (data not shown). (i) A dot  
plot depicting the number of metastases 
detected in each mouse injected with the PrEC cells in h. (j) Immunohistochemistry with antibodies that recognize NF-KB, pERK and pAKT in 
DAB2IP-deficient and H-RasV12–expressing tumors. Scale bars, 200 Mm. Error bars reflect s.d.
©
 2
01
0 
N
at
ur
e 
A
m
er
ic
a,
 In
c.
  A
ll 
ri
gh
ts
 r
es
er
ve
d.
 156 
 
A R T I C L E S
NATURE MEDICINE VOLUME 16 | NUMBER 3 | MARCH 2010 291
AKT in prostate tumors, NF-KB was activated 
exclusively in DAB2IP-deficient tumors, as 
indicated by the nuclear rather than cytoplas-
mic  staining of NF-KB in these cells, support-
ing the conclusion that DAB2IP has distinct 
effects on NF-KB (Fig. 4j and Supplementary Fig. 8a). Accordingly, we 
also observed an enhanced inflammatory response in DAB2IP-deficient 
tumors (Supplementary Fig. 8b). These observations challenge the concept 
that Ras and NF-KB exist in a simple linear pathway in this tumor type.
DAB2IP is a major EZH2 target
Thus far, our data identify a signaling cascade that drives metastatic 
disease and provide a tractable model system to interrogate the involve-
ment of other genes in metastasis. Another gene implicated in metastatic 
prostate cancer is EZH2, which encodes the histone methyltransferase 
component of the polycomb-repressive complex-2 and regulates epige-
netic gene silencing36. EZH2 is overexpressed in many tumor types, and 
its expression correlates with tumor grade36. EZH2 was also identified as 
the most differentially upregulated gene in metastatic prostate cancer37; 
however, EZH2 has never been shown to drive metastasis, thus a causal 
role for EZH2 in this process remains to be established.
Over 250 polycomb-repressive complex-2 targets have been identi-
fied, including DAB2IP (refs. 22,38,39). Therefore, we asked whether 
EZH2 could induce metastatic prostate cancer and investigated the 
potential contribution of DAB2IP silencing in EZH2-driven pheno-
types. Notably, ectopic EZH2 expression promoted invasive prostate 
adenocarcinoma and metastasis to proximal and distal lymph nodes, 
liver and spleen (Fig. 5a and Supplementary Table 1). Like DAB2IP-
deficient tumors, EZH2-driven tumors were detectable in lymphatic 
and blood vessels, and mice with these tumors developed thrombo-
emboli (Fig. 5a).
The observation that EZH2 overexpression phenocopies DAB2IP 
loss suggested that DAB2IP might be a key target of EZH2 in 
metastatic prostate cancer. EZH2 suppressed DAB2IP protein and 
messenger RNA expression in PrECs (Fig. 5b,c), as previously observed 
in other cell lines21. Chromatin immunoprecipitation (ChIP) indi-
cated that EZH2 bound the DAB2IP promoter (Fig. 5d), indicating 
a direct transcriptional suppression of DAB2IP by EZH2. When 
we reconstituted EZH2-expressing cells with endogenous levels of 
DAB2IP, tumor growth was suppressed, and in 2 of 14 cases the tumors 
eventually regressed (Fig. 5e; P = 4 × 10−12). Moreover, whereas we 
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Figure 5 EZH2 promotes tumorigenesis and 
metastasis via suppression of DAB2IP.  
(a) Histological images of tumors and 
metastases from orthotopic injection of EZH2-
expressing PrEC cells. Tumor cells observed 
within lymphatic vessels (LV) and blood vessels 
(BV) are circled. Metastasis data for all mice 
is in Supplementary Table 1. (b) Left, DAB2IP 
immunoblots of immortalized PrEC cells 
expressing a vector control or EZH2. The top 
band is EZH2. Right, immunoblots of cells in b 
reconstituted with ectopic DAB2IP with a V5 
epitope tag. (c) Suppression of endogenous 
DAB2IP mRNA expression in response to EZH2, 
as determined by real-time PCR. pBabe seves as 
a control vector. (d) ChIP of EZH2 bound to the 
DAB2IP promoter. (e) Tumor volume calculated 
from Xenogen images of mice injected with  
cells expressing EZH2 or EZH2 and DAB2IP.  
(f) A dot plot depicting the number of metastases 
detected in each mouse injected with EZH2-
expressing or EZH2- and DAB2IP-expressing 
PrEC cells. (g) Survival curves of mice 
orthotopically injected with iEZH2-expressing 
or EZH2- and DAB2IP-expressing PrEC cells. 
(h) Immunohistochemistry of EZH2-expressing 
or EZH2- and DAB2IP-expressing PrEC-derived 
tumors, using pERK–specific, pAKT–specific 
and NF-KB (p50) antibodies. On the left are 
confocal immunofluorescence images of EZH2-
expressing or EZH2- and DAB2IP-expressing 
PrEC-derived tumors, using human vimentin-
specific (green) and E-cadherin-specific (red) 
antibodies. (i) Immunoblots assessing the 
effects of EZH2 and DAB2IP reconstitution on 
Ras, ERK and AKT activation in PrEC cells, as 
described in the Online Methods. (j) Final weight 
of tumors and number of metastases detected in 
mice injected with the cells shown in i. All scale 
bars, 200 Mm, except for confocal images, where 
scale bars are 100 Mm. Error bars represent s.d.
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detected metastases in mice with EZH2-driven tumors within 
8–12 weeks, DAB2IP prevented metastasis, even in mice surviving 
1 year (Fig. 5f). Accordingly, mice injected with DAB2IP-expressing 
cells survived longer than those injected with cells expressing EZH2 
alone (Fig. 5g; P = 2.3 × 10−4, Yates correction).
EZH2 also activated Ras, ERK, AKT and NF-KB, whereas DAB2IP 
reconstitution substantially suppressed activation (Fig. 5h,i). 
Moreover, like DAB2IP-deficient tumors, metastatic EZH2-expressing 
lesions also underwent EMT at the invasive edge, which was pre-
vented by DAB2IP reconstitution (Fig. 5h). We also observed EMT 
in vitro (Supplementary Fig. 9). Finally, GAP domain (R289L) and 
period-like domain (S604A) mutants of DAB2IP had the same effects 
in EZH2-expressing cells as compared to DAB2IP-deficient PrEC 
and PC-3 cells on Ras signaling (Fig. 5i) and primary tumor growth 
and metastasis (Fig. 5j). Thus EZH2 activates Ras and NF-KB by epi-
genetically suppressing DAB2IP, providing the molecular mechanism 
by which an epigenetic regulator activates these two major signaling 
pathways (Fig. 6a).
DAB2IP is inactivated in human prostate cancer
DAB2IP deletions have not been reported in human tumors; how-
ever, our data suggested that epigenetic suppression might represent 
a key mechanism of DAB2IP loss in human prostate cancer. Although 
DAB2IP has been shown to be a target of EZH2 in a few prostate 
cancer cell lines21, its expression has not been examined in human 
tumors. We confirmed the specificity of the DAB2IP-specific anti-
body (Fig. 6b) and performed immunohistochemical analysis on 
tissue microarrays containing 589 specimens from 117 individuals 
with prostate cancer. Normal basal and secretory cells expressed high 
amounts of DAB2IP (Fig. 6c–f). By contrast, the majority of pros-
tatic intraepithelial neoplasias and adenocarcinomas showed weak 
or no DAB2IP expression, which was often restricted to stroma in 
these biopsies (Fig. 6c–f; Kruskal-Wallis test, P = 1.8 × 10−27). The 
low expression of DAB2IP can be appreciated in sections containing 
both normal and cancerous tissue (Fig. 6c). Notably, DAB2IP expres-
sion inversely correlated with Gleason grade (Fig. 6f; Kruskal-Wallis, 
P = 0.001). Finally, among 81 subjects for whom clinical information 
was available, we found that DAB2IP expression was significantly 
lower in subjects with a poor prognosis, as measured by a shorter 
time to elevated blood concentrations of PSA (univariate Cox regres-
sion analysis: hazard ratio, 0.51; 95% confidence interval, 0.2–0.9; 
P = 0.03). Taken together, these results support a causal role for 
DAB2IP loss in human prostate cancer progression.
To investigate whether DAB2IP suppression in prostate cancer is 
caused by EZH2-mediated transcriptional silencing, we examined 
DAB2IP and EZH2 expression in Oncomine data sets40. Consistent 
with the results of our immunohistochemical analyses, DAB2IP 
mRNA levels were lower in prostate cancer compared to normal 
prostate tissue and decreased with increasing tumor grade (Fig. 6g; 
Student’s t test r = 7.181, P = 2 × 10−7). We confirmed these results 
with three additional datasets40–43. By comparing DAB2IP and EZH2 
in individual tumors and metastases, we also found that DAB2IP levels 
inversely correlated with EZH2 levels (Fig. 6h; Spearman R = −0.5386, 
P value (two-tailed) = 0.0010 (ref. 40); Fig. 6i; Spearman R = −0.5604, 
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Figure 6 DAB2IP is suppressed in human 
prostate cancer. (a) Model of how EZH2 
regulates DAB2IP, Ras and NF-KB to promote 
tumor development and metastasis. (b) DAB2IP 
immunohistochemical staining of normal 
mouse prostate, DAB2IP-deficient PrEC-
derived tumors and Ras-driven tumors. (c) Top, 
immunohistochemical staining with a DAB2IP-
specific antibody in normal human prostate 
epithelium. Bottom, immunohistochemical 
DAB2IP staining in normal human tissue and 
adjacent tumor tissue (T) within the same biopsy. 
PCa, prostate cancer. (d) Immunohistochemical 
staining of human tissue maicroarrays (HTMAs) 
with a DAB2IP-specific antibody in human 
prostate cancer tissues. Right, high-power 
magnification of images at left. Arrows depict 
stromal cells. (e) Histogram of DAB2IP protein 
expression in prostate intraepithelial neoplasia 
(PIN) and in prostate cancer compared to the 
benign prostate tissue (prostate cancer (PCa) 
versus benign prostate tissue, P = 1.8 × 10−27).  
(f) Histogram comparing DAB2IP expression 
and Gleason grade (not score), evaluated as 
the most prevalent pattern on each individual 
core (Gleason grade 5 versus Gleason grade 3 
tumors, P = 0.001). Because the tissue sections 
on the arrays are relatively small, they were 
assigned a Gleason grade (1–5), rather than 
a Gleason score (1–10), the latter of which 
represents the combined total of the two most 
prevalent grades in an entire tumor. As such, 
Grade 4 and 5 tumors are high-grade tumors.  
(g) Box plots of DAB2IP mRNA expression data 
in prostate cancer compared to normal tissue  
(P = 2.0 × 10−7) and in high grade tumors as opposed to low grade and benign tissue (P = 0.003). (h,i) Expression of DAB2IP levels versus EZH2 levels 
in individual tumors and metastatic lesions using two different data sets described in text. All scale bars, 400 Mm. Error bars represent s.d.
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P value (two-tailed) = 0.0463)37. Analysis of the distribution of 
R values from these data indicated that DAB2IP ranks in the top 4.5% 
of inversely correlated genes, as compared to EZH2 (Supplementary 
Fig. 10). Collectively, these observations demonstrate that EZH2 and 
DAB2IP exist in a linear pathway that, when deregulated, promotes 
metastatic prostate cancer.
DISCUSSION
If detected early, prostate cancer is curable; however, there are no 
effective therapies for metastatic disease. The current treatment for 
recurrent prostate cancer is surgical or medical castration. However, 
patients ultimately relapse and develop androgen-independent, meta-
static tumors44. Therefore there is a considerable gap in our under-
standing of the mechanisms that underlie prostate cancer progression, 
metastasis and the development of effective therapies.
This knowledge deficit is, in part, due to the lack of tractable model 
systems. Genetically engineered mouse models have helped define 
genes involved in tumor initiation and aspects of tumor progression; 
however, few models develop metastases, and, in those that do, it is 
unclear which genes drive this transition45,46. Thus, orthotopic models 
represent a platform that can be used in a more high-throughput 
fashion for gene discovery, in particular for metastasis, which requires 
numerous prerequisite alterations. In this study we have identified 
DAB2IP as a regulator of metastatic prostate cancer. To our know-
ledge, no other gene has been shown to have a direct causal role in 
driving prostate cancer metastasis, underscoring the importance of 
this finding and the utility of this model.
These studies also provide insight into mechanisms that regulate 
tumor initiation versus metastasis. Specifically, DAB2IP loss promotes 
primary tumor growth by activating Ras and drives metastasis through 
NF-KB, serving as a signaling scaffold to coordinately regulate these 
two prominent oncogenic pathways (Fig. 6a). Although Ras and NF-KB 
are known to be activated in advanced prostate cancer, the genetic 
alterations that confer activation are largely unknown3–6,47. Our find-
ings reveal a molecular mechanism by which these two pathways can 
be activated in prostate cancer.
In some settings, Ras can promote NF-KB activation via its effects 
on the Ras-related protein RalB and the TANK-binding kinase-1 (refs. 
47,48); however, here we report that Ras is not sufficient to stimulate 
NF-KB in prostate tumors. Although these observations seem con-
tradictory, a mutation in the GAP domain of DAB2IP enhances the 
effects of a mutation in the period-like domain (on NF-KB activity), 
consistent with a cooperative role for Ras in this pathway. NF-KB is 
regulated by the integrated output of many signals, which may be 
differentially limiting in different tumor types. The data presented 
here suggest that DAB2IP is a crucial guardian of the NF-KB pathway 
in prostate tissue.
Finally, these studies suggest that epigenetic suppression of DAB2IP 
by EZH2 is a major mechanism of its inactivation in human prostate 
cancer. Of note, although EZH2 is highly expressed in advanced and 
metastatic prostate cancer37, it has never been shown to induce meta-
stasis, leading to the unresolved question of whether EZH2 upregula-
tion is a marker or driver of metastasis49. Our studies establish a causal 
role for EZH2 in driving metastasis and identify DAB2IP as a key tar-
get in this process among numerous target genes, although certainly 
others may contribute. These observations have major therapeutic 
implications. Because EZH2 is an enzyme, it has been proposed to 
be a potential therapeutic target36. Our data underscore the utility of 
developing EZH2 inhibitors, as such agents might suppress both Ras 
and NF-KB—proteins that have proven difficult to target directly—in 
prostate cancer. These findings also support the possibility that such 
inhibitors might affect primary tumors and metastatic lesions.
METHODS
Methods and any associated references are available in the online 
version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
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ONLINE METHODS
Cell culture. We established MEFs and immortalized PrECs expressing the 
adenoviral E1A-encoded protein and a dominant-negative p53 as previously 
described16,23. We obtained PrECs from Loza and grew them in defined prostate 
epithelial cells growth medium as previously described23. We obtained PC-3 
cells from American Type Culture Collection and cultured them according to 
the suppliers’ instructions.
Plasmids and retroviral and lentiviral infections. We obtained lentiviral pLKO 
shRNAs specific for the genes encoding DAB2IP2IP, NF1 and p120RasGAP 
from the Broad Institute RNAi consortium. The sequences for each siRNA set 
are as follows: DAB2IP shRNA 1: sense 5`-GCACATCACTAACCACTACCT-3`  
and antisense 5`-AGGTAGTGGTTAGTGATGTGC-3`; DAB2IP shRNA 2: sense 
5`-GTAATGTAACTATCTCACCTA-3` and antisense 5`-TAGGTGAGATAGTT 
ACATTAC-3`; NF1 shRNA 1: sense 5`-CAACAACTTCAATGCAGTCTT-3` and 
antisense 5`-AAGACTGCATTGAAGTTGTTG-3`; NF1 shRNA 2: sense 5`-TTATA 
AATAGCCTGGAAAAGG-3` and antisense 5`-CCTTTTCCAGGCTATTTATAA; 
p120RasGAP shRNA 1: sense 5`-GCTGCCTAACTTATCCATCTT-3` and 
antisense 5`-AAAAAGCTGCCTAACTTATCC-3`; p120RasGAP shRNA 2: sense 
5`-CCCTACATGGAAGGTGTCAAT-3` and antisense 5`-TAAAAACCCTACAT 
GGAAGGTG-3`; EZH2 shRNA 1: sense 5`-CGGAAATCTTAAACCAAGAAT-3` 
and antisense 5`-CAAAAACGGAAATCTTAAAC-3`; EZH2 shRNA 2: sense 
5`-TATTGCCTTCTCACCAGCTGC-3` and antisense 5`-CAAAAATATTGCC 
TTCTCACC-3`. We assessed knockdown was assessed by western blotting or 
qPCR, as noted. We performed retroviral and lentiviral infections as previously 
described16,23. We amplified full-length DAB2IP cDNA by RT-PCR, cloned it 
into pLenti4/V5-DEST vector (Invitrogen) and verified the sequence. We cloned 
the EZH2 cDNA into pBabe-myc retroviral vector. We used the PMMP-luc-neo 
retroviral luciferase construct to monitor tumor growth in live mice48.
Soft agar assay. We performed soft agar assays with MEFs or PrEC cells as previ-
ously described16. We analyzed colony size by ImageJ (US National Institutes 
of Health).
Nuclear factor-KB reporter assays. We seeded 2 × 104 cells in triplicate in 24-well 
plates. After 18 h, we transfected 100 ng of pNF-KB–luciferase (BD Bioscience) 
or pISRE-luciferase (Stratagene) plus 25 ng Renilla luciferase–encoding plasmid 
(pRL-TK) in triplicate wells with Fugene6 (Roche). We measured luciferase 
activity followed by Renilla luciferase activity 36 h after transfection with the 
Dual Luciferase Reporter Assay Kit (Promega). All data were normalized as rela-
tive luciferase light units / Renilla luciferase light units.
Chromatin immunoprecipitation assay. We performed the ChIP assay as 
described previously50 with the ChIP Assay Kit (Upstate).
Immunoblotting and immunofluorescence. We generated a DAB2IP-specific 
monoclonal antibody against the last 120 C-terminal amino acids and named 
it WF17.1 (Dana-Farber Cancer Institute core facility). We used a hybridoma 
supernatant at a dilution of 1:6. We also used antibodies to the following pro-
teins: NF1 (Santa Cruz, SC-67D), p120RasGAP (Transduction Laboratories), 
tubulin (Sigma), pERK(Ser473), pAKT, total ERK and total AKT (all ERK and 
AKT antibodies, Cell Signaling Technologies), E-cadherin (Santa Cruz), human 
vimentin (DakoCytomation) and EZH2 (monoclonal from BD, polyclonal from 
Invitrogen). We used Alexa Fluor 488 conjugated to mouse or rabbit secondary 
antibodies (Molecular Probes) for immunofluorescence. We performed confocal 
imaging with Zeiss LSM410 confocal microscopy systems.
Quantitative real-time PCR. We isolated total RNA with Trizol (Invitrogen). 
We obtained probes for specific genes from Applied Biosystems. We per-
formed quantitative real-time PCR with iscript (Applied Biosystems). We 
performed each reaction in triplicate and normalized values to glyceraldehyde 
3-phosphate dehydrogenase.
Orthotopic implantation. We obtained athymic male nude mice (nu/nu; 
6 weeks old) from Jackson Laboratory. Mouse handling and experimental pro-
cedures were approved by the Center for Animal and Comparative Medicine in 
Harvard Medical School in accordance with the US National Institutes of Health 
Guidelines for the Care and Use of Laboratory Animals and the Animal Welfare 
Act. We carried out orthotopic implantations as previously described23. Briefly, 
we injected a suspension of cells (5 × 105 cells per 10 Ml) in 50 Ml of a 1:1 mixture 
of PBS and Matrigel (BD Biosciences) into the prostate.
Immunohistochemistry and tissue microarrays. We counted 500 cells from 
five different fields and scored the percentage of Ki67-positive cells among 
DAPI-positive cells. We collected human prostate tissue samples with approval 
from the Brigham and Women’s Hospital Institutional Review Board and with 
informed subject consent for construction of tissue microarrays. We reassessed 
the Gleason grade on each individual core to ensure accuracy for these small 
tissue sections. We used a standard avidin-biotin complex immunohistochemical 
protocol to evaluate DAB2IP protein expression (1 in 6 DAB2IP antibody dilu-
tion overnight at 4 °C). We scanned tissue microarray slides with the Automated 
Imaging System Ariol SL-50 (Applied Imaging) and imported images into soft-
ware for Tissue MicroArrays (TMAJ), a Web-based software program for the 
management of tissue microarray data. We evaluated immunostaining blinded 
to clinicopathological information and scored the stains as negative (0), weak (1), 
moderate (2) or strong (3). We used the average value from replicate cores for 
correlation with clinical outcome. We used univariate Cox regression analysis 
to assess the ability of DAB2IP expression to predict time to PSA failure, defined 
as a PSA concentration in the serum greater than 0.2 ng ml−1 after radical pros-
tatectomy.
Gene expression analysis. We retrieved gene expression data discussed in this 
study from the Oncomine cancer microarray database.
Xenogen imaging. We imaged mice with an IVIS-100 CCD camera (Xenogen). 
For anatomical localization, we generated a pseudocolor image representing 
light intensity (blue, least intense; red, most intense) in LivingImage and super-
imposed it over the grayscale reference image.
Statistical analyses. If data were normally distributed, we used the Student’s 
t test. Otherwise, we used the Mann-Whitney U test. We performed all analyses 
with the SYSTAT 12 software package. Specific tests are noted in the text and 
figure legends.
50. Chen, H., Toyooka, S., Gazdar, A.F. & Hsieh, J.T. Epigenetic regulation of a novel 
tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J. Biol. Chem. 278, 
3121–3130 (2003).
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Reprint: Hematopoietic-specific Stat5-null mice display 
microcytic hypochromic anemia associated with reduced 
transferrin receptor gene expression 
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This Appendix consists of the following publication, which resulted from research during my year 
in Nancy Andrews’ laboratory, in collaboration with Bing-Mei Zhu and Lothar Hennighausen at 
the National Institutes of Health.  I helped to design and carry out experiments, analyze the 
results, and write the manuscript. 
 
Hematopoietic-specific Stat5-null mice display microcytic hypochromic anemia 
associated with reduced transferrin receptor gene expression. 
Bing-Mei Zhu*, Sara K. McLaughlin*, Risu Na, Jie Liu, Yongzhi Cui, Cyril Martin, Akiko Kimura, 
Gertraud W. Robinson, Nancy C. Andrews and Lothar Hennighausen 
Blood 112, pp. 2071-2080 (2008). 
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RED CELLS
Hematopoietic-specific Stat5-null mice display microcytic hypochromic anemia
associated with reduced transferrin receptor gene expression
*Bing-Mei Zhu,1 *Sara K. McLaughlin,2 Risu Na,1 Jie Liu,3 Yongzhi Cui,1 Cyril Martin,1 Akiko Kimura,1
Gertraud W. Robinson,1 Nancy C. Andrews,2 and Lothar Hennighausen1
1Laboratory of Genetics and Physiology, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDKD), National Institutes of Health (NIH),
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Iron is essential for all cells but is toxic in
excess, so iron absorption and distribu-
tion are tightly regulated. Serum iron is
bound to transferrin and enters erythroid
cells primarily via receptor-mediated en-
docytosis of the transferrin receptor (Tfr1).
Tfr1 is essential for developing erythro-
cytes and reduced Tfr1 expression is
associated with anemia. The transcrip-
tion factors STAT5A/B are activated by
many cytokines, including erythropoi-
etin. Stat5a/b!/! mice are severely ane-
mic and die perinatally, but no link has
been made to iron homeostasis. To study
the function of STAT5A/B in vivo, we
deleted the floxed Stat5a/b locus in hema-
topoietic cells with a Tie2-Cre transgene.
These mice exhibited microcytic, hypo-
chromic anemia, as did lethally irradiated
mice that received a transplant of Stat5a/
b!/! fetal liver cells. Flow cytometry and
RNA analyses of erythroid cells from mu-
tant mice revealed a 50% reduction in Tfr1
mRNA and protein. We detected STAT5A/B
binding sites in the first intron of the Tfr1
gene and found that expression of consti-
tutively active STAT5A in an erythroid cell
line increased Tfr1 levels. Chromatin im-
munoprecipitation experiments confirmed
the binding of STAT5A/B to these sites.
We conclude that STAT5A/B is an impor-
tant regulator of iron update in erythroid
progenitor cells via its control of Tfr1
transcription. (Blood. 2008;112:2071-2080)
Introduction
Iron is an essential metal, used primarily by erythrocytes for
hemoglobin synthesis. Intracellular iron levels must be controlled
because iron can participate in redox reactions leading to the
generation of damaging free radicals. Since there is no mechanism
for regulated iron excretion, iron intake and distribution are tightly
regulated. Serum iron circulates bound to transferrin and is taken
up by cells via receptor-mediated endocytosis as iron-bound
transferrin binds the transferrin receptor (Tfr1).1 Mice lacking Tfr1
display severe anemia and die before embryonic day 12.5 (E12.5),
thus supporting its critical role in erythropoiesis.2 Tfr1"/! mice
survive to adulthood but have microcytic, hypochromic erythro-
cytes, which are most likely due to a reduction of cell surface Tfr1
leading to iron-deficient erythropoiesis.2
Hepcidin, a secreted peptide hormone produced primarily by
hepatocytes, is a key regulator of iron homeostasis. Hepcidin binds
the iron exporter ferroportin, causing its internalization and degra-
dation. Dietary iron enters circulation by traversing intestinal
epithelial cells, exiting through ferroportin. Similarly, tissue macro-
phages that have phagocytosed senescent red blood cells release
iron back into circulation through ferroportin. Therefore, hepcidin
binding to ferroportin prevents dietary iron uptake and the release
of iron from tissue macrophages. Hepcidin production responds to
iron stores and erythroid demand and thereby balances iron release
into the serum.3
STAT5A and STAT5B are transcription factors that are activated
by numerous cytokines, including erythropoietin (Epo).4-6 Upon
binding of Epo to its receptor (EpoR), the receptor-associated
tyrosine kinase Jak2 activates STAT5A/B, which in turn regu-
lates erythropoiesis.7-10 However, the molecular understanding
of this process remains fragmented. Mice from which the entire
Stat5a/b locus has been deleted (Stat5a/b!/! mice) display
severe anemia and die perinatally,8 precluding definitive analy-
sis of the role of STAT5A/B in erythropoiesis in vivo. In
particular, the perinatal lethality has prevented studies of the
role of STAT5A/B in iron homeostasis.
To address the function of STAT5A/B in erythropoiesis in vivo,
we deleted the Stat5a/b locus in hematopoietic stem cells (HSCs)
through the use of mice that carried the Stat5a/b locus flanked by
loxP sites and also a Tie2-Cre (TC) transgene11,12 (Stat5a/bf/f; TC),
which is known to be active in HSCs. Stat5a/bf/f; TC neonates and
adult mice displayed microcytic, hypochromic anemia and liver
iron deposition. Here we analyze the molecular basis of the
microcytic, hypochromic anemia and link STAT5A/B to transcrip-
tional regulation of Tfr1.
Methods
Mice and genotype analysis
Stat5a/b!/! mice were generated using Cre-mediated recombination.8
Stat5a/bfl/fl mice8 were bred with mice carrying the Tie2-Cre transgene.11,12
Genotyping was performed by polymerase chain reaction (PCR) as
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described.8,12 The Stat5a/b floxed allele was amplified with primers
5!-AGCAGCAACCAGAGGACTAC-3! and 5!-TACCCGCTTCCATTGCT-
CAG-3!. Primers specific for the recombined Stat5a/b allele were 5!-
AGCAGCAACCAGAGGACTAC-3! and 5!-CCCATTATCACCTTCTTTA-
CAG-3!. Tie2-Cre primers were 5!-CGCATAACCAGTGAAACAGCATT-
GC-3! and 5!-CCCTGTGCTCAGACAGAAATGAGA-3!. Wild-type
recipient mice (6- to 8-week-old B6.SJL-CD45.1 mice) were purchased
from The Jackson Laboratory (Bar Harbor, ME). Animals were handled and
housed in accordance with the guidelines of the National Institutes of
Health (NIH, Bethesda, MD) Animal Care and Use Committee.
RNA isolation from erythroid cells and quantitative real-time
PCR analysis of Stat5 deletion efficiency and Tfr1 and DMT1
expression
Ter119-positive and -negative cells were isolated from fetal liver or adult
bone marrow and spleen using magnetic positive selection with anti-Ter119
microBeads (Miltenyi Biotec, Auburn, CA) according to the manufactur-
er’s instructions. RNA was extracted and purified using an RNeasy Plus
mini kit (Qiagen, Valencia, CA). Total RNA (0.5 "g) was reverse tran-
scribed into cDNA using the Superscript III First-strand synthesis Supermix
(Invitrogen, Frederick, MD). Taqman real-time quantification of mRNA
transcript levels was performed using mouse-specific FAM STAT5a primer
Mm00839861_m1, Tfr1 primer Mm00441941_ml, DMT1 primer
Mm00435363_ml (Applied Biosystems, Foster City, CA), and VIC #-actin
primers for normalization. The assay was run on a 7900 HT fast real-time
PCR system (Applied Biosystems) and analyzed with SDS2.3 Software
(Applied Biosystems).
Complete blood count
Neonates and adult mice were bled from the mandibular vein into 1.5-mL
microcentrifuge tubes through heparinized capillary hematocrit tubes
(Drummond Scientific, Broomall, PA). Complete blood count (CBC) was
measured by HEMAVET multispecies hematology system-HV950FS (Drew
Scientific, Dallas, TX) per the manufacturer’s instructions.
Giemsa staining
Blood smears were made using peripheral blood from the mouse
mandibular vein. Slides were fixed in 100% methanol for 30 minutes,
rinsed in water, and stained with freshly made 10% Giemsa for
30 minutes. The right femur was isolated from E18.5 embryos, fixed in
neutral buffered formalin (Fisher Scientific, Pittsburgh, PA) at 4°C
overnight, dehydrated, and embedded in paraffin. Tissue blocks were
sectioned at 5 "m. Bone sections were deparaffinized and stained with
freshly made 10% Giemsa for 30 minutes.
Images were captured on an Olympus (Tokyo, Japan) BX51 light
microscope equipped with Plan 10$/0.25, Plan-NEOFLUAR 20$/0.50,
and UPlan Fl 60$/1.25 Oil Iris lenses and a Nikon (Tokyo, Japan) digital
still DXM 1200 camera using ACT-1 (version 2.6.3.0) software. Captured
images were processed by Adobe Photoshop (version 9) and Illustrator
(version 10) software (Adobe Systems, San Jose, CA).
Tissue iron analyses
Liver and spleen samples were digested in acid and tissue non–heme iron
was determined as described previously.13
Serum iron analyses
Serum was separated from whole blood that had been collected by
retro-orbital bleed in microtainer serum separator tubes (Becton Dickinson,
Franklin Lakes, NJ) and stored at % 20°C. Serum iron and unsaturated iron
binding capacity (UIBC) were determined using the Serum Iron/UIBC kit
(ThermoDMA, Louisville, CO) according to the manufacturer’s instructions.
Perls Prussian blue iron staining
Liver tissues were fixed in neutral buffered formalin (Fisher Scientific) at
4°C overnight, dehydrated, and embedded in paraffin. Tissue blocks were
sectioned at 5 "m. Liver sections were deparaffinized and hydrated in
distilled water, and incubated in stock potassium ferrocyanide solution for
5 minutes and in working potassium ferrocyanide–hydrochloric acid
solution for 20 minutes. Sections were rinsed in distilled water and
counterstained in nuclear fast red solution for 5 minutes. Sections were
washed in running water and dehydrated in 95% and 100% alcohol, cleared
in xylene, and then mounted with Permount (Fisher Scientific).
RNA isolation and quantitative real-time PCR analysis of
hepcidin levels
Total RNA was isolated from liver tissue that had been snap-frozen at
% 80°C and stored in RNALater (Qiagen). Livers were homogenized in
RNA STAT-60 (Leedo Medical Laboratories, Houston, TX). RNA was
extracted according to the manufacturer’s instructions. Total RNA was
treated with DNase I (Roche, Indianapolis, IN) to remove trace DNA, and
cDNA was synthesized using the iScript cDNA Synthesis Kit (Bio-Rad,
Hercules, CA), according to the manufacturer’s instructions. Real-time
quantification of mRNA transcript levels was performed using the iQ SYBR
Green Supermix (Bio-Rad), according to the manufacturer’s instructions.
Hepcidin (Hamp1) mRNA was amplified using primers mHamp1-F 5!-
CTGAGCAGCACCACCTATCTC-3! and mHamp1-R 5!-TGGCTCTAG-
GCTATGTTTTGC-3!. #-Actin (Actb) mRNA was amplified as an internal
control using primers mbact F 5!-ACCCACACTGTGCCCATCTA-3!
and mbact R 5!-CACGCTCGGTCAGGATCTTC-3!.14 Standard curves
for hepcidin and #-actin were generated from dilutions of cDNA made from
liver in parallel to other experimental samples. Samples were run in
triplicate and results were reported as the ratio of the mean values for
hepcidin to #-actin.
Flow cytometry
Fetal livers were mechanically dissociated in phosphate-buffered saline
with 0.5% bovine serum albumin (PBS/0.5% BSA) through a 40-"m
strainer and resuspended in PBS/0.5% BSA. Cells were incubated with a
phycoerythrin (PE)–conjugated &-Ter119 antibody, FITC-conjugated
&-CD71 (Tfr1) antibody, and 7-AAD (7-amino-actinomycin D) for
15 minutes at room temperature. Blood from fetuses, neonates, or adults
was collected and stained with a PE-conjugated &-CD71 antibody for
15 minutes at room temperature. After washing with PBS/0.5% BSA, cells
were stained with Reti-COUNT (thiazole orange) reagent (BD Biosciences,
San Diego, CA) for 30 minutes at room temperature followed directly by
fluorescence-activated cell sorting (FACS) analysis. Constitutively active
STAT5A-transfected MEL cells were stained with PE-conjugated&-phospho-
STAT5A (Y694) or PE-conjugated &-CD71 antibodies for 15 minutes at
room temperature. Cells were washed with PBS/0.5% BSA and FACS
analysis was performed. All antibodies were purchased from BD Pharmin-
gen (San Diego, CA) and antibody titers were determined before
experiments. FACS analyses were carried out using FACSCalibur (BD
Biosciences). Data analyses were performed using FlowJo (TreeStar,
Eugene, OR).
Microarray analysis
Isolated Ter119-positive fetal liver cells from 3 to 5 E14.5 embryos of the
same genotype were combined, and total RNA was extracted using TRIzol
reagent (Life Technologies, Bethesda, MD) with 2 additional ethanol
precipitations. RNA quality was verified using an Agilent Bioanalyzer
(Agilent Technologies, Palo Alto, CA). Microarray analyses were per-
formed using Affymetrix Mouse Genome 430 2.0 array GeneChips
(Affymetrix, Santa Clara, CA). Microarray signals were analyzed using the
Affymetrix RMA algorithm. Up- and down-regulated genes were selected
based on P values less than .05 and fold changes of more than 1.5 or less
than 1.5 as assessed by ANOVA using Partek Pro software (Partek, St
Louis, MO). Microarray data have been deposited in Gene Expression
Omnibus (GEO) under accession number GSE11777.15
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Retrovirus production and transfection with constitutively
active STAT5A
Recombinant mouse stem cell virus (MSCV) vectors expressing STAT5A
(R20, constitutively active mouse STAT5A), in which STAT5A was
mutated at the N-terminus and amino acids 1 to 136 were deleted, and green
fluorescent protein (GFP) were gifts from Dr Richard Moriggl (Vienna,
Austria). The MEL cell line was maintained in Dulbecco modified Eagle
medium (DMEM) with 10% FBS, penicillin, and streptomycin. MEL cells
that express constitutively active mouse STAT5A were established by
transfecting MEL cells with STAT5A/GFP retroviral vectors. MSCV-GFP–
transfected MEL cells were set as control. MEL cells were transfected with
the cell line Optimization Nucleofector kit (Amaxa, Gaithersburg, MD).
Nucleofector Solution L (Amaxa) in combination with program A-20 was
used in transfection. Four to 5 hours after transfection, 1.5% DMSO was
added to the medium. The cultures were maintained at 37°C with 5% CO2.
After 72 hours, the MSCV-STAT5A-GFP– and MSCV-GFP–transfected
MEL cells were collected, and activated STAT5A and Tfr1 expression
levels were analyzed by FACS.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were performed as previ-
ously described16 using the Upstate Biotechnology ChIP kit (Temecula,
CA). STAT5A/GFP- or GFP-transfected MEL cells were sorted by BD
FACSAria Flow Cytometer (BD Biosciences) and were cross-linked
immediately using 1% formaldehyde (Protocol Formalin; Fisher Scientific).
Cell lysates were sonicated and immunoprecipitated with an !-Stat5
antibody (R&D Systems, Minneapolis, MN) or rabbit serum as a control
(Upstate Biotechnology). Immunoprecipitated DNA was eluted and ampli-
fied by real-time PCR using a 7900 HT fast real-time PCR system (Applied
Biosystems) and analyzed using SDS2.3 Software (Applied Biosystems).
Sequence-specific primers and probes used for amplification of the putative
STAT binding sites (GAS sites) within the Tfr1 gene were as follows: GAS
1: 5"-CATGGTAGGATCTCAGTTCATGGC-3" and 5"-CAGGTTACT-
GAAGGCTTACGATGG-3"; GAS 2: 5"-CTCCCAAGTGCTAGGATTA-
AAGGC-3" and 5"-GACTGGATGCTGAATAGAGGTGGG-3"; GAS 3:
5"-GCTCTAGCGATTGGGTCTGTTTC-3" and 5"-GCCTCTTGCCTC-
CCAAGTACTAG-3". Sequence primers outside the GAS sites were as
follows: 5"-AGTGTCACGGACATTTAGAGGGG-3" and 5"-CAGCGT-
TCAGACCTATTCTGCC-3". As a positive control, primers that detect the
binding site for STAT5A/B on the IGF-1 gene were designed based on the
sequences in rat.17 The sequence primers were 5"-GCATATGTCTCT-
GAAAGGGGTGA-3" and 5"-GGCACAAGCTAGCCGATGGTTAG-3",
which detect 2 GAS sites in intron 2. All Ct values were normalized to the
values from primers outside the Tfr1 GAS sites (2 kb away from GAS
3 site) (#Ct), and then #Ct values were normalized to rabbit serum (##Ct).
The results (2ˆ ##Ct) were expressed as fold enrichment relative
to GFP control.
Apoptosis assay
Spleens were taken from 8- to 10-week-old Stat5a/bf/f; TC mice or littermate
control mice and were resuspended in PBS/0.5% BSA. Ter119-positive
cells were separated using magnetic positive selection with anti-Ter119
microBeads (Miltenyi Biotec) according to the manufacturer’s instructions.
An aliquot of the Ter119-positive cells were stained with annexin V–PE
apoptosis detection kit I (BD Pharmingen) following the manufacturer’s
instructions and then incubated with an APC-conjugated !-Ter119 antibody
(BD Pharmingen) for 15 minutes at room temperature. FACS analysis was
performed as described in “Flow cytometry.” The splenic Ter119-positive
cells were cultured for 24 hours in IMDM with 15% FBS, 1% BSA,
200 $g/mL holo transferrin, 10 $g/mL recombinant human insulin, 2 mM
L-glutamine, 10%4 M &-mercaptoethanol, and 5 U erythropoietin and then
subjected to FACS analysis for apoptosis at the indicated time points.
Transplantation
Embryonic day-14.5 (E14) fetal liver cells were harvested from Stat5a/b%/%
fetuses or control littermates and dispersed with a 21-gauge needle. The
cells were resuspended in phosphate-buffered saline containing 2% fetal
bovine serum. Cells (1 ' 106) were injected via the lateral tail vein into
recipient mice that were lethally irradiated with 11G( 4 to 5 hours before
injection. FACS analysis was used to determine the reconstitution of donor
cells. PerCP-Cy5.5–conjugated CD45.2 was used as donor cell marker; and
PE-conjugated CD45.1 was used as recipient cell marker. Mice were killed
5 months after transplantation and analyzed.
Results
Deletion of the Stat5a/b locus in the germ line and
hematopoietic cells
Stat5a/b)/% mice8 were generated through the deletion of the
Stat5a/b locus flanked by loxP sites by an MMTV-Cre transgene,
which is active in the female germ line.18 The Stat5a/b locus was
selectively deleted in hematopoietic cells in mice carrying 2 floxed
Stat5a/b alleles and a Tie2-Cre transgene11 (Stat5a/bf/f; TC mice).
Quantitative real-time PCR confirmed the deletion of the Stat5a/b
locus in Stat5a/bf/f; TC mice, and Stat5a/b mRNA levels in fetal
Ter119-positive and -negative cells were reduced by more than
90% (data not shown).
Stat5a/b)/% males and females were mated, and from the more
than 2000 mice weaned only 9 were Stat5a/b%/%. Prior to parturi-
tion, Stat5a/b%/% fetuses were present in a normal Mendelian
ratio, suggesting that Stat5a/b%/% mice died perinatally. Newborn
Stat5a/b%/% mice were anemic with hematocrits of approximately
1.6 (16%; Table 1) and died of unknown cause within hours after
delivery. In contrast, Stat5a/bf/f; TC mice were born at the expected
Mendelian ratio. Stat5a/bf/f; TC neonates had hematocrits of approxi-
mately 2.5 (25%) compared with 4.7 (47%) in controls, and
hematocrits in adult mutant mice remained low at 2.9 (29%; Table
1). Both red cell size (mean corpuscular volume) and hemoglobin
content (MCH) were significantly reduced in Stat5a/b%/% and
Stat5f/f; TC neonates as well as in adult Stat5a/bf/f; TC mice (Table 1),
Table 1. Hematologic indices of neonate and adult mice
RBC, 109/L Hb, g/L HCT MCV, fl MCH, pg RDW, %
Adults
Control 9600 * 300 141 * 3 4.95 * 0.07 51.9 * 1.2 15.2 * 0.3 19.1 * 0.2
Stat5a/bf/f 6600 * 500* 84 * 5* 2.86 * 0.19* 47.4 * 0.9* 13.9 * 0.3* 23.2 * 1.4*
Neonates
Control 4500 * 400 133 * 14 4.73 * 0.35 112.4 * 2.6 30.1 * 0.8 20.7 * 0.3
Stat5a/bf/f 2600 * 200* 67 * 5* 2.55 * 0.21* 100.1 * 3.8* 26.6 * 1.1* 28.8 * 1.1*
Stat5a/b%/% 1900 * 600* 36 * 10* 1.6 * 0.03* 84.8 * 1.6* 19.2 * 0.3* 19.6 * 0.8
RBC indicates red blood cell count; Hb, hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; and RDW, red blood cell
distribution width.
*P+ .05 compared with control. n, 10 adults and n, 20 neonates for each group.
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demonstrating that loss of STAT5A/B results in microcytic, hypo-
chromic anemia. Increased red cell distribution width (RDW) in
Stat5a/bf/f; TC neonates and adult mice was suggestive of iron
deficiency. Stat5a/b!/! neonates were severely anemic, although
their RDWs were not elevated, most likely due to a complete
inability to produce normal cells. Consistent with the measured
parameters, peripheral blood smears of Stat5a/bf/f; TC embryos and
neonates subjected to Giemsa staining (Figure 1) showed microcy-
tosis, anisocytosis, poikilocytosis, and hypochromia. The number
of mature red blood cells was greatly reduced in Stat5a/bf/f; TC
fetuses and neonates compared with wild-type controls, and a
higher ratio of nucleated erythroid cells was observed (Figure 1).
The morphology of bone marrow from Stat5a/bf/f; TC mice estab-
lished the presence of red cell hypoplasia (Figure S1, available on
the Blood website; see the Supplemental Materials link at the top of
the online article). These findings all are consistent with a defect in
delivery of iron to developing erythroblasts.
To determine whether phenotypic differences observed in
Stat5a/b!/! and Stat5a/bf/f; TC mice compared with controls are
autonomous to the hematopoietic lineage or due to changes in other
tissues potentially affected by the loss of STAT5A/B, we trans-
planted Stat5a/b!/! fetal liver cells (CD45.2) into lethally irradi-
ated hosts (CD45.1). Five months after transplantation, mice that
received a transplant of control fetal liver cells had hematocrits of
3.8 (38%), whereas mice that received a transplant of Stat5a/b!/!
cells had hematocrits of 2.6 (26%; Table 2). Both MCV and MCH
were reduced in mice that received a transplant of
Stat5a/b!/! cells. These data support our conclusion that loss of
STAT5A/B in hematopoietic cells alone is sufficient to cause
microcytic, hypochromic anemia. In lysed peripheral blood from
mice that received a transplant of control cells, 95% of cells were
CD45.2 (donor derived). In contrast, only 63% of these cells from
mice that received a transplant of Stat5a/b!/! cells were C45.2,
suggesting that surviving control recipient cells had a competitive
advantage over Stat5a/b!/! cells (data not shown).
Analysis of tissue and serum iron
Microcytic, hypochromic anemia is commonly caused by insuffi-
cient iron available to developing erythrocytes. To determine
whether Stat5a/b mutant mice had a defect in iron metabolism,
tissue and serum non–heme iron levels were analyzed. We mea-
sured non–heme iron content in liver tissue from Stat5a/bf/f; TC and
wild-type adult mice and Stat5a/bf/f; TC and wild-type neonates and
found that the livers of Stat5a/bf/f; TC mice were iron loaded
compared with wild-type controls (Figure 2A). In addition, Prus-
sian blue iron staining of liver sections revealed periportal hepato-
cyte iron staining in Stat5a/bf/f; TC livers but not in controls (Figure
2E). There was no significant difference in spleen non–heme iron
content by tissue iron assay or Prussian blue staining (data not
shown). Serum iron levels (Figure 2B) and transferrin saturation
(Figure 2C) were elevated in Stat5a/bf/f; TC mice compared with
controls. These data demonstrate that Stat5a/bf/f; TC mice have
sufficient or excess total body iron, suggesting that the anemia is
not caused by overall iron insufficiency. Therefore, the anemia is
likely caused by an inability of the erythrocytes to assimilate iron.
To confirm cell autonomy, we analyzed iron parameters in lethally
irradiated control mice that had received a transplant of control or
Figure 1. Peripheral blood smears from control,
Stat5a/bf/f; TC, and Stat5a/b!/! E14.5 embryos and
neonates, subjected to Giemsa staining. Peripheral
blood smears revealed microcytosis, anisocytosis, and
hypochromia in Stat5a/b mutant mice, suggestive of iron
deficiency.An increase in nucleated erythroblasts (long!)
and reticulocytes (short !) further indicates stressed
erythropoiesis in mutant mice. " indicates mature red
blood cells. Original magnifications: top and middle
panels,"200; bottom panel,"600.
Table 2. Hematologic indices of mice that received a transplant of Stat5a/b!/! or control fetal liver cells
RBC, 109/L Hb, g/L HCT MCV, fl MCH, pg RDW, %
Control 8800 # 200 120 # 3 3.83 # 0.08 43.6 # 0.2 13.7 # 0.1 17.1 # 0.2
Stat5a/b!/! 6100 # 300* 82 # 5* 2.63 # 0.13* 41.9 # 0.6* 12.9 # 0.3* 17.3 # 0.5
The mice were analyzed 5 months after transplantation.
RBC indicates red blood cell count; Hb, hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; and RDW, red blood cell
distribution width.
*P$ .05 compared with control. n% 5 in each group.
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Figure 2. Iron overload in the absence of STAT5A/B.
Iron content and hepcidin expression in control and
Stat5a/bf/f; TC mice (A-E) and in mice that received a
transplant of control or Stat5a/b!/! fetal liver cells (F-I).
(A) Non–heme liver iron in adult and neonate female
control and Stat5a/bf/f; TC mice. n " 5 neonates; n " 6
adults. (B,C) Serum iron (B) and transferrin saturation
(C) in adult female control and Stat5a/bf/f; TC mice. n " 12
in each group. (D) Hepcidin mRNA expression in neonate
and adult control and Stat5a/bf/f; TC mice (males and
females). Hepcidin expression in control neonate and
adult mice is set to 1. n " 9 in each group. (E) Perls
Prussian blue iron staining of liver paraffin sections from
adult female control and Stat5a/bf/f; TC mice. Original
magnification, #100 in top panel and #200 in bottom
panel. Non–heme iron is stained blue. (F) Non–heme
liver iron. (G) Serum iron. (H) Serum transferrin satura-
tion. (I) Hepcidin mRNA expression. Hepcidin expression
in mice that received a transplant of control cells is set to
1. n " 5 in each group for all the measurements. *P $ .05
compared with control samples. P values were deter-
mined by 2-tailed unpaired t test. Error bars represent
SEM.
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Stat5a/b!/! fetal liver cells. Liver iron levels from mice that
received a transplant of Stat5a/b!/! cells were increased more
than 2.5-fold compared with controls (Figure 2F), and serum
iron levels and transferrin saturation were also significantly
increased (Figure 2G,H).
Hepcidin mRNA levels were analyzed in liver tissue from
Stat5a/bf/f; TC and control adult and neonate mice by quantitative
real-time PCR. Hepcidin mRNA levels were approximately
2.5-fold higher in mutant neonates than in wild-type controls, and
approximately 1.9-fold higher in mutant adults than in wild-type
controls (Figure 2D). Similarly, hepcidin levels in mice that
received a transplant of Stat5a/b!/! fetal liver cells were elevated
2-fold over controls (Figure 2I).
Transferrin receptor expression in erythroid cells
Iron uptake into erythrocytes occurs by receptor-mediated endocy-
tosis of iron transferrin bound to Tfr1. We assessed cell surface
Tfr1 levels on similar populations of reticulocytes from control and
Stat5a/bf/f; TC mice by FACS, using reticulocyte RNA content as a
measure of cell maturity. We determined that Tfr1 levels were
decreased by approximately 50% in adult mutant mice (Figure
3A,B). Tfr1 levels also were significantly reduced in fetal liver
Ter119-positive cells from Stat5a/b!/! mice (Figure 3B). As
determined from FACS analysis forward scatter, neonate and adult
Stat5a/bf/f; TC Ter119-positive cells were 6% to 7% smaller than
controls, and Stat5a/b!/! Ter119-positive cells were 23% smaller
Figure 3. Decreased Tfr expression in the absence of STAT5A/B. Transferrin receptor
expression in control and Stat5a/b mutant Ter119-positive cells and (A-C) transferrin
receptor mRNA expression in Stat5a/bf/f; TC and control adult mice (D). (A,B) Gated
Ter119-positive cells were analyzed for fluorescence of an "-CD71 (Tfr1) antibody in fetal
liver and adult bone marrow and spleen cells. Peripheral blood data were generated by
double staining with the "-CD71 antibody and thiazole orange dye, which stains RNA and
can be used to isolate reticulocytes of a narrow age range as the amount of RNA changes
significantly during maturation. (A) Representative data from 8 adult peripheral blood
analyses. Top panels show the gate for thiazole orange–positive cells (right) in the whole
red blood cell population (left panel). (B) Quantification of Tfr1 protein levels, expressed as
the median measurements of "-CD71 fluorescence. E14 data were generated from
Stat5a/b!/! embryos. n# 10 in each group. Adult data were generated from Stat5a/bf/f; TC
mice. n# 6 for each group. (C) Quantification of Tfr1 protein levels in mice that received a
transplant of control or Stat5a/b!/! fetal liver cells, expressed as the median measure-
ments of"-CD71 fluorescence. n# 5 for each group. FL indicates fetal liver; PB, peripheral
blood; and BM, bone marrow. *P$ .05 compared with control mice. Error bars represent
SEM. (D) Total RNA was extracted from Ter119-positive cells isolated from bone marrow
and spleen. Tfr1 expression levels in control mice are set to 1. n# 3 in control group; n# 4
in Stat5a/bf/f; TC group. *P$ .05 compared with control mice. Error bars represent SEM.
Table 3. Microarray analysis of fetal liver Ter119-positive cells from
Stat5a/b!/! or control E18.5 embryos
Gene symbol Mean, KO Mean, WT Mean ratio, KO/WT P
Socs3 67.50 601.83 0.11 .00
Stat5a 29.80 221.33 0.13 .01
Stat5b 110.03 571.53 0.19 .01
Pim1 4657.77 12268.10 0.38 .01
Cish 540.93 1209.23 0.45 .02
Hbb-bh1 10666.70 22056.97 0.48 .04
Osmr 111.93 176.20 0.64 .25
Bcl2l 11875.93 18033.90 0.66 .14
Osm 257.67 369.60 0.70 .04
Trf 12056.83 22319.70 0.54 .04
Trfr 2666.63 3803.30 0.70 .03
Bcl2l 2093.47 2570.73 0.81 .18
Hbb-y 57118.80 65485.93 0.87 .32
Hba-a1 60582.80 68668.43 0.88 .31
Ccnd1 1399.73 1561.93 0.90 .58
Actb 53338.57 58914.40 0.91 .33
Eraf 58985.63 64714.10 0.91 .36
Hbb-b2 43897.70 45628.30 0.96 .74
Ccnd3 12132.47 12562.27 0.97 .79
Pim2 646.43 659.43 0.98 .86
Pim3 749.00 739.33 1.01 .94
Hba-x 44065.57 42822.47 1.03 .93
Stat3 1292.90 1196.63 1.08 .13
Gapd 21993.63 20195.33 1.09 .39
Gbif-pending 269.13 236.60 1.14 .59
Stat1 766.13 660.93 1.16 .50
Epor 8875.87 7350.00 1.21 .14
Jak2 4147.47 3208.57 1.29 .13
Ireb2 911.00 917.77 0.99 .94
Biologic and technical triplicates were analyzed. Highlighted genes’ expression
levels differ significantly between mutant and control. Listed genes include those
considered erythropoiesis-related genes. The entire data set is available in Table S1.
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(data not shown). Gated Ter119-positive cells from lethally irradi-
ated recipient mice that had received a transplant of Stat5a/b!/!
cells also expressed significantly less Tfr1 (Figure 3C).
To investigate whether the reduction in cell surface Tfr1 was
due to a change in transcriptional regulation, we isolated total
RNA from Stat5a/b!/! and control fetal liver Ter119-positive
cells and subjected it to microarray analyses (Document S1).
This approach also allowed us to monitor the expression of other
genes involved in iron metabolism and erythropoiesis. Tfr1
mRNA levels were decreased by approximately 30% in
Stat5a/b!/! erythroid cells, suggesting that the decrease in Tfr1
protein is due to reduced Tfr1 mRNA. Real-time reverse-
transcription (RT)–PCR showed Tfr1 mRNA levels reduced by
60% in bone marrow and 80% in splenic cells from adult
Stat5a/bf/f; TC mice (Figure 3D). As erythrocytes have a high
demand for iron and obtain it only via transferrin and Tfr1,2,19
this reduction in Tfr1 levels could cause iron-restricted erythro-
poiesis in the Stat5a/b mutant mice. Microarray analyses also
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confirmed reduced expression of bona fide STAT5A/B target
genes, such as Socs3 and Pim1 (Table 3;0).
Induction of Tfr1 expression by constitutively active STAT5A
The decreased amount of Tfr1 mRNA and protein in Stat5a/bf/f: TC
erythrocytes suggested that STAT5A/B regulates expression of the
Tfr1 gene. To investigate whether STAT5A/B activity leads to the
induction of Tfr1 gene transcription and protein expression, we
transfected the murine erythroleukemia cell line MEL with a viral
vector expressing a constitutively active STAT5A.20 FACS analysis
of cells 72 hours after transfection revealed activated STAT5A
(Figure 4A,B) and a 2-fold increase in cell surface Tfr1 compared
with GFP-transfected controls (Figure 4C,D). These analyses
demonstrate that STAT5A induces Tfr1 levels in MEL cells.
Stat5 binds to GAS sites in the Tfr1 gene
To investigate whether STAT5A/B directly induces Tfr1 transcrip-
tion, we searched for putative STAT5A/B binding sites (GAS sites)
surrounding the Tfr1 gene (http://www.ensembl.org).21 We identi-
fied 3 GAS consensus sequences in the first intron of Tfr1 (Figure
5A). STAT5A/B previously has been shown to induce transcription
via intronic GAS sites in other genes.17 Therefore, we hypothesized
that STAT5A/B directly induces Tfr1 transcription by binding to
one or more of these putative GAS sites.
We used chromatin immunoprecipitation (ChIP) to determine
whether STAT5A binds to any of the putative GAS sites. MEL cells
were transfected with plasmids encoding constitutively active
STAT5A or GFP as a control and STAT5A binding to GAS sites
was analyzed. STAT5A binding was detected on all 3 GAS sites,
and the most conserved GAS site (site 1) had a 16-fold enrichment
compared with the GFP control (Figure 5B). Taken together, these
data demonstrate that STAT5A binds to GAS sites in a putative Tfr1
regulatory region and that STAT5A activity leads to increased Tfr1
expression.
Increased apoptosis in the absence of STAT5A/B
Earlier studies have shown that erythroid cells expressing
hypomorphic STAT5A/B undergo unscheduled apoptosis due to
reduced levels of Bcl-x.9,10 To further establish to what extent
apoptosis contributed to the anemia observed in Stat5a/bf/f; TC
mice, we analyzed the survival response of splenic Ter119-
positive cells to Epo. Ter119-positive cells from mutant and
control mice were cultured in the presence of Epo and cell death
was determined using annexin V staining (Figure 6). At day 0,
10% of freshly isolated Ter119-positive cells from control mice
and 42% from Stat5a/bf/f; TC mice were positive for annexin V.
Twenty-four hours after initiating the culture, 53% of control
cells and 78% of mutant cells were annexin V positive. The
elevated cell death in the absence of STAT5A/B strongly
supports the notion that STAT5A/B also controls Epo-mediated
cell survival. Bcl-x levels in STAT5A/B-null Ter119-positive
cells were only slightly reduced and the significance of this
remains to be determined.
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Discussion
Deletion of the Stat5a/b genes in HSCs and in the germ line results
in microcytic, hypochromic anemia, and mutant mice display
increased serum iron levels and liver iron deposition. In the
absence of STAT5A/B, Tfr1 levels on erythroid precursors are
reduced by 50%. Furthermore, STAT5A/B binds to GAS sites
within the first intron of the Tfr1 gene and induces Tfr1 gene
expression. Based on these data, we suggest that STAT5A/B
controls erythropoiesis in part by regulating Tfr1 expression, which
in turn allows unimpeded iron acquisition by erythroid cells.
Stat5a/b!/! neonates display a hematocrit of 1.6 (16%) com-
pared with 4.7 (47%) in controls. They die within hours after birth,
which has precluded detailed studies of the in vivo function of
STAT5A/B in adults.8 To further understand the molecular basis of
the erythropoietic defects, we deleted the Stat5a/b locus specifi-
cally in HSCs and endothelial cells using the Tie2-Cre transgene.
Complete blood count analyses revealed that mutant mice were
anemic (decreased red blood cell count, hemoglobin, and hemato-
crit), and had decreased mean corpuscular volume and mean
corpuscular hemoglobin, indicating a microcytic, hypochromic
anemia. The microcytic anemia was more profound in Stat5a/b!/!
neonates than in Stat5a/bf/f; TC mice, suggesting that there might be
additional defects from the whole body absence of STAT5A/B.
Stat5a/b!/! neonates were smaller than control littermates or
Stat5a/bf/f; TC mice. Possible explanations include more severe
anemia, placental insufficiency, or a defect in IGF signaling.
Microcytic, hypochromic anemia is most commonly caused by
insufficient iron acquisition by developing erythroid precursors.
Stat5a/b mutant mice had increased serum iron levels and in-
creased hepatocyte iron deposition, suggesting that the microcytic,
hypochromic anemia was the result of insufficient erythroid iron
utilization. The presence of abundant periportal hepatocyte iron
further supported the hypothesis that excess unused iron had been
removed from serum. Although some cells can use non–Tfr1-
mediated mechanisms of acquiring iron, erythroid cells depend
exclusively on Tfr1-mediated iron uptake.2 Tfr1!/! mice display
severe anemia and die before embryonic day 12.5. Since anemia
occurred in animals with hematopoietic-specific inactivation of
Stat5a/b, we hypothesized that there was a defect in iron transport
into erythroid precursors. RNA expression and FACS analyses
revealed a decrease in Tfr1 mRNA and surface protein levels,
respectively, on mutant erythroid cells. In addition, we found that
active STAT5A stimulates expression of Tfr1 and binds to GAS
sites in the first intron of the Tfr1 gene. Functional intronic GAS
sites have been identified in other genes, such as the IGF-1 gene,
which is highly activated by STAT5A/B.17 Given the known
function of STAT5A/B as a transcriptional regulator, these data
strongly suggest that STAT5A/B up-regulates Tfr1 transcription.
Erythroid cells must increase surface Tfr1 levels even as cellular
iron content increases, because large amounts of iron are needed for
hemoglobin production.22,23 Therefore, although we cannot exclude
posttranscriptional regulation of Tfr1 mRNA stability by STAT5A/B,
these data support a role for STAT5A/B in controlling Tfr1
transcription.
To determine whether the phenotypic differences observed in
Stat5a/b mutant mice compared with controls are autonomous to
the hematopoietic lineage or due to changes in other tissues
potentially affected by the loss of STAT5A/B, we transplanted
Stat5a/b!/! fetal liver cells into lethally irradiated hosts. We found
that mice that received a transplant of Stat5a/b!/! cells displayed a
phenotype that mimicked that of Stat5a/bf/f; TC mice. These mice
had microcytic, hypochromic anemia, increased liver iron, serum
iron, and transferrin saturation and decreased erythroid Tfr1 levels.
We conclude that loss of STAT5A/B in hematopoietic cells is
sufficient to induce these phenotypes.
In addition to erythroid iron deficiency, globin chain imbalance
can be a primary cause of microcytosis. We analyzed globin mRNA
levels in Stat5a/b!/! fetal liver Ter119-positive cells and found that
expression of all but one globin gene was unimpaired (Table 3).
Steady-state levels of Hbb-hb1 mRNA (encoding hemoglobin Z,
beta-like embryonic chain) were reduced by 50%. We do not
believe that decreased embryonic beta chain expression explains
the microcytosis that we observed. Mutations in the gene encoding
the divalent metal transporter 1 (DMT1) in humans also cause iron
overload and hypochromic microcytic anemia.24 Although DMT1
mRNA levels in Stat5a/bf/f; TC mice were reduced by approximately
60% (data not shown), we were unable to locate GAS sites within
putative regulatory sequences, suggesting that the reduced expres-
sion was a secondary event. However, the absence of bona fide
GAS sides does not rule out that the Dmt1 gene is under the control
of STAT5A/B.
Unlike the well-studied posttranscriptional regulation of Tfr1
mRNA, transcriptional regulation of Tfr1 remains less well
characterized. It has been shown that various growth and
differentiation factors can stimulate erythroid Tfr1 transcrip-
tion.25 In this study, we identified STAT5A/B as critical for
efficient expression of the Tfr1 gene in erythroid precursors.
STAT5A/B is considered a cytokine-inducible modulator and
does not necessarily control basal levels of transcription. An
accepted role of STAT5A/B is in the induction of target genes in
hormone-responsive tissues to achieve high levels of specific
mRNAs rapidly.26-28 Similarly, Epo-induced stimulation of
STAT5A/B activity would lead to the induction of erythroid Tfr1
transcription, which would allow sufficient iron to enter erythro-
cyte precursors for hemoglobin synthesis.
Production of the iron-regulatory hormone hepcidin is modu-
lated in response to changes in iron stores and erythroid demand.
Accelerated or ineffective erythropoiesis induces an unknown
signal, “the erythroid regulator,” which leads to down-
regulation of hepcidin expression in the liver, and consequently
an increase in iron entering the system. Conversely, under
conditions of iron overload, hepcidin expression is up-regulated
by the “stores regulator” to prevent additional iron intake.29
Under some circumstances, mice that are anemic but iron
overloaded may have coexisting signals to both down-regulate
and up-regulate hepcidin production. In most characterized
cases of anemia coupled with iron overload, such as transferrin-
deficient mice19 and "-thalassemic mice,30 the erythroid signal
is dominant and hepcidin production is markedly reduced.
Therefore, we had expected hepcidin expression to be reduced
in Stat5a/bf/f; TC mice. However, hepcidin expression was slightly
increased in these mice, suggesting that the stores regulator is
the dominant signal. As the genetic defect in Stat5a/bf/f; TC mice
is restricted to hematopoietic cells, we hypothesize that the
stores regulator dominates due to a deficiency in production or
signaling of the erythroid regulator.
Similar to Stat5a/bf/f; TC mice, Tfr1#/! mice exhibit decreased
cell surface Tfr1 and have microcytic, hypochromic erythrocytes.2
However, unlike Stat5a/bf/f; TC mice, which have fewer red blood
cells than wild-type controls, Tfr1#/! mice have a compensatory
induction of erythropoiesis and an increased red blood cell count.
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Whereas Stat5a/bf/f; TC mice have decreased hemoglobin and hemat-
ocrit, Tfr1!/" mice display normal hemoglobin levels and hemat-
ocrits due to the increase in red blood cell number. It is an open
question why Tfr1!/", but not Stat5a/bf/f; TC, mice exhibit a
compensatory increase in red blood cell production. In addition to
decreased erythroid iron, Tfr1!/" mice have decreased hepatocyte
iron due to the global reduction in Tfr1 expression. This contrasts
with Stat5a/bf/f; TC mice, which have a hematopoietic-specific
reduction in Tfr1 expression and have increased hepatocyte iron
deposition.
In summary, this study provides evidence that STAT5A/B is an
important transcriptional regulator of Tfr1 in erythroid cells. Transcrip-
tional regulation of Tfr1 has not been fully characterized in these or other
cells. It will be interesting to investigate the importance of STAT5A/B-
driven Tfr1 transcription in nonerythroid cell types and to compare how
STAT5A/B activity is stimulated in each context.
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